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Abstract 
ENZVME STUDIES IN VARIEGATE PORPHYRIA 
Peter Nicholas Meissner 
Department of Medicine, University of Cape Town Medical School, 
Observatory, 7925, South Africa. 
This thesis investigates a mechanism for the potential accumulation of 
o-arninolaevulinic acid (ALA) and porphobilinogen (PBG) observed 
during the acute attack of variegate porphyria (VP). The hypothesis 
that a decrease in the activity of protoporphyrinogen oxidase results 
in an accumulation of distal porphyrin intermediates which in turn 
inhibit PBG dearninase is examined. 
PBG dearninase activity was measured in Epstein-Barr virus 
transformed lymphoblasts (lyrnphoblasts) from · subjects with 
quiescent VP and found to be decreased by approximately 25%. 
Additional evidence of partially inhibited PBG dearninase activity in 
VP was provided by finding a small but significant increase in urinary 
ALA and PBG concentrations in a series of 221 VP patients when 
compared to a series of normal controls. 
A kinetic comparison between control and VP lymphoblast PBG 
dearninase using the Hill equation was performed. Results revealed 
that control lyrnphoblast PBG dearninase had a hyperbolic 
substrate-velocity curve which obeyed Michaelis-Menten kinetics 
whereas that of VP lyrnphoblasts yielded a · sigmoidal 
substrate-velocity curve which did not. 
xvi 
Secondly, addition of protoporphyrinogen-IX to control lymphoblast 
PBG deaminase transformed the hyperbolic substrate-velocity curve 
to a sigmoidal form similar to that exhibited by PBG deaminase in VP 
lymphoblasts. Coproporphyrinogen-III had a similar but less potent 
effect. In contrast, uroporphyrinogen-III, protoporphyrin-IX, 
coproporphyrin-III and uroporphyrin-III had no effect on PBG 
deaminase. 
Sephadex ( G25) chromatography was used to separate PBG 
deaminase from accumulated porphyrin( ogen)s in VP lymphoblasts. 
This restored normal kinetic behaviour to PBG deaminase in VP 
lymphoblasts. 
Similar kinetic alterations to those described above were observed 
using purified erythrocyte PBG deaminase with and without addition 
of protoporphyrinogen-IX. 
VP lymphoblasts appeared to be a valid model of VP tissue as they 
exhibited an increase in protoporphyrin-IX and, to a lesser extent, 
coproporphyrin-III when compared to normal control cells. 
These findings lend support to the potentially rate-limiting nature of 
PBG deaminase in the haem biosynthetic pathway and thus provide a 
possible mechanism for the accumulation of ALA and PBG in VP. The 
finding that uroporphyrinogen-III exerted no influence on PBG 
deaminase is in keeping with the hypothesis since PCT is a non-acute 
porphyria and ALA and PBG never appear to be elevated in this 
condition. 
xvii 
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Chapter One 
General Overview 
This section aims at providing an introduction to haem biosynthesis, 
the structural chemistry of porphyrins and the porphyrias. 
Conventions and nomenclature used in this dissertation are defined 
(see Appendix 15 for abbreviations). While pertinent literature is 
reviewed and some specific comment made additional detailed 
literature review is provided in further chapters. Some historical 
perspectives are included since these might allow useful insight into 
the processes which have resulted in the development of knowledge 
of haem biosynthesis, the porphyrias in general, and more specifically, 
in variegate porphyria ( covered in detail in chapter 2). 
Essential structures and nomenclature 
Figure 1.1 depicts a macrocycle 
consisting of four pyrrole rings 
joined by methene (-CH=) 
bridges. This tetrapyrrole is termed 
the porphin nucleus (Smith, 
l975b).Porphyrins are derived from 
porphin by substitution of some or 
all of the peripheral positions with 
various side-chains (IUPAC-IUB 
Joint Commission on Biochemical 
Nomenclature, 1980). Thus the 
different types of porphyrins found 
2 .3 
8 
7 6 
Figure 1.1 : The tetrapyrrolic porphin 
nucleus, the "backbone" of all 
porphyrin(ogen) structures. The 
conventional Fischer nomenclature is 
indicated. 
2 
Table 
Chapter 1 
in nature, or produced synthetically in the laboratory, derive their 
differences from the composition of the side-chains attached to the 
tetrapyrrole ring. Earlier reviews cover detailed aspects of the 
structural and physical chemistry of porphyrins (Burnham, 1968; 
Marks, 1969; Adler, 1973; Smith, 1975a; Dolphin, 1979a). 
The classical (Fischer) system of nomenclature numbers the 
peripheral positions from 1 to 8 and the interpyrrolic carbon bridges 
(sometimes termed the mesa carbons) are designated a, {3, y and o 
(Fischer and Orth, 1934 ). The individual pyrrole rings are named A, 
B, C and D (Falk, 1964) (figure 1.1). Typically, and perhaps 
understandably, trivial rather than systematic names are normally 
used. Table 1.1 (Smith, 1975; Bales, 1979; Kappas et al, 1983) lists the 
trivial names and stn.ictures of those naturally occurring porphyrins 
relevant to this dissertation. Most of these are derived from 
mammalian haem biosynthetic pathways. Haem (ferroprotoporhyrin) 
is a porphyrin macrocycle with a centrally bound iron atom. 
1. 1: Trivial names and side-chain substituents of porphyrins pertinent to this 
dissertation. Abbreviations as follows: 
A: -CH2COOH, M: -CH31 V: -CH= CH2, P: -CH2CH2COOH, E: -CH2CH3 
Substituent on positions 1-8 
PORPHYRIN 1 2 3 4 5 6 7 8 
U roporphyrin-1 A p A p A p A p 
Uroporphyrin-111 A p A p A p p A 
Heptacarooxylic porphyrin · A p A p A p p M 
Hexacarboxylic porphyrin M p A p A p p M 
Pentacarboxylic porphyrin M p M p A p p M 
Coproporphyrin-1 M p M p M p M p 
Coproporphyrin-111 M p M p M p p M 
lsocoproporphyrin-111 M E A p M p p M 
Harderoporphyrin-lX M V M p M p p M 
Protoporphyrin-lX M V M V M p p M 
Deuteroporphyrin-lX M H M H M p p M 
Mesoporphyrin-lX M E M E M p p M 
·. 
.[ 
' 
:: 
: 
' 
': 
' 
General Overview 
The hexahydro-reduced form of the 
porphyrins (ie. six additional 
hydrogen atoms, two attached to the 
"pyrrolic" nitrogens and one to each 
of the four meso-carbons resulting in 
four methylene groups) are termed 
the porphyrinogens (Mauzerall, 
1979) (figure 1.2). Porphyrinogens 
are important since they form the 
immediate and obligatory 
precursors of all but the penultimate 
step of haem biosynthesis 
(Rimington, 1937; Bissell, 1985). 
3 
H2 µc~ 
"'ttc;j"' 
Figure 1.2: Essential structure of the 
porphyrinogens, the hexahydro-reduced 
form of the porphyrins. 
Some general aspects of the chemistry of the 
porphyrins and porphyrinogens 
Metal binding 
Porphyrins readily complex with metals, such as iron to form haem, 
magnesium to form the chlorophylls or cobalt to form vitamin B12 via 
the corrins (Scott et al, 1972; Battersby and McDonald, 1975, Jones, 
1976; Bissell and Schmid, 1987). These metalloporphyrins are widely 
distributed throughout the plant and animal kingdoms where they are 
essential for photosynthesis, oxygen transport, electron transport, the 
reduction of molecular oxygen and various hydroxylation reactions. 
Free porphyrins serve no known biological function in man (Bissell, 
1985). Haem itself is only biologically functional when bound to 
various proteins to form the "haemoproteins". These include all the 
cytochromes, various catalases, peroxidases, mono- and dioxygenases 
and the cytochrome P 450 series central to a variety of biological 
hydroxylation reactions (Dolphin, 1979). Thus for many organisms 
', 
' 
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oxygen transport, storage, reduction and activation are mediated by 
haemoproteins. 
Aromaticity 
Porphyrins, "the pigments of life" (Battersby et al, 1980), are highly 
coloured compounds. Their main absorption bands have very high 
extinction coefficients (up to 4X105M), and they have intense "Soret" 
bands, at wavelengths in the region of 400nm (Smith, 1975b). They also 
exhibit red fluorescence when irradiated with ultraviolet light of 
wavelength approximately 400nm. These properties are indicative of 
a high degree of conjugation of the macrocycle. There are 22 
.n-electrons, but only 18 of these are included in any one delocalisation 
pathway; this is consistent with Huckel's 4n + 2 rule for aromaticity. 
Porphyrins are thus considered to be highly aromatic with the-electron 
clouds lying above and below the planar macrocycle, rather "like a ring 
doughnut" (Bonnett, 1981). 
The porphyrinogens, on the other hand, are relatively non-aromatic 
(ie. aliphatic) compounds; the macrocycle exists in an unconjugated 
state since the methene bridges are replaced by four methylene 
bridges. This results in colourless, nonfluorescent compounds, with no 
"Soret" absorption band and with less rigid, more "floppy" structural 
characteristics (Smith, 1975b). 
Isomeric forms 
Where dissimilar side-chains occur on the particular pyrrole rings of 
the tetrapyrrole different isomeric forms are possible. Thus, in the case 
of an octasubstituted porphyrin or porphyrinogen with two types of 
side-chain, such as uroporphyrin and coproporphyrin, there are four 
possible isomers (Fischer and Orth, 1934). These are termed isomers 
I, II, III and IV (Falk, 1964). When there are three different 
side-chains, as in protoporphyrin, fifteen isomers are possible. In 
nature only the type III and I isomers have been found to exist. In 
mammals only the type III uroporphyrin(ogen) through to type III 
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coproporphyrin( ogen) and the type IX protoporphyrin( ogen) are used 
in the synthesis of haem. 
Unless othenvise stated in this dissertation the terms uro-, hepta-, hexa-, 
pent a- and co pro- porphyrins or porphyrinogens will ref er to the type III 
isomer and in the case of protoporphyrin( ogen), the type IX isomer. 
Haem biosynthesis 
General description 
(Meyer and Schmid, 1974; Tait, 
1978; Elder, 1980; Kappas et al, 
1983; Moore et al, 1987) 
Haem biosynthesis (figure 1.3) consists of a series of chemical 
reactions and modifications catalysed and linked by a number of 
enzymes forming an irreversible, unbranched metabolic pathway. The 
haem synthetic enzymes are compartmentalised within the cell, the 
first step and the last three steps occurring in the mitochondrion and 
the intermediate steps in the cytosolic compartment. 
Haem synthesis commences with the condensation of succinyl CoA 
(formed by the citric acid cycle) and the amino acid glycine to form 
o-aminolaevulinic acid (ALA). This takes place in the mitochondrion 
and is catalysed by the enzyme ALA synthetase. Succinic acid and 
glycine, two relatively small but readily available molecules, can thus 
be viewed as providing the constituent carbon and nitrogen atoms for 
haem. ALA leaves the mitochondrion and once in the cytosol, ALA 
dehydratase catalyses the condensation of two molecules of ALA to 
form the pyrrole subunit of the porphyrin ring,porphobilinogen (PBG ). 
Next, four molecules of PBG are assembled by PBG deaminase to 
form an "unrearranged" bilane, hydroxymethylbilane. Working 
concurrently, uroporphyrinogen cosynthetase performs the necessary 
intramolecular rearrangement and ring closure of the bilane to form 
6 
SUCCINY1. CoA 
O H H SCoA 
' I I I c-c-c-c 
/ I I \ 
HO H H 0 co,0 
0 H H O H 
'\ I I I I 
·.· .. · 
·.·.·. 
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8 
~----... /-7-~-C-;-NH1 
CLYCINE 
K~~N u ~\ .--c: ,:: u p p U PROTOPORPHYRIN-IX 
u 
u 
p 
CCPROPORPHYRINOGEN - 111 
u © 
u 
co, 
p 
p 
HO H H H 
u 
URO?ORPHYRINOGEN-1 
I ®1 
I 
7CciOH PORPHYRINOG~N-1 
OH 
A 
© 
7 
co, 
HYOROXYMErrlYl31LANE 
© r ~ H,O 
' 
? A 
URCPORPHYRINOGEN-111 
0l 
' co, 
p A 
p p 
5COOH PORPHYRINOGEIHU 6COOH PORPHYRINOGEN-IU 7COOH PORPHYRINOGEN-111 
Figure 1.3: The haem biosynthetic pathway. The numbers refer to the enzymes of haem 
biosynthesis as follows: 1, ALA synthetase; 2, ALA dehydratase; 3, PBG 
deaminase; 4, Uroporphyrinogen cosynthetase; 5, Uroporphyrinogen 
decarboxylase; 6, Coproporphyrinogen oxidase; 7, Protoporphyrinogen oxidase; 
8, Ferrochelatase. 
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urop01phyrinogen, the first of a series of porphyrinogens. In the 
absence of uroporphyrinogen cosynthetase hydroxymethylbilane 
spontaneously undergoes chemical cyclisation to form the type I 
uroporphyrinogen isomer which is apparently biologically 
functionless. Uroporphyrinogen decarboxylase catalyses the stepwise 
decarboxylation of uroporphyrinogen, which has eight carboxylated 
side-chains, through hepta-, hexa- and penta-carboxylic porphyrinogen 
intermediates to form the tetracarboxylic porphyrinogen, 
coproporphyrinogen. The process returns to the rnitochondrion where 
coproporphyrinogen oxidase produces the dicarboxylic 
porphyrinogen, protoporphyrinogen by oxidative decarboxylation of 
the propionate side-chains in peripheral positions 2 and 4 to vinyl 
groups. Protoporphyrinogen is enzymatically oxidised by 
protoporphyrinogen oxidase to give protop01phyrin and the final step 
of the pathway is the chelation of the protoporphyrin ring structure 
with ferrous iron (Fe2 +) to form haem. 
Historical aspects of the study of porphyrins and haem 
biosynthesis 
Porphyrin research began with the acid treatment of haemoglobin to 
produce "iron-free" haematin (Berzelius, 1840; Scherer, 1841; 
Mulder, 1844 ). This was later purified and characterised by 
Thudichum who noted its fluorescence which he described as "a 
splendid blood-red colour" (Thudichum, 1867). The terms 
"haematoporphyrin", "phylloporphyrin" ( chlorophyll) and indirectly 
"porphyrin" were introduced by Hoppe-Seyler in the 1870's 
(Hoppe-Seyler, 1871 and 1879). Around this time the first description 
of the appearance of "porphyrin" pigment in the urine of a human 
subject appeared (Schultz, 1874; Baumstark, 1874) (see Historical 
aspects of the porphyrias). In 1883 Soret discovered the highly 
distinctive spectroscopic 400nm wavelength absorption band in 
haemoglobin (Soret, 1883). Further studies on the nature of the 
pigments found in urines of the rather rare patients who excreted 
abnormal amounts of porphyrins ensued (Stokvis, 1889; Harnmarsten 
1891 a,b; Salkowski, 1891; Garrod, 1892, 1893, 1896; Gunther, 1911 a) 
8 Chapter 1 
but it was not until 1912 that the correct tetrapyrrolic nature of the 
pigments was predicted by Kuster (Kuster, 1912). At that time it was 
thought that such a large ring would be unstable, and this structure was 
not accepted by Hans Fischer, the father of contemporary porphyrin 
chemistry, until much later. However, Fischer did have a hand in the 
final proof, which was provided by his total synthesis of 
"koproporphyrin" and "protohaem" in 1929 (Fischer et al, 1929; 
Fischer and Zeile, 1929). Fischer had been active in porphyrin 
chemistry since around 1915 (Fischer, 1915 and 1916), and continued 
to be so for approximately 30 years. His studies were both broad and 
deep. He inspired many pupils, including Watson and Waldenstrom 
(see Chapter 2, Historical aspects of the porphyrias). His profound 
contribution to knowledge was recognised by the award of the Nobel 
prize for Chemistry in 1930. 
In the 1930's and 1940's a young chemist named Claude Rimington 
shed important new light on the porphyrins. His early work included 
studies on the urinary porphyrins excreted by cattle with congenital 
porphyria (Rimington, 1936), work which he was able to apply to 
human congenital porphyria (Rimington, 1937), and on the flight 
feathers of the South African Turaco (Rimington, 1939). Later, he did 
research to elucidate the chemistry and structure of the monopyrrole, 
PBG ( Cookson and Rimington, 1954) and described many important 
analytical and separative te·chniques for the investigation of porphyrins 
(Rimington, 1943; Nicholas and Rimington, 1949; Rimington and 
Sveinsson, 1950). 
Important contributions to knowledge of haem biosynthesis during the 
1940's and '50's are generally ascribed to the radioisotope experiments 
of Shemin, and Neuberger although it must be remembered that many 
others such as Watson and his colleagues made significant 
contributions using similar techniques. These studies led to the 
description of the incorporation of 15N glycine into haem in both 
humans and animals (Shemin and Rittenberg, 1946; Grinstein et al, 
1949; Radin et al, 1950; Muir and Neuberger, 1950; Gray and 
Neuberger, 1950; Gray et al, 1950; Grinstein et al, 1950; Shemin and 
Wittenberg, 1951; Gray, 1952; Shemin et al, 1955). It was thus 
established that glycine and succinate supplied all the carbon and 
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nitrogen atoms of haem. Importantly, it was realised that AlA 
(Shemin and Russell, 1953; Neuberger and Scott, 1953) and PBG (Falk 
et al, 1953) were the precursors of all the porphyrins and of haem. 
Simultaneously the necessary "tool" with which to study and confirm 
the synthetic steps of haem production came to hand with the discovery 
of experimental porphyria in animals by Schmid and Schwartz (Schmid 
and Schwartz, 1952), who used the drug Sedormid to induce porphyria 
in rabbits. Shortly after this the drug allylisopropylacetamide (AIA) 
was shown to have a similar effect (Goldberg, 1954) and thereafter 
followed the description of a number of other drug-related 
experimental porphyrias (Granick, 1953; De Matteis, 1967). Using 
these models, the sequence of haem biosynthesis was clearly 
established by the mid-1950's. It is of interest to observe that Lemberg 
and Legge had predicted virtually the correct sequence in 1949 
(Lemberg and Legge, 1949). 
The next major period of porphyrin biochemistry saw the investigation 
of the enzymes responsible for the catalysis of the haem biosynthetic 
pathway. This b_egan in 1953 with the description of an enzyme 
facilitating conversion of PBG to porphyrins (Bogorad and Granick, 
1953). This step was well studied and attributed to two distinct 
enzymes, namely PBG deaminase and uroporphyrinogen cosynthetase 
by 1958 (Bogorad, 1958). AlA dehydratase was described in 1954 
(Granick, 1954), AlA synthetase (Kikuchi et al, 1958; Gibson et al, 
1958) and uroporphyrinogen decarboxylase (Granick and Mauzerall, 
1958) in 1958, ferrochelatase in 1959 (Goldberg, 1959) and 
coproporphyrinogen oxidase in 1961 (Sano and Granick, 1961). The 
last haem synthetic enzyme to be described was protoporphyrinogen 
oxidase in 1974 (Jackson et al, 1974; Poulson and Polglase, 1975). 
Much productive work on the enzymes of haem biosynthesis continues 
today. 
The most recent areas of porphyrin research involve the application 
of the techniques of molecular biology to the study of the control and 
synthesis of the haem synthetic enzymes and the disturbances which 
result from disease. 
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Thus evolved the current era of porphyrin chemistry/biochemistry. A 
more detailed examination of each enzymatic step of the pathway 
follows. 
Enzymes of haem biosynthesis 
Formation of ALA by ALA synthetase (EC 2.3.1.37) 
ALA synthetase is a pyridoxal phosphate requiring enzyme that 
promotes the condensation of succinyl CoA and glycine to form ALA 
(Kikuchi et al, 1958; Granick and Sassa, 1971; Jordan and Shemin, 
1972). A sulphydryl group associated with initial binding of the 
pyridoxal phosphate co-factor has been identified at the catalytic site 
in rat liver ALA synthetase (Scholnick et al, 1972). The proposed 
catalytic mechanism involves initial condensation of glycine and 
succinate (activated as succinyl CoA) via a Schiff's base mechanism 
with formation of a-amino-,8-ketoadipic acid as an enzyme-bound 
unstable intermediate, followed by decarboxylation of the glycyl 
carboxyl group (with release of CO2) and release of ALA from the 
enzyme (Zaman et al, 1973; Akhtar et al, 1976). 
In mammalian systems ALA synthetase appears to have a widespread 
tissue distribution (Kappas et al, 1983). It is present in high 
concentrations in immature erythrocytes where it is required for the 
synthesis of haemoglobin and in the liver where it is involved in the 
synthesis of a number of haemoproteins including cytochrome P 450, 
peroxisomal catalase and tryptophan pyrrolase. 
Subcellularly it is found mainly in the mitochondria (Whiting and 
Elliott, 1972; Batlle, 1986). Smaller amounts of ALA synthetase have 
been detected in the cytosol. The latter is presumed to be newly 
synthesised ALA synthetase en route to the mitochondrion (Hayashi 
et al, 1969; Patton and Beattie, 1973). Indeed, in the rat liver ALA 
synthetase is synthesised on the cytoplasmic polysomes of the rough 
endoplasmic reticulum as a larger molecular weight complex than the 
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fully functional, processed, translocated mitochondrial form (Hayashi 
et al, 1970; Whiting and Elliott, 1972; Yamauchi et al, 1980) (see 
below). Within the mitochondrion it may be loosely associated with 
the inner mitochondrial membrane (McKay et al, 1969) but 
submitochondrial localisation studies in mitoplasts (intact inner 
membranes containing matrix) using established marker enzymes 
show it to be an enzyme of the mitochondrial matrix (Scotto et al, 
1983). In vitro studies of rat liver AlA synthetase also suggest that is 
localised in the mitochondrial matrix (Ohashi and Sinohara, 1978). 
The purification of AlA synthetase has led to discrepant ( and 
confusing !) reports of its properties, contingent on the source and 
conditions of preparation. Its propensity to form aggregates both with 
itself and other proteins (Ohashi and Kikuchi, 1977; Batlle, 1986), 
explains some of these varied results. 
3,5-Dicarbethoxy-1,4-dihydrocollidine (DDC) induced rat liver 
mitochondrial AlA synthetase has a reported molecular weight of 
77000. The molecular weight of its cytosolic unprocessed form is 
178000 (Whiting and Elliott, 1972). In contrast, the uninduced rat liver 
mitochondrial AlA synthetase has a molecular weight of 126000 
(Paterniti and Beattie, 1979). Rat liver cytosolic AlA synthetase has 
also been reported to consist of a trimeric unit with an active subunit 
of molecular weight 110000, and two inactive subunits of 150000 and 
60000 (Ohashi and Kikuchi, 1972). Mitochondrial AlA synthetase 
purified from chick liver embryos gave molecular weights in the 
presence of sodium dodecyl sulphate (SDS) of 49000 (Whiting and 
Granick, 1976) and more recently, 68000 (Pirola et al, 1983) and 65000 
(Watanabe et al, 1983). The unprocessed AlA synthetase 
accumulating in the cytosol of chick liver has a molecular weight (in 
SDS) of 73000 (Watanabe et al, 1983). 
Molecular biological approaches to AlA synthetase have thus far 
produced complementary DNA ( cDNA) (Borthwick et al, 1984; 
Borthwick et al, 1985) and genomic clones to chick liver AlA 
synthetase (Maguire et al, 1986) and cDNA clones to rat liver AlA 
synthetase (Srivastava et al, 1988). Using this approach it was shown 
that rat AlA synthetase mRNA was identical in all tissues examined 
(liver, heart, kidney, erythroid spleen, brain and testis) and that only a 
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single species existed (Srivastava et al, 1988). This is consistent with a 
report that erythroid ALA synthetase in mouse spleen was coded for 
by the same gene as that in mouse liver (Schoenhaut and Curtis, 1986), 
but contrary to the proposal favouring the existence of a multigene 
family for ALA synthetase with different mRNA species in different 
tissues (Yamamoto et al, 1985). Further studies involving this approach 
should be most enlightening. 
Hepatic ALA synthetase has a short half-life of 60-70min for the 
mitochondrial form in mammalian systems (Marver et al, 1966; 
Hayashi et al, 1969; Barnes et al, 1971) and is highly inducible ( Granick 
and Sassa, 1971), responding rapidly to haem requirement. The 
amount of active ALA synthetase is also very sensitive to induction by 
a wide variety of compounds such as allyl isopropyl acetamide (AIA) 
and phenobarbital (Granick, 1966). These facts fit well with the 
concept that the formation of ALA by ALA synthetase is the 
rate-limiting step of haem synthesis. This is supported by the finding 
that ALA synthetase has a lower activity than any of the other enzymes 
involved in haem synthesis (Elder, 1982; Kappas et al, 1983). ALA 
synthetase is thus widely regarded as the flux controlling step in haem 
biosynthesis. Further aspects of its role in the regulation of haem 
production will be considered below. 
Finally, mention must be made of the intriguing observation that the 
precursor of ALA formation in plant systems, 4,5-dioxovaleric acid 
(DOVA) (Beale et . al, 1975) is present in bovine liver extracts 
(Vartikovski et al, 1980) and that there is an enzyme (DOVA 
transaminase) mediating its conv.ersion to ALA which can be used for 
haem production (Morton et al, 1981 ). The significance and role of this 
alternative metabolic route of ALA formation in mammalian 
mitochondrial systems is obscure (Bissell and Schmid, 1987; Batlle, 
1986; Moore et al, 1987). 
Formation of PBG by ALA dehydratase (EC 4.2.1.24) 
Purified ALA dehydratase is a relatively large protein complex with 
reported molecular weights of the order of 280000 (Kappas et al, 1983; 
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Batlle, 1986). It has been shown to consist of eight subunits, probably 
identical, which combine to form an active complex residing in the 
cytosolic compartment (Wu et al, 1974; Shemin, 1975; Anderson and 
Des nick, 1979). The gene encoding the human enzyme has been shown 
by linkage and by somatic cell hybridisation and specific immunoassay 
to reside on chromosome 9 (Eiberg et al, 1983; Beaumont et al, 1984a). 
Zinc (Zn2 +) is required for maximal activity (Abdulla and 
Haeger-Aronsen, 1971; Pinelli et al, 1984), each ALA dehydratase 
octamer binding up to eight ions (Wu et al, 1974; Tsukamoto, 1980). 
Zn2 + may play a structural role, allowing the enzyme to adopt the 
correct conformation for activity (Hasnainet al, 1985). However, there 
is also evidence to suggest that zinc may protect the active site by 
preventing autoxidation of essential sulphydryl groups to a disulphide 
bond (Tsukamoto, 1980). Other metals such as aluminium are also 
activators of ALA dehydratase (Shemin, 1972; Elder, 1980). The 
enzyme is inactivated by sulphydryl blocking agents and its activity in 
vitro may be maximised by addition of sulphydryl-reducing agents such 
as -mercaptoethanol, cysteine, reduced glutathione or dithiothreitol 
(Kappas et al, 1983; Batlle, 1986). ALA dehydratase is very sensitive 
to inhibition by lead (Pb2 +)(Gibson and Goldberg, 1970; Granick et 
al, 1973). Pb2 + can replace the intrinsic Zn2 + stoichiometrically 
(Pinelli et al, 1975) probably by O oH o oH 
occupying the same, or a nearby, site \ I \ 1 
C (Tsukamoto, 1980). Ethanol (Moore , 1 
CH GHz 
et al, 1971) and succinylacetone 
I 
z , 
( accumulation of which may occur in ~Hz ~Hz 
hereditary tyrosinaemia) may also c =o c =o 
exert inhibitory effects on ALA ~Hz ~Hz 
dehydratase (Sassa et al, 1981). 1 ~ =o 
NHz Succinylacetone, is · structurally ; 
similar to ALA in that it also has a HJc 
keto group in the gamma position 
relative to the carboxyl carbon 
(figure 1.4). 
Figure 1.4: Structural similarit,; of ALA 
(left) and succinyl acetona (right), a 
competitive inhibitor of tha enzyma ALA 
dehydratasa. 
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Mechanistically ALA dehydratase (from Rhodopseudomonas 
spheroides) catalyses a series of reactions (Nandi and Shemin, 1967; 
Shernin, 1976) which result in the condensation of two identical 
substrate (ALA) molecules to form tbe monopyrrole PBG (figure 1.3) 
with the removal of two molecules of water. One molecule of ALA is 
covalently bound to· the enzyme through the formation of a Schiff's 
base between the -amino group of a lysine residue and the keto group 
of ALA. The ALA molecule initially bound to the enzyme has been 
shown to provide the propionate side-chain of PBG (Jordan and 
Seehra, 1980). 
ALA dehydratase has a relative activity many times higher than that 
of ALA synthetase (Kappas et al, 1983). Thus ALA dehydratase is 
thought not to have any significant role in the regulation of haem 
biosynthesis. 
Formation of uroporphyrinogen by PBG deaminase (EC 
4.3.1.8) and uroporphyrinogen cosynthetase (EC 4.2.1 ;75) 
The formation of uroporphyrinogen from PBG has been a subject of 
interest and debate since the earliest days of porphyrin biosynthetic 
chemistry. It has been referred to as "the type III problem in porphyrin 
synthesis" (Battersby et al, 1979) and only oflate have most of the clues 
to the solution of the "problem" been assembled into a coherent 
picture (Battersby, 1988). In essence the problem revolves around the 
fact that the symmetrical type I uroporphyrinogen isomer which one 
would think to be the easiest and most logical isomeric form to 
synthesise, cannot be metabolised further than to 
coproporphyrinogen-I and is thus not a source of haem. Although 
uroporphyrinogen-I has recently been shown to be a substrate for the 
methylases of the vitamin B12 pathway (Muller et al, 1986; Muller et 
al, 1987), it is generally accepted that Nature demands the series III 
isomer for haem production in man. 
Production of the series III isomer is facilitated as follows: Ingenious 
single turnover experiments with labelled substrate have shown that 
PBG deaminase operates as the assembly enzyme by catalysing the 
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head-to-tail assembly of four units of PBG, starting with ring A and 
ending with ring D (Battersby et al, 1979; Seehra and Jordan, 1980). 
The product of this action was shown by 13C nuclear magnetic 
resonance (NMR) spectroscopy to be the linear (ie. uncyclised, open 
chain) tetrapyrrole hydroxymethylbilane * (Battersby et al, 1976; 
Burton et al, 1979) (figure 1.3). The structure of this product has been 
confirmed by total in vitro synthesis (Battersby et al, 1982). Clearly, 
PBG deaminase is not a ring-closing enzyme; its function is to build 
the hydroxymethylbilane and release it for subsequent processing. 
Were spontaneous chemical cyclisation to occur at this stage ( as 
happens in the absence of uroporphyrinogen cosynthetase) the 
arrangement of the pyrrole side-chains would be such that the series I 
isomer is formed (figure 1.3). 
Hydroxymethylbilane is the substrate for uroporphyrinogen 
cosynthetase which effects cyclisation and concomitant inversion of 
the terminal D ring by an intramolecular process (Jordan et al, 1979). 
Thus the asymmetric series III isomer of the cyclic tetrapyrrole 
uroporphyrinogen is formed. There is evidence that formation of a 
spiro system is the means by which Nature performs the "conjuring 
trick" of converting the hydroxymethylbilane into uroporphyrinogen 
(Jordan et al, 1979; Battersby et al, 1980; Stark et al, 1985). This is 
supported by elegant experiments (Stark et al, 1986) involving the 
synthesis of two isomeric, very close analogues of the proposed 
spirane-structured intermediate. PBG deaminase and 
uroporphyrinogen cosynthetase can thus be viewed as acting 
concertedly and concurrently to form uroporphyrinogen-111 firstly by 
assembly of four monopyrroles, followed by intramolecular 
rearrangement and ring closure (Battersby, 1988). 
One mole of ammonia is released for every mole of PBG assembled, hence the designation 
PBG deaminase. The alternative name hydroxymethylbilane synthase is perhaps more 
appropriate; however the older, more commonly recognised name PBG deaminase is used 
in this thesis. 
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PBG deaminase has been purified from a wide variety of sources 
(Sancovich et al, 1969; Davies and Neuberger, 1973; Jordan and 
Shemin, 1973; Anderson and Desnick, 1980; Fumagalli et al, 1985). It 
is a cytosolic enzyme, appears to be · monomeric and reported 
molecular weights have varied between 34000 and 44000. The gene 
coding for PBG deaminase in E. coli (hem C) has been cloned and 
sequenced (Thomas and Jordan, 1986). In man the gene is thought to 
resideonchromosome 11 (Meisleretal, 1980, 1981; Wangetal, 1981). 
PBG deaminase has an unusual property in that it is able to form 
relatively stable intermediate complexes, sharing one, two, three or 
four pyrrole units (substrate) bound to the catalytic site (Anderson and 
Desnick, 1980; Berry et al, 1981). It has also been established that a 
covalent bond is formed between the enzyme and the first bound 
substrate (Jordan and Berry, 1981; Battersby et al, 1983; Evans et al, 
1986). This linkage is remarkable in that it appears that an 
enzyme-bound cofactor, in the form of a dipyrromethane, is 
responsible for "binding of the substrate and for directing the synthesis 
of the tetrapyrrole at the catalytic site" (Jordan and Warren, 1987; 
Scott et al, 1988). The dipyrromethane cofactor is itself formed from 
two molecules of PBG, the suggestion being that the PBG required 
for this is incorporated into the apoenzyme before folding (Scott et al, 
1988). It is thought to be anchored to the enzyme via the second 
cysteine residue found in human and E. coli PBG deaminase (Evans 
et al, 1986; Scott et al, 1988). 
All facts considered, the putative mechanism of PBG deaminase is 
shown in figure 1.5 (Scott et al, 1988). The process begins with the 
dipyrromethane cofactor covalently bonded to the enzyme 
cysteine-SH residue via its free, terminal -pyrrole carbon. Thereafter, 
the first (kinetic) encounter with substrate involves attachment of a 
single molecule of PBG (with loss of ammonia) to the dipyrromethane 
to form the so-called ES1 complex. This process is repeated until the 
"tetra PBG" (ES4) complex is formed. The latter can best be envisaged 
as a "growing oligopyrrolic chain". Once the final hexapyrrole chain 
has been formed the complex is cleaved (site-specifically) to yield a 
linear tetrapyrrole and the remaining bound dipyrromethane (figure 
1.5). The tetrapyrrole is in the form of an azafulvene bilane which may 
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either become the substrate of uroporphyrinogen cosynthetase, or, in 
the absence of this enzyme, may be stereospecifically hydrated to 
hydroxymethylbilane at pH 12, or cyclised chemically to 
uroporphyrinogen-I at pH 8. 
A p 
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Figure 1.5: Detail of action of PBG deaminase involving the dipyrromethane cofactor and 
formation of ES 1, ES2, ES3, and ES4 intermediates prior to site-specific cleavage 
(marked with arrow) to give hydroX1Jmethylbilane. 
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Kinetically PBG deaminase has been described as a relatively simple 
enzyme displaying classical Michaelis-Menten kinetics (Frydman and 
Frydman, 1970; Anderson and Desnick, 1979; Sassa et al, 1978; Hart 
et al, 1984; Scott et al, 1988). There are reports from one group 
describing more thorough kinetic investigations (Sancovichet al, 1969; 
Llambias and Batlle, 1970; Fumagalli et al, 1985). These report 
inhibition of the enzyme at PBG concentrations above 400µM, and 
that PBG deaminase may possess two cooperative substrate binding 
sites per molecule of enzyme. The latter finding is based on the 
observation of non-linear double reciprocal substrate-velocity plots 
and Eadie plots (velocity/[substrate] versus velocity), and by 
application of the Hill equation (Segel, 1975). Eadie plots are 
particularly useful. for demonstrating deviation from 
Michaelis-Menten behaviour and the Hill equation yields a Hill 
coefficient (n) which indicates the number of cooperatively interacting 
ligand binding sites on the protein. Although no specific inhibitors or 
allosteric effectors of PBG deaminase have been described it is 
conceivable, particularly in the case of an enzyme with multiple 
cooperative binding sites that inhibition may occur through interaction 
at one or other, or all of the sites. 
Uroporphyrinogen cosynthetase is also a cytoplasmic enzyme. 
Purified uroporphyrinogen cosynthetase from Euglena gracilis has 
been shown to have a molecular weight of between 30000 and 40000 
(Hart and Battersby, 1985). It appears to be present in relative excess 
to the deaminase which, under normal circumstances ensures that 
PBG is completely metabolised to uroporphyrinogen-III (Bissell and 
Schmid, 1987) 
Formation of coproporphyr!nogen by uroporphyrinogen 
decarboxylase (EC 4.1.1.37) 
After the formation of the basic tetrapyrrole ring, uroporphyrinogen 
decarboxylase successively decarboxylates the four acetyl side-chains 
to yield coproporphyrinogen. It has been established that 
decarboxylation of the octacarboxylic uroporphyrinogen commences 
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on the asymmetric D ring and proceeds through rings A, B and C to 
give heptacarboxylic, hexacarboxylic and pentacarboxylic 
porphyrinogen intermediates (Mauzerall and Granick, 1958; Jackson 
et al, 1976) (figure 1.3). These intermediates are not merely transient 
enzyme-substrate complexes, but relatively stable individual 
porphyrinogen species and are detectable in vivo. Both the series III 
and I isomer uroporphyrinogens are suitable substrates for 
uroporphyrinogen decarboxylase but the series III isomer is 
decarboxylated more rapidly than the series I isomer (Granick and 
Mauzerall, 1958; Smith and Francis, 1981), which appears to be 
decarboxylated in any order (Jackson et al, 1977). The dissimilarity 
presumably results from the difference in symmetry offered by the 
series III isomer. 
The erythrocytic form of the enzyme has been purified to apparent 
homogeneity from human (De Verneuil et al, 1983; Elder et al, 1983) 
and chicken erythrocytes (Kawanishi et al, 1983). Chicken erythrocyte 
studies suggest that uroporphyrinogen decarboxylase exists as a dimer 
consisting of two subunits, each with a molecular weight of 
approximately 40000 (Kawanishi et al, 1983) whereas the human 
erythrocyte enzyme appears to exist as a catalytic unit of molecular 
weight reportedly ranging between approximately 40000 (Elder et al, 
1983) and 46000 (De Verneuil et al, 1983) in the presence of SDS. It 
is not entirely clear whether this is a monomer or a dimer. 
Specific antibodies to the human erythrocyte enzyme have been 
generated and quantitative immunoprecipitation and crossed 
immunoelectrophoresis indicate that the erythrocyte and liver 
enzymes are similar but not immunochemically identical (Elder et al, 
1983). The gene encoding human uroporphyrinogen decarboxylase 
has been localised to chromosome 1 (De Verneuil et al, 1984; Dubart 
et al, 1986) and the cDNA sequence determined (Romeo et al, 1986). 
At least one sulphydryl group appears to be involved in the 
decarboxylation process and titration of the purified 
uroporphyrfoogen decarboxylase with 5,5' -dithiobis(2-nitrobenzoic 
acid) (DTNB) suggests the presence of five free sulphydryl groups in 
the protein structure as a whole (De Verneuil et al, 1983). The enzyme 
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is sensitive to inhibition by sulphydryl blocking agents and by certain 
divalent metals such as eu2 +, Hg2 + and Pt2 + (Batlle, 1986; Woods 
and Fowler, 1987). Because of clinical evidence that iron promotes the 
expression and aggravates the biochemical features of conditions 
related to uroporphyrinogen decarboxylase deficiency, it has been 
suggested that the essential sulphydryl group may render 
uroporphyrinogen decarboxylase susceptible to inhibition by iron. 
However, iron (Fe2 + and Fe3 +) has variously been reported to 
stimulate (Blekkenhorst et al, 1979), to have no effect on (Woods et al, 
1981), or to inhibit uroporphyrinogen decarboxylase (De Verneuil et 
al, 1983; Smith and Francis, 1983; Mukerji et al, 1984). The different 
effects may depend on the specific enzyme preparation and on the 
conditions under which the experiments are carried out ( opinion). 
Formation of protoporphyrinogen by coproporphyrinogen 
oxidase (EC 1.3.3.3) 
The next step in haem synthesis is the decarboxylation and oxidation 
( dehydrogenation) of the propionyl side-chains of rings A and B of 
coproporphyrinogen to vinyl groups yielding protoporphyrinogen 
(figure 1.3). This transformation is catalysed by coproporphyrinogen 
oxidase (Batlle et al, 1965). This enzyme is reported to be located in 
the intramitochondrial space (mitochondrial matrix) (Batlle et al, 
1965; Sano and Granick, 1961; Poulson and Polglase, 1971) although 
more recent evidence shows it to be an enzyme residing in the 
intermembrane space of the mitochondrion (Elder and Evans, 1978; 
Grandchamp et al, 1978). It appears not to be bound to the 
mitochondrial membrane. It requires molecular oxygen as a hydrogen 
acceptor (Sano and Granick, 1961; Batlle et al, 1965). The gene 
encoding human coproporphyrinogen oxidase has been assigned to 
chromosome 9 (Grandchamp, 1983). Coproporphyrinogen oxidase 
purified from bovine liver has been shown to exist in a monomeric 
form and has a molecular weight approximately 71000 (Yoshinago, 
1980). Rat liver coproporphyrinogen oxidase has a similar molecular 
weight (Batlle, 1965). 
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The enzyme accepts the III and IV isomers of coproporphyrinogen as 
substrate, but not the I or II isomers (Sano and Granick, 1960; Porra 
and Falk, 1964; Batlle et al, 1965). Thus any uroporphyrinogen-I 
formed at an earlier step will be metabolised only as far as 
coproporphyrinogen-I. Nature thus ensures that only the correct 
isomeric form of protoporphyrinogen, the series IX form, necessary 
for haem production, enters the final stage of haem biosynthesis. 
Because two decarboxylations are involved formation of an 
intermediate tricarboxylic, monovinyl porphyrinogen might be 
anticipated. This appears to be the case (Jackson et al, 1980) although 
under normal circumstances it is difficult to detect. It has been shown 
that this tricarboxylic porphyrinogen (harderoporphyrinogen) 
consistently bears its vinyl group in position 2 of the A ring, rather than 
that of the 4 position in ring B (Jackson et al, 1978; Yoshinago and 
Sano, 1980). Thus enzymatic conversion of the propionate side-chains 
is envisaged as occurring in a step-wise manner from positions 2 to 4, 
with the formation of tricarboxylic (-hydroxypropionate) 
porphyrinogen as an obligatory intermediate (Sano, 1966). 
Formation of protoporphyrin by protoporphyrinogen oxidase 
(EC 1.3.3.4) 
The next step, oxidation of protoporphyrinogen to protoporphyrin, is 
catalysed by the enzyme protoporphyrinogen oxidase (Jackson et al, 
1974; Poulson and Polglase, 1975; Poulson, 1976). This was the last of 
the haem synthetic enzymes to be "discovered" and its existence was 
doubted for some time. Since the simple oxidation of 
protoporphyrinogen required to facilitate iron insertion into the 
tetrapyrrole ring to produce haem is a spontaneous chemical reaction 
proceeding rapidly and unaided in vitro, the necessity for enzymatic 
assistance was initially not appreciated (Moore et al, 1987). However, 
in the highly-reducing environment of the mitochondrion spontaneous 
oxidation is not possible and an enzyme is required to remove six 
hydrogen atoms from protoporphyrinogen to form protoporphyrin. 
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The reported characteristics of this inner mitochondrial membrane 
(Deybach et al, 1985), oxygen-requiring enzyme (Poulson and 
Polglase, 1975; Poulson, 1976) are discrepant in some respects. 
Reported molecular weights are 57000 (bovine), 35000 (rat) and 65000 
(murine) (Siepker et al, 1987; Poulson, 1976; Dailey and Karr, 1987 
[respectively]). In all reports the enzyme does, however, appear to be 
present as a single subunit. It has been suggested that sulphydryl 
groups are functionally important in rat liver protoporphyrinogen 
oxidase (Poulson, 1976); yet the lack of inhibition of activity by 
N-ethylmaleimide or iodoacetamide, or stimulation by 
,B-mercaptoethanol or dithiothreitol in murine protoporphyrinogen 
oxidase argue against catalytically important sulphydryl groups 
(Dailey and Karr, 1987). Whereas recent studies point to a flavin 
adenine dinucleotide (FAD) prosthetic group associated with bovine 
protoporphyrinogen oxidase (Siepker et al, 1987) initial work on 
murine protoporphyrinogen oxidase showed no evidence of a 
chromophoric cofactor such as a flavoprotein. Subsequently, however, 
the use of a more rapid purification procedure for murine 
protoporphyrinogen oxidase has resulted in detection of a flavin 
mononucleotide (FMN) chromophoric cofactor (Proulx and Dailey, 
1989). 
VP family studies demonstrating linkage between the 
alpha-1-antitrypsin gene and the gene locus for VP suggest that 
protoporphyrinogen oxidase is encoded on chromosome 14 (Bissbort 
et al, 1988). There is evidence to suggest significant homology between 
bovine protoporphyrinogen oxidase and ferrochelatase. This is based 
on the demonstration of common epitopes in antibodies raised to the 
two enzymes and of common peptides resulting from chymotryptic 
digestion of the two enzymes (Siepker et al, 1987). Others, however, 
argue against sequence homology between the two enzymes, based on 
the dissimilar specific functions of each of the two enzymes. 
The properties of this enzyme are thus not yet fully elucidated. The 
precise mechanism whereby the oxidation of protoporphyrinogen is 
accomplished remains to be clarified. 
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Formation of haem by ferrochelatase (EC 4.99.1.1) 
The final step of haem biosynthesis is the insertion of ferrous iron 
(Fe2+) into protoporphyrin to form ferroprotoporphyrin (ie. haem) 
(figure 1.3) (Goldberg et al, 1956; Rimington, 1958). Ferrochelatase 
is found on the inner mitochondrial membrane (Jones and Jones, 
1969; McKay et al, 1969). Lipids appear to be necessary for activity, 
indicating that it may exist as a lipoprotein complex in vivo (Sawada et 
al, 1969; Yoneyama et al, 1969). Lipid moieties may be necessary for 
transferring iron from an aqueous to the nonaqueous membrane 
environment; for maintaining solubility of protoporphyrin which is 
relatively hydrophobic, or for both of these functions (Moore et al, 
1987). An intramitochondrial pool of iron, not associated with 
cytochromes or iron-sulphur proteins, has been postulated as the 
source of iron (Tangeras, 1985). It is probable that the reduction of 
ferric iron (Fe3 +) to Fe2 + takes place in close proximity to 
ferrochelatase (Moore et al, 1987). 
Purified bovine ferrochelatase has a molecular weight of 
approximately 40000 (Dailey and Fleming, 1983). It is of low 
substrate-specificity and will insert Fe2 + into other dicarboxylic 
porphyrins such as meso- and deuteroporphyrin (Dailey et al, 1986). 
Indeed, it is not specific for Fe2+ either, and will effect the chelation 
of several divalent metals such as Zn2 + and Co2 + (Johnson and Jones, 
1964; Jones and Jones, 1969; Elder, 1980). 
Ferrochelatase is activated by sulphydryl containing agents. This 
suggests that sulphydryl group(s) may be involved at the catalytic site 
(Goldberg et al, 1956; Dailey et al, 1986). It also suggests that 
sulphydryl agents may be necessary to maintain the substrate iron in 
its reduced form (Porra and Jones, 19633,b) and may also be necessary 
to protect the enzyme and substrate against phospholipid peroxidation 
(Petersen et al, 1980; Dailey and Fleming, 1986) 
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Tissue localisation and activities of haem 
biosynthetic enzymes 
* 
All cells requiring haem are presumed able to synthesise this 
compound (Elder, 1980; Bissell, 1985). Thus all tissues capable of 
aerobic metabolism synthesise haem. Erythrocyte precursors are able 
to synthesise haem to meet their requirement for haemoglobin 
production during the early stages of their differentiation. The 
concentration and turnover rates of the many haem-requiring proteins 
differ significantly. Similarly individual tissue requirement for haem 
synthesis is equally varied. 
The liver, which via enzyme systems such as the cytochrome P450 
family*, plays a major role in the detoxification and metabolism of a 
wide range _ of endogenous and exogenous compounds, is one of the 
organs most active in haem synthesis (Bloomer and Straka, 1988). It is 
estimated that of all the ALA synthesised by the liver, approximately 
65% is used as the prosthetic group of the various cytochrome P45o's, 
15% for peroxisomal catalase, 8% for cytochrome b5 and 6% for 
mitochondrial cytochromes (Sassa and Kappas, 1981). While the 
actual amount of haem contained in the cytochrome P45o's in the liver 
is small in comparison with the amount contained in the body's 
haemoglobin pool, they have a short half life compared to that of 
haemoglobin (hours as opposed to many days) (Bissell, 1985). Thus a 
significant proportion of total haem production in the body is required 
by the liver for the cytochrome P 450 enzymes. 
A detailed discussion of the family of enzymes which constitute 
cytochrome P 450 is beyond the scope of this dissertation. A recent 
review (Waterman et al, 1986) once again stresses the fact that the 
synthesis of the cytochrome P45o's is highly inducible and appears to 
be related to metabolic needs of the cell. A large number of endo- and 
The term cytochrome P 450 used in this dissertation embodies all the haemoproteins of the 
cytochrome P 450-P 448 series. 
.; 
:: 
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xenobiotics are capable of inducing cytochrome P45o's. These include 
the barbiturates and gonadal steroids. 
Thus the haem requirement varies and haem synthesis appears to be 
regulated to meet . this need. Under normal circumstances this 
regulation is highly efficient and is discussed below. 
Haem formation by erythroblasts accounts for approximately 85% of 
total body haem (Jones et al, 1971; Berk et al, 1976; Elder, 1980) and 
can thus be considered a major, if not the major, site of haem synthesis. 
Erythroblast haem synthesis is apparently effected by the same 
pathway described above, yet little is known about the effect of 
erythroblast differentiation on the activity and regulation of haem 
biosynthesis in erythropoietic tissue (Moore et al, 1987). 
Within developing erythroid cells haem may be required, not only as 
the prosthetic group in haemoglobin, but also for other purposes. Free 
intracellular haem may play a role in control of globin gene expression 
(Harrison, 1984 ), may regulate iron uptake (by controlling the release 
of iron from transferrin (Ponka et al, 1974) and/or by regulating the 
number of transferrin receptors on differentiating erythroid cells 
(Pelicci et al, 1982) ), and may play a role in the overall coordination 
of erythroblast metabolism and differentiation (Glass et al, 1975; 
Ibrahim et al, 1982; Monette et al, 1984). 
In considering the nett flux through a metabolic pathway it is of interest 
to compare the activity of each enzyme with the others. Such data has 
been collated previously in descriptions of haem biosynthesis (Elder, 
1980, 1982; Kappas et al, 1983; Moore et al, 1987) and is summarised 
in table 1.2. Inter-laboratory variation in absolute enzyme activities 
and the varied sources and methods of preparation of tissue for assay 
make comparison difficult, yet one point is clear. When all activities 
are calculated as nmol of ALA equivalents per h per g of tissue or per 
g of protein (see table 1.2) and expressed relative to ALA synthetase 
activity, the activities of all the other enzymes are well in excess of that 
of ALA synthetase. The exception is PBG deaminase, which has a 
marginally greater activity than ALA synthetase. This observation is 
crucial to the work described in this thesis. 
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Table 1.2: Control activities of haem biosynthetic enzymes. (A, Activity; RA, Relative Activity). 
ENZVME 
Units of activity are nmol of ALA or ALA equivalents produced or utilised/h/g of 
liver tissue or Jg of fibroblast protein. To obtain relative activity all activities were 
divided by the ALA synthetase activity. The values are extracted from the cited 
references and represent work collated from many laboratories. References 1 
and 3: Elder, 1986; Reference 2: Bishop and Desnick, 1982 
Fibroblasts Rat liver Human liver 
(Reference 1) (Reference 2) (Reference 3) 
A RA A RA A RA 
ALA synthetase 36 1 41 1 22 1 
ALA dehydratase 3300 80 ±12850 ±584 
PBG deaminase 95 2.6 110 2.7 150 6.8 
Uro'gen cosynthetase 6160 150 
Uro'gen decarboxylase 8900 247 2544 62 11000 500 
Copro'gen oxidase 4300 119 1176 29 13000 591 
Proto'gen oxidase 26400 733 1200 29 
Ferrochelatase 200 5.6 17560 450 16600 754 
Regulation of haem biosynthesis 
The finding that some cells produce more haem than others suggests 
the existence of regulatory mechanisms for haem production in each 
tissue. The precision, specificity and efficiency of this system in vivo is 
shown by the close coupling of the rates of synthesis of haem and of 
the various apoproteins to which it is bound. It is also demonstrated 
by the extremely small losses of haem intermediates occurring from 
the pathway under normal circumstances (Bissell, 1985); in other 
words, the amount made is closely matched to the amount required. 
These losses consist of those porphyrinogens transported out of cells, 
and those intracellularly oxidised to porphyrins. The proportion of 
ALA entering the pathway which is lost in this way is estimated to be 
of the order of 1- 2.5% (Neuberger, 1980; Elder, 1982). 
The mechanism by which haem biosynthesis is regulated appears to 
vary from one tissue to another (Elder, 1980); and it is thus difficult to 
generalise. The following description is an outline of some of the 
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putative mechanisms by which haem biosynthesis may be regulated; 
not all will necessarily be operative in a specific tissue or cell type. 
Regulation by ALA synthetase 
The chief means by which the rate of haem biosynthesis in mammalian 
systems is controlled is through regulation of ALA synthetase 
(Granick and Urata, 1963; Granick, 1966; Granick and Sassa, 1971; 
Meyer and Schmid, 1978; Kappas et al, 1983). Thus alterations in the 
rate of haem synthesis are accompanied by corresponding alterations 
in ALA synthetase activity. This is consistent with other pathways of 
intermediary metabolism where the enzyme catalysing the first 
committed step of an unbranched, irreversible pathway frequently 
controls the flux of substrate down the pathway (Newsholme and 
Crabtree, 1979; Kaeser and Burns, 1979). In broad terms this 
regulation is achieved by feedback regulation of ALA synthetase by 
haem. 
The first direct evidence for such feedback was the observation that in 
chick embryos, the induction of hepatic ALA synthetase by drugs was 
prevented by the simultaneous administration of haem (Granick, 
1966). The mechanism by which this inhibition is achieved has 
remained a central question ever since. Much research has generated 
conflicting data and the mechanism is still not entirely clear. It was 
originally suggested that haem and inducing drugs compete for a site 
on a gene-controlling protein. This appears not to be so. Most of the 
available evidence indicates that repression of ALA synthetase by 
haem appears to be the sole mechanism controlling ALA synthetase 
(Srivastava et al, 1980). Thus the induction of ALA synthetase by drugs 
is currently thought to be a consequence of haem removal and not a 
direct effect of the drug (May et al, 1986). Subsequently some workers 
have suggested that haem influences ALA synthetase at a translational 
level, while others have proposed an effect at the transcriptional level 
(Yamamoto, 1982; May et al, 1986). Recently probes derived from a 
cDNA clone for rat liver ALA synthetase were used to examine control 
of the production of ALA synthetase-coding messenger RNA 
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(mRNA) (Srivastava, 1988). This work provided strong evidence that 
control of ALA synthetase by haem was exerted, at least in rat liver, at 
the transcriptional level. In this case haem regulated ALA synthetase 
mRNA levels predominantly by inhibiting transcription of the ALA 
synthetase gene. 
The primary translation product of ALA synthetase mRNA is a 
cytosolic protein which undergoes further processing to a smaller 
functional unit while it is translocated to the mitochondrion (Hayashi 
et al, 1970; Whiting and Elliott, 1972; Ohashi and Kikuchi, 1978; 
Yamauchi et al, 1980). Thus, interference with the post-translational 
processing of newly synthesised enzyme, or its transit from cytosol to 
mitochondrion, may well be a control point of haem biosynthesis. 
Indeed, there is evidence that haem lowers the rate of transfer of 
cytosolic ALA synthetase to the mitochondrion (Yamauchi et al, 1980; 
Hayashi et al, 1983). · 
Thirdly, haem synthesis might be retarded by direct inhibition of ALA 
synthetase activity by haem. This has been demonstrated using 
partially purified enzyme (Scholnick et al, 1969). Haem caused a 50% 
inhibition of ALA synthetase activity at a concentration of 2x10-5M 
(Aoki et al, 1971) which is approximately 200 times greater than the 
10-7M concentration required to produce a 50% repression of 
synthesis of the enzyme in chick embryo liver (Granick et al, 1975; 
Sassa et al, 1979). This is, however, a less efficient mechanism for the 
regulation of ALA synthetase activity. That direct inhibition of ALA 
synthetase by haem is physiologically significant is uncertain. ALA 
synthetase in isolated intact rat liver mitochondria was not inhibited 
at rates of heme formation estimated to be approximately 75 times that 
occurring in vivo (Wolfson et al, 1979). 
In summary, haem modulates ALA synthetase activity by feedback 
control and this appears to be mediated principally by repression of 
synthesis of the enzyme at the transcriptional level (Srivastava et al, 
1988). Control by varying the rate of .transfer of cytosolic ALA 
synthetase to the mitochondrion and by direct inhibition of enzyme 
activity may constitute subsidiary mechanisms (Bloomer and Straka, 
1988). The circumstances under which these latter mechanisms 
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become important are unknown. It is possible that they may operate 
as "back-up" mechanisms, particularly in the presence of unusually 
high concentrations of haem (personal opinion). 
The role of haem 
It is clear that haem plays a central part in the regulation of its own 
synthesis. This has led to the need for a hypothetical "regulatory pool 
of free haem" (Meyer and Schmid, 1978; Kappas et al, 1983; Bissell 
and Schmid, 1987). Although no free haem can be detected under 
normal circumstances (Elder, 1980,1982; Tschudy and Lamon, 1980), 
it has been estimated that in cultured rat hepatocytes 20% of newly 
formed haem is directly converted to bile pigment without being 
incorporated into haemoproteins (Grandchamp et al, 1981). The pool 
would thus consist of newly-synthesised haem, and would be in 
equilibrium with haemoprotein-associated haem (Bissell, 1985). In 
addition, the "pool" would be small and have a rapid turnover. Any 
factor affecting the concentration of haem in this "pool" would either 
increase (up-regulate) or decrease (down-regulate) haem biosynthesis 
as a result of feedback derepression or repression of ALA synthetase 
activity via the mechanisms discussed above (Bloomer and Straka, 
1988). 
The data from several experiments are consistent with this theory. Free 
haem can be increased by administering exogenous haem. This has 
been shown to reduce ALA synthetase activity in experimental 
animals. Free haem is decreased by the induction of haem-requiring 
proteins (such as apo-cytochrome P450), with consequent 
incorporation of haem into newly-synthesised haemoproteins. There 
is a concomitant, presumably resultant, increase in ALA synthetase 
activity (Marver et al, 1969; Bissell and Schmid, 1987; Correia and 
Meyer, 1975; Rajamanickam et al, 1975). Decreases in hepatic haem 
levels could also be mediated by induction of haem oxygenase, an 
enzyme catalysing the first step of haem degradation (Tenhunen et al, 
1970; Bissell and Hammaker, 1976) or by stimulation of lipid 
peroxidation (which decreases cytochrome P450 levels) (De Matteis, 
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1970). It is not clear what the nature of the relationship between haem 
synthesis and degradation is. Studies have demonstrated reciprocal 
oscillations in hepatic ALA synthetase and haem oxygenase activity in 
vivo following intravenous haemin administration (Schaiter, 1979), but 
it is not known whether haem oxygenase can be stimulated 
independently and not only by the presence of excessive amounts of 
hepatic haem (Bissell, 1985). 
The role of glycine 
The availability of substrate, and in particular of glycine, may play a 
role in regulation of synthesis of haem but this has not received much 
attention in the past. ALA synthetase has a low affinity for glycine with 
reported Km's ranging from 5 to 19mM (Kappas et al, 1983). The 
intracellular concentration of glycine is variable but, at least in the 
liver, lies just below lmM (Cowtan et al, 1973). Thus the intracellular 
concentration of glycine could be a rate-determining factor in hepatic 
haem synthesis (Neuberger, 1980). That glycine availability may 
regulate haem biosynthesis is borne out by studies showing that the 
administration of compounds which complex glycine, such as 
benzoate or para-aminobenzoate, greatly reduce the formation of 
cytochrome P450 previously stimulated by phenobarbital (Piper et al, 
1973). However, in the absence of such pharmacological manipulation 
glycine is unlikely to become depleted and the mechanism must 
therefore remain a theoretical possibility. 
Regulation of haem biosynthesis in erythroid tissue 
The regulation of haem biosynthesis in erythroid tissue is not well 
understood. There are contradictory reports of induction ( Granick 
and Sassa, 1978) and inhibition (Beaumont et al, 1984b) of erythroblast 
ALA synthetase activity by haem. These inconsistent results may, in 
part, reflect the wide variety of erythroid systems that have been used 
for haem regulatory studies. These include chick embryo blastoderm 
(Levere and Granick, 1965), foetal . mouse hepatic erythroblasts 
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(Freshney and Paul, 1971), Friend cells (Sassa, 1976), human 
erythroleukemia cells (Hoffman et al, 1980), and more recently, 
mammalian bone marrow cultures (Ibrahim et al, 1982). 
Understanding of erythroid ALA synthetase regulation is complicated 
by the concurrent influences exerted by the processes of cell division 
and differentiation. It is possible that erythropoietin, hypoxia and 
some steroid metabolites (Meyer and Schmid, 1978; Tschudy, 1980), 
act by promoting differentiation rather than by directly increasing 
ALA synthetase activity per se (Sassa, 1976). 
Haem has, however, clearly been shown to inhibit the activity of ALA 
synthetase in reticulocytes (Karibian and London, 1965; Aoki et al, 
1971). In contrast to other rat tissues studied by Srivastava et al, the 
erythroid elements of rat spleen did not show repression of ALA 
synthetase-mRNA synthesis by haem (Srivastava et al, 1988). It 
therefore appears that erythroid ALA synthetase is subject to 
feedback control by haem. It is therefore unclear whether haem acts 
directly by inhibiting ALA synthetase activity or represses mRNA 
transcription. 
The Porphyrias 
Since the activity of the haem biosynthetic pathway is governed by 
haem requirement and the pathway is extremely efficient with less 
than 2% wastage due to unused intermediates, the finding of easily 
measurable concentrations of porphyrins or porphyrin precursors in 
tissue or excreta implies a disturbance of haem synthesis. These 
disturbances are associated with specific clinical syndromes which are 
collectively called the porphyrias. The main clinical features are 
twofold: photocutaneous sensitivity and the acute attack. The latter 
consists of mild to severe abdominal and neuropsychiatric symptoms 
and may be fatal. 
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Historical aspects of the porphyrias 
The first cases of porphyria were described in the second half of the 
19th century. In 1.874, Schultz described a case diagnosed as "atypical 
leprosy" (Schultz, 1874). Urinary pigments from this patient were 
analysed by Baumstark (Baumstark, 1874) who described them as 
having similar absorption spectra to that of iron-free haematin 
(haematoporphyrin), a compound which had been characterised some 
years previously (Hoppe-Seyler, 1871). Baumstark's interpretation of 
the origin of the urinary pigments in Scultz's patient was brilliant in its 
foresight. He believed they arose from an error of haemoglobin 
biosynthesis rather than from an error in its degradation. Some 50 
years were to pass before this idea was re-established, this time with 
"modern" scientific data (Lemberg and Legge, 1949). 
Towards the end of the 19th century there was an outbreak of a new, 
apparently acquired disease following the introduction of the 
hypnotic, Sulphonal. In 1889 Stokvis reported a 
haematoporphyrin-like pigment in the urine of a woman who had 
taken a few grams of Sulphonal, and subsequently died (Stokvis, 1889). 
This appears, in fact, to be the first description of the acute attack of 
porphyria. There were other case reports around this time, the most 
penetrating of which (With, 1976) were published in 1891 by Geill and 
Fehr who gave clinical descriptions of what they termed "Sulphonal 
poisoning" (Harley, 1890; Geill, 1891; Fehr, 1891; Bresslauer, 1891; 
Friedemeich, 1892). Simultaneously chemical studies revealed that 
the urinary pigment in "Sulphonal poisoning" was, as Stokvis had 
indicated, broadly similar but not identical to haematoporphyrin 
(Hammarsten, 1891 a,b) and in 1916 Hans Fischer showed conclusively 
that the pigment was a unique· one - "urineporphyrin" (from whence 
comes the term uroporphyrin) (Fischer, 1916). 
The first serious attempt to classify and define the porphyrias was by 
Gunther in 1911. He described a group of patients with skin sensitivity, 
who excreted large quantities of porphyrin-type pigments in their 
urine and appeared to suffer from a hereditary condition (Gunther, 
1911a,b). He subdivided porphyria into "congenital", "acute toxic", 
"acute genuine", and "chronic" forms. Remarkably, considering the 
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dearth of knowledge of porphyrin biochemistry at the time, this 
subdivision is not all that dissimilar to that in use today. Early workers 
generally used the term haematoporphyria to describe what we now 
refer to as the porphyrias. 
In the 1920's and 30's a distinct type of porphyria, characterised by the 
excessive excretion of the Ehrlich's aldehyde-reacting porphyrin 
precursor PBG and manifesting clinically with acute neuropsychiatric 
attacks but not by skin disease was recognised (Sachs, 1931: 
Waldenstrom, 1937). The term PBG, which replaced the older term 
"chromogen" was coined in 1939 by Waldenstrom, one of the fathers 
of modern porphyrinology (Waldenstrom and Vahlquist, 1939). 
Waldenstrom was largely responsible for the clinical and genetic 
description in Swedish families of what we now term acute intermittent 
porphyria. His data showed that the condition was inherited as a 
Mendelian autosomal dominant trait. In addition he documented the 
fact that unaffected relatives of clinically symptomatic patients 
excreted excess urinary PBG. This he described as "latent" porphyria 
(Waldenstrom, 1937). Waldenstrom also drew attention to the role of 
barbiturates in precipitating acute attacks. Subsequent reports 
described porphyrias with only cutaneous symptoms or "acute" 
symptoms or both (Schmid et al, 1954; Waldenstrom, 1957). The 
"mixed" type of porphyria (Watson, 1960) subsequently became 
known as variegate porphyria which is dealt with in more detail later 
in part of this dissertation. 
The efforts of Waldenstrom cannot be documented without 
mentioning the work of another pioneer of porphyrinology, Watson. 
Watsons' group were largely responsible for establishing some order 
out of descriptive chaos. Indeed, it was in a paper by his colleague 
Schmid that the concept of hepatic and erythropoietic porphyrias 
emerged for the first time (Schmid et al, 1954 ). In addition, Watsons' 
group were the first to document the existence of latency in all types 
of porphyria: "It seems quite clear that latent cases may be observed 
in any form of porphyria, but latency is much more frequent and 
prolonged in the hepatic type" (Schmid et al, 1954; page 187). 
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The period 1930-1960 witnessed the elucidation of the haem synthetic 
pathway and its disorders. The ability to correlate events in the haem 
biosynthetic pathway with the clinical features of the various 
porphyrias, allow_ed these "disturbances of haem metabolism" to be 
identified in terms of specific enzyme deficiencies. Simultaneously the 
el~cidation of the factors regulating haem biosynthesis greatly 
improved the understanding of the porphyrias as a specific family of 
diseases. 
Enzyme deficiencies and the classification of the porphyrias 
Each specific type of porphyria is associated with a characteristic 
enzyme deficiency (Brodie et al, 1977a; Elder, 1982; Kappas et al, 1983; 
Moore et al, 1987; Bloomer and Straka, 1988). In the inherited 
porphyrias as a rule the enzyme defects should be, and in many cases 
have beeri shown to be, present in ·all haem-synthesising tissue 
( assuming a single enzyme coded for by a single gene). There are a few 
exceptions to this, however, and this has led to the notion that while 
the defect is universal, its expression may be variable. Of course 
expression can only occur in cells able to synthesise haem. Thus fully 
differentiated erythrocytes, which lack mitochondria, cannot be used 
to assess defects related to coproporphyrinogen oxidase, 
protoporphyrinogen oxidase or ferrochelatase activity. 
Most of the enzyme deficiencies may be identified by the pattern of 
overproduction of haem pathway intermediates. The pattern is specific 
for each type of porphyria and generally reflects accumulation of the 
intermediates immediately prior to the defective enzyme (Elder, 
1982). 
Table 1.3 lists the various porphyrias and presents some aspects of the 
older classifications, while table 1.4 gives a current classification of the 
porphyrias in terms of the primary enzyme deficiency (Moore et al, 
1987 - with modification). The main advantage of the latter 
classification is that it remains clinically relevant. It is clear in its 
prediction of whether acute attacks are to be expected or not (acute 
or non-acute), while at the same time allowing a differential diagnosis 
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to be made based on a combination of clinical and biochemical 
features. 
While each each type of porphyria should have a unique pattern of 
porphyrin accumulation a number of the porphyrias are exceedingly 
variable and subtle in their biochemical ( and clinical) expression. Thus 
the porphyrin excretion patterns may be equivocal and thorough 
laboratory investigation is essential. 
The laboratory investigation of the porphyrias has been fully reviewed 
previously (Moore, 1983; Bissell, 1982; Moore et al, 1987) and is 
outside the scope of this dissertation. Suffice to say that most 
diagnostic laboratories employ high performance liquid 
chromatography (HPLC) or thin layer chromatography (TLC) for 
obtaining quantitative chromatographic profiles of porphyrin excretion. 
Where the diagnosis is equivocal, it is wise to determine activity of 
specific enzymes. However, at present only assays for PBG deaminase 
(for AIP), ALA dehydratase (useful for differentiating a true 
porphyria from lead poisoning or hereditary tyrosinaemia) and 
uroporphyrinogen decarboxylase (for PCT) are generally available. 
Quantitative porphyrin profiles give two vital pieces of diagnostic 
information; which porphyrin species are present and in what 
proportion or amount they are present. This is certainly of greater 
value than simple comparison of total concentrations of porphyrins 
with normal values (Day et al, 1978). The profile obtained in urine, 
stool, plasma and erythrocytes is most often, though not always, 
characteristic in each type of porphyria, almost like a "fingerprint" of 
the porphyria. Thus where fully quantitative data is not available but 
a good profile is, it may be possible to make an accurate diagnosis. 
Indeed, even when total porphyrin concentrations lie within the 
normal range, as in latent porphyria, alterations in the 
chromatographic profiles may suggest a diagnosis to the experienced 
porphyrinologist (Lim et al, 1983). 
With this background to the study of porphyrins and porphyrias, the 
disease central to this thesis, VP, will be considered. 
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Table 1.3 : The various types of porphyria, including some historical references to their 
classification and description. Note that only a selection of the older 
classifications are included. 
Porphyria 
Acute intermittent 
porphyria (AIP) 
Variegate porphyria (VP) 
Historical classification and comment 
Gunther (1911) 
Haematoporphyria acuta (and acuta "toxica'J 
Waldenstrom (1937) 
Porphyria acuta (noted "latent" form and degrees 
of severity of the acute attack) 
Schmid et al (1954) 
Porhyria hepatica tintermittent acute" type) 
Waldenstrom (1957) 
Acute intermittent porphyria 
Watson (1960) 
Porphyria hepatica (Hereditary acute 
intermittent - dominant) 
Goldberg and Rimington (1962) 
Acute intermittent porphyria 
Schmid et al (1954) 
Porphyria hepatica f'Mixed" type) 
Watson (1960) 
Porphyria hepatica (Hereditary, mixed or 
"variegate" group) 
Goldberg and Rimington (1962) 
Cutaneous hepatic porphyria 
(Hereditary form - Porphyria variegata) 
Hereditary coproporphyria First described in 1955 (Berger and Goldberg, 1955) 
(HCP) Difficult to establish when included as a distinct 
disease entity. Possibly included as "Porphyria 
hepatica, mixed group" (Waldenstrom, 1957) and 
"Cutaneous hepatic porphyria, hereditary form, mixed 
type" (Goldberg and Rimington, 1962) 
Plumboporphyria 
(PLP) 
Recently described 
(Bird et al, 1979; Doss et al, 1979) 
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Table 1.3: Continued 
Porphyria 
Porphyria cutanea 
tarda (PCT) 
- Familial 
PCT -Acquired 
(Sporadic and Toxic) 
PCT-Acquired 
(Chronic renal failure) 
PCT 
-Hepatoerythropoietic 
porphyria (HEP) 
Historical classification and comment 
Waldenstrom {1957) 
Porphyria cutanea tarda hereditaria 
Watson {1960) 
Porphyria hepatica (Hereditary cutaneous) 
Goldberg and Rimington {1962) 
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Cutaneous hepatic porphyria (Porphyria cutanea tarda) 
Gunther {1911) 
?Haematoporphyria chronica 
Waldenstrom {1937) 
Porphyria cutanea tarda 
Schmid et al {1954) 
Porhyria hepatica {'Cutanea tarda" type) 
Waldenstrom {1957) 
Porphyria cutanea tarda symptomatica 
Watson {1960) 
Porphyria hepatica (Different "causes" such as 
chemicals, systemic disease, hepatoma etc. made 
allowance for, including Turkish epidemic) 
Goldberg and Rimington {1962) 
Cutaneous hepatic porphyria (Acquired forms: 
symptomatica, "Bantu", "Turkish", porphyrin producing 
adenoma) 
Recently described 
(Korting, 1975) 
First described in 1969 
(Pinal Aquade et al, 1969) 
Characterised as ?homozygous PCT (Elder et al, 1981) 
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Table 1.3: Continued 
Porphyria Historical classification and comment 
Erythropoietic First recognised and characterised as a distinct porphyria In 1961 
protoporphyria (EPP) (Magnus et al, 1961) 
------------------------------------------------------------------------------------------ -----
Congenital erythropoletic Gunther (1911) 
porphyria (CEP) Haematoporphyria congenita 
Waldenstrom (1937) 
Porphyria congenita 
Schmid et al (1954) 
Porphyria erythropoietica 
Waldenstrom (1957) 
Congenital porphyria 
Watson (1960) 
Porphyria erythropoetica (recessive) 
Goldberg and Rimington (1962) 
Congenital (erythropoietic) porphyria 
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Table 1.4 : A current classification of the porphyrias. The terms acute and non-acute are 
used in the sense of whether the acute attack of porphyria is likely to be 
encountered or not. Synoptic comment is included. Abbreviations in Table 1.3. 
Porphyria Affected Enzyme Cutaneous Involvement 
A. Acute porphyrias 
1. 
2. 
3. 
4. 
Mainly hepatic expression 
AIP PBG deaminase No 
Comment 
Diminished PBGD activity shown in erythrocytes 1, liver2, lymphocytes3, fibroblasts4 and amniotic cells5. 
Dominant inheritance. Genetically heterogeneous8. Usually manifests postpubertally and degree of clinical 
expression highly variable and dependant on additional.,Preclpitating factors. Enzyme deficiency detectable 
from birth . Clinical syndrome more frequent in females . Majority of carriers are clinically latent throughout 
adult life8. Excessive PBG and to a lesser extent ALA and uroporphyrin in the urine. PBG, ALA and porphyrin 
levels very high in the acute attack. 
VP Protoporphyrinogen Oxidase Yes 
Comment 
Discussed in detail in Chapter 2. 
HCP Coproporphyrinogen Oxidase Yes 
Comment 
Diminished CO activity shown in leukocytes9, liver10, cultured fibroblasts11 and lymphocytes 12• Dominant 
inheritance,homozygous form 13, and a variant form with 10% CO activity (harderoporphyria) 14 have been 
described. Majority of carriers are clinically latent throughout adult life. Photocutaneous skin lesions occur 
rarely in the absence of acute attacks. Characterised by excessive excretion of coproporphyrin in the stool 
and to a lesser extent in the urine. 
PLP ALA Dehyd ratase No 
Comment 
Diminished ALAD activity in erythrocytes 15, due to enzyme structural alterations 18. Inherited recessively 17, 
homo- and heterozygotes exist 18. Presents prepubertally19. Similar to lead poisoning - characterised by 
elevated urinary ALA and coproporphyrin 
81. Non-acute porphyrias 
Mainly hepatic expression 
1. PCT Uroporphyrinogen Decarboxylase Yes 
Comment 
Many forms (see below). All characterised by deficient UROD activi~. Most common form of the porphyrias 
world-wide21 • Also referred to as the cutaneous hepatic porphyrias . Main biochemical features are elevated 
urinary and plasma uro- and heptacarboxlic porphyrin. Lesser elevations of hexa-, pentacarboxylic and 
coproporphyrin . Stool porphyrins similarly raised in addition to a striking olevaticn of isocoproporphyrin. 
REFERENCES: 
1. Strand et al, 1972 
4. Meyer, 1973 
7. Stem and Tschudy, 1970 
10. Hawk et al, 1978 
13. Grandchamp et al, 1977 
16. Doss et al, 1983 
19. Thunell et al, 1985 
22. Moore et al, 1987 
2. Miyagi, 1970 
5. Sassa et al, 1975 
8. Kappas et al, 1983 
11. Elder et al, 1976 
14. Nordmann et al, 1983 
17. Labbe and Bird, 1985 
20. Mascaro et al, 1986 
3. Sassa et al, 1978 
6. Anderson et al , 1981 
9. Brodie et al, 1977b 
12. Grandchamp and Nordmann, 1977 
15. Doss et al, 1982 
18. De Verneuil et al, 1978 
21 . Pimstone, 1982 
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Table 1.4: Continued 
Porphyria Affected Enzyme Cutaneous Involvement 
PCT continued Uroporphyrinogen Decarboxylase Yes 
(a) Familial 
Comment 
50% decreased UROD in liver23 and erythrocytes24 . Dominant inheritance. 
(b) Acquired 
- Sporadic 
Comment 
Appears as an unusual res~onse to alcohol abuse, sex steroids and some forms of iron overload 
including "Bantu" siderosis 1• 
. 
-Toxic 
Comment 
Appears in response to certain toxic chemicals, particularly polyhalogenated hydrocarbons25, 
includes "Turkish" porphyria26• 
- Chronic renal failure 
Comment 
Occurs in a small number of patients with CRF on haemodialysis27. Must be ditinguished from 
"pseudoporphyria" which resembles PCT clinically but there is no evidence of UROD deficiency22 
(c) HEP 
Comment 
UROD activity approximately 10% of normal. Probably represents homozygous familial PCT28• 
Appears to be genetically heterogeneous. Severe photosensitivity from infancy. Elevated erythrocyte 
Zn protoporphyrin is a feature29 
82. Non-acute porphyrias 
2. 
3. 
Mainly erythropoietic expression 
EPP Ferrochelatase Yes 
Comment 
Diminished FE activity found in all tissue types30• Dominant lnher.itance (probably), partial penetrance31 • 
Clinical expression highly variable32. Manifest in infancy. Homozygous state exists33. Elevated erythrocyte 
free protoporphyrin is the outstanding biochemical feature. 
CEP Uroporphyrinogen Cosynthetase Yes 
Comment 
Decreased UC activity (10-30%) has been demonstrated in erythrocytes34 and skin fibroblasts35. Recessive 
inheritance36• Manifest from infancy. Severely photomutiiating37• Characterised by accumulation of uro- and 
coproporphyrinogen-i in the erythrocytes (and plasma) . 
REFERENCES: 
23. Elder et al, 1978 
26. Schmid, 1960 
29. Smith, 1986 
32. Poh-Fitzpatrick, 1986 
35. Romeo et al, 1970 
24. De Verneuil et al, 1978 
27. Day and Eales, 1980 
30. Bloomer, 1982 
33. Deybach et al, 1986 
36. Darocha et al, 1971 
25. Silbergeld and Fowler, 1987 
28. Elder et al , 1981 
31 . Went and Klasen, 1969 
34. Romeo and Levin, 1969 
37. Nordmann and Deybach, 1986. 
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Chapter Two 
Variegate porphyria - Review 
The following is a review of VP based not only on the literature; but 
also on the knowledge systematically accumulated over approximately 
35 years by the Porphyria Service of the Department of Medicine, 
University of Cape Town and Groote Schuur Hospital.It is appropriate 
to refer to the outstanding contribution to the clinical biochemistry 
and medicine of the porphyrias made by Professor Lennox Bales who 
headed this unit from 1957 till his retirement in 1983. Indeed, his 
review of VP, based on some 300 index cases (Bales et al, 1980), 
remains one of the most comprehensive descriptions to date. It is of 
interest that the first South African case report of porphyria was that 
of Bales, who, in 1939, as a young 5th year medical student, wrote a 
brilliantly perceptive description of what he called acute idiopathic 
porphyria, now presumed to be a case of AIP (Bales and Chait, 1939). 
Shortly thereafter a further case of acute porphyria was reported in the 
South African medical literature (Kooy, 1939). 
VP in South Africa 
The origins of VP in South Africa 
An unusually high incidence of porphyria was noted in South Africa 
during the late 1940's and 1950's (Barnes, 1945; Barnes, 1951; Dean, 
1953; Dean and Barnes, 1955; Dean and Barnes, 1959) and by the early 
1960's it was realised that the incidence of porphyria in South Africa 
was amongst the highest, if not the highest in the world (Dean and 
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Barnes, 1959; Sweeney, 1963; Bales, 1963). Further investigation 
resulted in fascinating genealogical studies in which the unusually high 
prevalence of VP, particularly amongst white Afrikaner and coloured 
(mixed-descent) South Africans was ascribed to a founder effect 
(Dean, 1971) amongst the early settlers in South Africa. The term 
"variegate", which refers to the presence of either, neither or both skin 
lesions and acute attacks, arose from early case reports from South 
Africa (Dean and Barnes, 1959) though the first description of VP was 
probably in 1937 (Van der Bergh and Grotepass, 1937). VP is inherited 
as an autosomal dominant trait (Dean and Barnes, 1955; Bales et al, 
1971) and is thought to have been imported to the Cape Colony in 1688 
by a Rotterdam orphan, Ariaantjie Ariens, who was part of a 
contingent of young women sent to the Cape as potential wives for the 
Free Burghers, or early Dutch settlers. She married Gerrit J ansz van 
Deventer. Which of these two carried the VP gene is not proven, but 
approximately 50% of their offspring appear to have inherited the trait 
(Dean, 1971). For the next two centuries, the disease appears to have 
been relatively benign, perhaps because the absence of potent 
pharmacological agents limited the number of acute attacks. Thus the 
founder effect was sufficient to result in widespread distribution of the 
trait. 
VP on a world-wide basis 
Interestingly, although the VP gene in South Africa almost definitely 
originated from the Netherlands, no direct family link between Dutch 
VP families and South African patients has been found (te Velde and 
Noordhoek, 1970; Bales et al, 1980). VP is found in other parts of the 
world, but it is infinitely less common than it is in South Africa. Most 
other cases have been reported from Europe, especially Finland and 
Gr.eat Britain, and the USA (Barnes et al, 1965; Hamnstromet al, 1967; 
Baxter and Permowicz, 1967; Cochrane and Goldberg, 1968; Freinkel 
and Ashman, 1974; Fowler and Word, 1975; Wechsler, 1975; Mustajoki 
and Koskelo, 1976; Fromke et al, 1978; Corey et al, 1980; Muhlbauer 
et al, 1982; Kostrzewska and Gregor, 1982; Martasek et al, 1983; Day, 
1986). A few patients have been described in India (Bhargova and 
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Gupta, 1970; Randa et al, 1975) and Taiwan (Tu et al, 1970). VP is also 
known to exist in Australia (personal communication, Potgieter K). 
There are also individual cases described in a Curacao Negroid woman 
(Van der Sar and Den Ouden, 1976) and an American black man 
(Hughes and Davis, 1983) but both are of unspecified ancestry. 
Whether VP occurs in any subjects of pure Negroid descent is unclear. 
Homozygous VP has been described in Europe (Kordac et al, 1984; 
Murphy et al, 1986) but not conclusively in the South African VP 
population to date (Cartwright et al, 1978; Kramer, 1980). 
Current experience in South Africa 
Two important misconceptions have arisen in South Africa: that VP 
is a disease of Afrikaners, and that it is limited to white South Africans. 
Both are dangerous generalisations which give rise to both missed and 
mis-diagnoses. In the early days of the Cape Colony interracial 
marriage was common and this led to a founder effect amongst 
coloured South Africans. Furthermore, many so-called "English" 
South African families have had the gene for several generations so 
that the apparent lack of an Afrikaner connection cannot be used to 
exclude the disease. 
Estimates of the incidence of VP based on genealogical data have been 
as high as 3 per 1000 within the white Afrikaner population alone 
(Dean and Barnes, 1955; Dean and Barnes, 1958). Current estimates 
put the total figure of affected individuals between 10000 and 20000 
(Bales et al, 1980; Day, 1986). No accurate figure exists. Many subjects 
with the disease remain asymptomatic throughout their lives and, like 
AIP, VP is only rarely manifest before puberty (Eal es and Dowdle, 
1968; Mustajoki and Koskelo, 1976). Even the most characteristic 
biochemical feature, elevated faecal protoporphyrin may not be 
unequivocally raised on occasion (Bales, 1960; Hamnstrom et al, 1967; 
Mustajoki, 1978; Day, 1986). The biochemically latent carrier is 
impossible to detect at present. These major limitations make accurate 
determination of gene prevalence impossible. 
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Figures representing the number of new cases of porphyria diagnosed 
by our Centre (situated in the Western Cape, population ±3.5 million) 
per year (figure 2.1) show that there has been an increase in the 
number of VP cases diagnosed since 1978 when fully quantitative TLC 
porphyrin measurements of urine, stool and blood replaced the 
original solvent extraction technique, with more new cases of VP 
diagnosed in 1988 than in any other year during this period. 
Since an adaptation of the fluorometric TLC method was introduced 
in the Northern Transvaal region of South Africa in 1985, there has 
been a dramatic increase in the number of VP patients diagnosed there 
too (Day, 1986; Personal communication, Hitzeroth H). There could 
thus be a substantial pool of undiagnosed VP carriers in large areas of 
South Africa where less accurate methods of diagnosis are in use. 
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Figure 2.1 : Number of individuals with VP diagnosed per year since 1975 (new cases). The 
number of AIP and PCT cases are included for comparison. 
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The acute attack of VP 
Clinical features of the acute attack 
This description is based on data from more than 160 acute attacks of 
VP documented in our Centre. Some of this data has formed the basis 
of previous publications (Bales et al, 1980; Disler and Moore, 1985; 
Day 1986; Meissner et al, 1987). Studies of the acute attack in AIP and 
HCP have shown a similarity of the acute attack for all of the acute 
porphyrias (Bloomer, 1976; Meyer and Schmid, 1978; Mustajoki, 
1978; Kappas et al, 1983). In our studies acute attacks occurred three 
times more frequently in women than men, 70% occurred in the 20-40 
year age group; and repeated attacks in the same patient were 
relatively common. Although the acute attack is thought to occur more 
frequently in AIP than in VP it is an ever-present risk in both (Bales 
et al, 1980). The acute attack consists of varying combinations of 
abdominal, cardiovascular, psychiatric and neurological features. 
The incidence of the main symptoms and signs are given in table 2.1. 
Abdominal pain (present in 93% of cases) was the presenting 
complaint in most of the Cape Town series. The pain was "often severe 
but accompanied by rather unimpressive signs". It was usually 
continuous, deep-seated and gnawing with fluctuations in intensity 
which at times became intolerable, "leading to incessant pleas for 
medicinal relief" ( quotes from Bales et al, 1980). The pain was most 
frequently situated in the upper abdomen, especially in the 
epigastrium, but could also affect the central area or the right or left 
iliac fossae. Palpation usually evoked complaints of severe tenderness 
but did not reveal true rigidity or rebound tenderness. Gastrointestinal 
disturbance resulting in constipation, vomiting and ileus was fairly 
common. Diarrhoea was rare. · 
Autonomic instability resulting in hypertension and tachycardia 
frequently occurred during the early stages of the acute attack. These 
features were occasionally associated with marked orthostatic changes 
in blood pressure. A severe anxiety state was also invariably present. 
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Table 2.1: Clinical presentation of the acute attack of VP. Based on Ea/es et al, 1980, Dis/er 
and Moore, 1985 and Meissner et al, 1987. 
Symptoms % 
Abdominal pain .......... 93 
Vomiting ............ . .. . 70 
Pain in limbs . . . . ......... 50 
Pain in back ............. 50 
Coristipation ........ . ... 43 
Confusion . . . . ........... 32 
Urinary frequency . . ...... 30 
Dysuria .. ... ..... ... .... 28 
Abnormal behaviour . .. ... 23 
Seizures ... ... . . . ... ... . 12 
Diarrhoea .... . . . ....... . . 5 
Stupor ..... .... . .. . . . ... 3 
Physical Findings % 
Tachycardia ......... .. .. 75 
Hypertension . . . . . . . . . . . . 55 
Motor neuropathy . . . . . . . . . 53 
Pyrexia . ... .... .. ....... 38 
Leucocytosis . . . . . . . . . . . . 20 
Bulbar involvement . . . . . . . . 18 
Sensory loss . . . . . . . . . . . . . 15 
Proteinuria . . . . . . . . . . . . . . . 8 
Cranial nerve involvement . . . 2 
This, plus a tendency to overreact and to hyperventilate, often led to 
the patient being labelled as hysterical. 
Neurological signs included encephalopathy, possibly with 
generalised seizures, and paraesthesia which often preceded the onset 
of a predominantly motor peripheral neuropathy which occasionally 
involved the respiratory muscles. Psychiatric disturbances included 
confusion and abnormal behaviour, in addition to the anxiety state 
already mentioned. 
Acute attacks may be associated with leucocytosis and an elevated 
erythrocyte sedimentation rate. The most frequent abnormal routine 
biochemical finding was hyponatraemia which was present in 95% of 
cases (Disler and Moore, 1985). In half these attacks sodium 
concentration was less than 120mmol/l. Dehydration was also present 
in some cases. Hypokalaemia, hypomagnesaemia, hypocalcaeinia, 
hypochloraemia and alkalosis were recorded on a few occasions. 
In VP in particular, patients appear to be subject to milder versions of 
the acute attack than in AIP, complaints of pain, nausea or malaise 
often being the only symptoms. Furthermore, we have noted a marked 
decrease in the incidence of central nervous system involvement over 
the last decade. 
Variegate porphyria - Review 47 
Pathogenesis of the acute attack 
The symptoms of the acute attack can be explained almost entirely on 
a n:eurogenic basis (Moore et al, 1987). Despite many studies however, 
the pathogenesis of the neurologic manifestations remains uncertain. 
Intermittent ischaemia, abnormal myelin or heavy metal metabolism, 
impaired synthesis of acetylcholine, and depletion of essential 
substrates or cofactors such as pyridoxal phosphate, zinc and glycine 
have all been considered as mechanisms (Bonkowsky and Schady, 
1982; Bloomer and Straka, 1988). The two hypotheses most favoured 
are first; the direct neurotoxic effects of ALA and/or PBG, the 
concentrations of which are always grossly elevated during the acute 
attack (see below), and second; the possibility of a haem deficiency in 
neural tissue, or indirectly in liver. These two hypotheses are not 
necessarily mutually exclusive. For example neurons with a partial 
defect in haem synthesis could be uniquely susceptible to ALA toxicity, 
alternatively ALA might potentiate the effect of neural haem 
deficiency (Bonkowsky and Schady, 1982; Moore et al, 1987). 
Neurotoxicity of ALA and/or PBG 
Neuropsychiatric symptoms of porphyria are always associated with 
increased excretion of ALA and PBG. This has led to the belief that 
these compounds are neurotoxic. PBG is thought by some to be able 
to inhibit synaptic transmission (Feldman et al, 1971); however, this 
claim has not been universally supported (Goldberg et al, 1954; Loots 
et al, 1975; Nicoll, 1976). 
ALA is a more likely to be neurotoxic. Neurological abnormalities 
reminiscent of acute porphyria are found in other disorders in which 
ALA excretion is increased. These include lead poisoning (Moore and 
Goldberg, 1985) and hereditary tyrosinemia (Gentz et al, 1969; 
Lindblad et al, 1977). Furthermore, ALA is neurotoxic when injected 
into the brain ventricles of experimental animals (Shanley et al, 1975; 
McGillion et al, 1975). In crayfish neuromuscular preparations 
short-term exposure to 2x10-5M ALA, a concentration seen in the 
plasma of porphyric patients during an acute attack, resulted in a 
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reversible misfiring of electrically stimulated neurons (Bonkowsky 
and Schady, 1982). ALA also inhibits brain Na+ ,K +-ATPase in vitro 
(Becker et al, 1971; Russell et al, 1983), though relatively high 
concentrations of ALA (lo-4 and 10-3M) were required for this effect. 
ALA is a partial agonist of and is structurally similar to 
gamma-aminobutyric acid (GABA), a major inhibitory 
neurotransmitter. It is possible that ALA may mimic or antagonise the 
effects of GABA, depending on the circumstances: At relatively high 
concentrations (1 to sx10-5M) ALA may compete for 
GABA-receptors of rat brain synaptosomes (Muller and Snyder, 1977; 
Brennan et al, 1980). At lower concentrations (10-4 to 10-6M) ALA 
inhibits K + -stimulated release of GABA from loaded synaptosomes 
(Brennan and Cantrill, 1979). 
Despite these . findings, the major difficulty in ascribing the 
neurological symptoms to ALA is the poor correlation of the severity 
of acute symptoms with serum and urinary ALA concentrations. Some 
patients remain asymptomatic despite excreting large amounts of 
ALA. Furthermore, ALA is not consistently present in the 
cerebrospinal fluid of patients during acute attacks of porphyria 
(Bloomer, 1982). 
Haem deficiency (and haematin administration) 
Neuronal haem deficiency has been suggested as a cause of the acute 
attack. Such deficiency could conceivably limit the formation of 
important haemoproteins thereby influencing normal nerve 
functioning (Shanley et al, 1977). 
Brain tissue appears to be capable of synthesising haem, although it is 
much less active than in hepatic and erythropoietic tissue. ALA 
synthetase has been identified in rat brain (Barnes et al, 1971; 
Paterniti, 1978b; Percy and Shanley, 1979; De Matteis et al, 1981) and 
in cultured dorsal root ganglia (Sassa et al, 1979). Low levels of ALA 
and PBG, total porphyrins and cytochrome P450 are present in brain 
tissue. Indeed, brain tissue has been shown to be able to perform 
certain haemoprotein-dependent functions (Cohn et al, 1977; Paul et 
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al, 1977; Sassaet al, 1979). It is not clear, however, whether regulation 
of haem synthesis in neural tissue is subject to negative feedback 
control by haem. Furthermore it is not certain whether brain ALA 
synthetase is induced by known inducers of hepatic ALA synthetase 
(Paterniti et a[, 1978b; Percy and Shanley, 1977; De Matteis, 1981). It 
is possible that neural tissue haem may, at least in part, be supplied 
from other sources such as the liver. This supply could be impaired 
during an acute attack when intrahepatic haem is depleted (Bissell, 
1985). However, it is currently unclear whether inherited defects of 
haem biosynthesis actually result in haem depletion in neural tissue. 
Another theoretical mechanism by which hepatic haem deficiency may 
lead to altered neurological function concerns the requirement that 
tryptophan pyrrolase ( the rate-controlling enzyme for the degradation 
of tryptophan) has for haem. Tryptophan pyrrolase activity is reduced 
when free haem availability is decreased (Druyan and Kelly, 1972). 
This has been linked to the regulatory free haem "pool" and to the 
effects of porphyrinogenic drugs (Badawy and Evans, 1973; Badawy 
and Morgan, 1980; Badawy et al, 1981). Decreased activity of 
tryptophan pyrrolase results in elevation of plasma levels of 
tryptophan, increased tryptophan uptake by the brain, and increased 
levels of neuroactive metabolites such as 5-hydroxytryptamine 
(serotonin) (Litman and Correia, 1983). It is significant that serotonin 
administered to humans results in abdominal pain, psychomotor 
disturbances and other symptoms reminiscent of the acute attack of 
porphyria (Douglas, 1980). 
Haematin has been used successfully in the treatment of acute 
porphyric symptoms (Bonkowsky et al, 1971; Watson et al, 1973; Dhar 
et al, 1975; Watson et al, 1978). The efficacy of administration of 
haematin is consistent with any of the above hypotheses. Administered 
haem suppresses ALA synthetase, reducing overproduction of ALA 
and PBG (McColl et al, 1979); it could supply the nervous system 
directly with haem and, in repleting hepatic haem, it may restore 
tryptophan pyrrolase to full activity thereby "normalising" serotonin 
levels (Litman and Correia, 1983). 
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Factors precipitating the acute attack 
Most patients with VP go through life without ever experiencing an 
acute attack (Bales, 1963; Bales et al, 1980; Day, 1986). Indeed, as 
illustrated by the relatively benign nature of the disease prior to the 
introduction of powerful pharmacological agents during the early part 
of this century, haem biosynthetic enzyme deficiencies only become 
hazardous when some factor or factors further increase ALA 
synthetase activity. Known precipitating factors include many drugs, 
synthetic steroid hormones, alcohol, physiological hormone 
fluctuations, infection, fasting and stress (Bales, 1971; 'Ischudy, 1978; 
Kappas et al, 1983; Disler and Moore, 1985). Many Porphyria Units 
have drug information available in the form of "Porphyria Drug Lists" 
which are normally composite lists compiled from reported, anecdotal 
and experiential information. An extract from a porphyria information 
booklet compiled by our Centre (Hift et al, 1989a) is included as 
Appendix 2 and comprises such a drug list. Spontaneous acute attacks 
precipitated by hormonal fluctuations related to the menstrual cycle 
(McColl et al, 1982) appear to be more of a problem in AIP than in 
VP. 
Several different mechanisms may be involved in the induction of an 
acute attack. AU appear ultimately to result in either direct or indirect 
induction of A1A synthetase activity. The most obvious mechanism is 
an increase in the production of cytochrome P 450 synthesis resulting 
in depletion of the haem "pool" and thus derepression of A1A 
synthetase synthesis (Kappas et al, 1983). Other agents may exert their 
effect by inhibiting enzymes of the haem biosynthetic pathway 
resulting in decreased free haem concentration (Moore and Disler, 
1983). Alcohol possibly acts via both routes (Moore et al, 1984). The 
exact mechanism is complex and beyond the scope of this dissertation. 
Similarly, the precise mechanisms by which hormones, fasting, stress 
and infections precipitate the acute attack remains to be shown 
(Moore et al, 1987). 
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Incidence of the acute attack 
Figure 2.2 shows the incidence of acute attacks admitted to the Groote 
Schuur group of hospitals (which covers the Western Cape) between 
the years 1957 and 1988. Note the dramatic lowering of the incidence 
of VP acute attacks from 63 in the 10 years spanning 1957-66 to 11 in 
the 12 years, 1977-88. Acute attacks of AIP are included for 
comparison and have remained constant. The falling incidence of 
acute attacks of VP may reflect both identification and education of 
patients, or a change in the prescribing habits of South African doctors. 
However, the observation that the number of admissions of patients 
with AIP has not decreased suggests that currently-used drugs still 
precipitate acute attacks. While 21 patients died at Groote Schuur 
Hospital as a result of acute attacks of porphyria between 1954 and 
1973, there have been no deaths due to porphyria recorded in our 
hospital in the last 16 years, though we are aware of deaths in the wider 
community. 
With increasing awareness of porphyria, the major acute attack has 
definitely become rarer, and those acute attacks seen are milder than 
those cared for in our unit 20 to 30 years ago. 
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70 
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Figure 2.2: Incidence of the acute attack of VP and AIP in the Groote Schuur group of hospitals 
over the last 32 years. 
52 Chapter2 
Treatment of the acute attack 
A guideline on the management of the acute attack is given in 
Appendix 3. The approach described is that practised by our unit and 
has been extracted from our porphyria information booklet (Hift et al, 
1989a). 
The outcome of the acute attack is greatly influenced by the time taken 
before the correct diagnosis is made (Meissner et al, 1987). The 
principles of management are to remove and subsequently avoid any 
precipitating factors (Moore et al, 1987), to alleviate symptoms (Disler 
and Moore, 1985) and to apply specific measures aimed at decreasing 
porphyrin production by decreasing AIA synthetase activity. 
Cutaneous manifestations of VP 
Clinical features 
(Eales, 1963, 1980; Mustajoki, 
1978; Corey et al, 1980; Day, 
1986, Moore et al, 1987) 
The cutaneous features of VP are characterised by photosensitivity 
and increased fragility of the skin in sun-exposed areas, especially the 
face, the neck and the back of the hands. Minor trauma leads to 
blistering and to well-defined eroded areas. The lesions tend to be 
superficial and although they may heal without scarring, they are 
inclined to leave the patient with hyper- or hypopigmentation, atrophy 
and a disfigured skin. With repeated trauma and sun-exposure some 
patients develop pseudoscleroderma of the hands. Hypertrichosis is 
not uncommon. In females in particular, growth of a downy hair on the 
sides of the face may be noticed. Characteristically patients 
demonstrate a combination of lesions ranging from fresh blisters 
through pigmented and depigmented scars. Photocutaneous 
involvement in VP is identical to that observed in PCT (Bickers et al, 
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1979; Mascaro et al, 1986) and much of our understanding of the 
pathogenesis of the cutaneous lesions of VP comes from studies of the 
identical lesions associated with PCT. 
Pathogenesis of the photocutaneous symptoms 
(Spikes, 1975; Poh-Fitzpatrick, 
1985; Day, 1986) 
Although there is evidence to suggest that the photoactivity of excess 
porphyrins in the plasma and/or skin are involved in all types of 
cutaneous porphyria, the precise underlying mechanisms are not fully 
understood. The generally accepted hypothesis revolves around the 
absorption of photons of near ultraviolet light ( 400nm) by porphyrin 
molecules to produce a singlet-excited state. Excited porphyrin 
molecules in the singlet state are thought to react directly with 
biomolecular targets via a free radical mechanism. Alternatively 
singlet-excited porphyrin molecules may convert to the metastable 
triplet-excited state, allowing transfer of the excitation energy to 
molecular oxygen, producing potentially destructive singlet oxygen 
( oxygen free radical). 
Other hypotheses follow on a report of the activation of · the 
complement system by porphyrins plus appropriate wavelengths of 
ultraviolet light (Lim et al, 1984; Torinuki, 1985). This system is the 
most probable mechanism for endothelial damage in porphyria. The 
various hypotheses are not mutually exclusive. Indeed different 
mechanisms may act synergistically to amplify tissue injury (Meurer et 
al, 1985). 
A puzzling aspect of the cutaneous lesions of VP is the lack of 
correlation between circulating plasma porphyrin concentrations and 
cutaneous symptoms in VP and further, that the porphyrin profiles 
measured in skin biopsies from VP subjects did not resemble the 
plasma porphyrin profile (Day et al, 1978). Uro- and heptacarboxylic 
porphyrin rather than copra- and protoporphyrin were the 
predominant porphyrin species present in the skin (Day, 1986). It has 
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therefore been suggested that excess porphyrins may be synthesised 
locally, in the dermis. It has also been suggested that the pattern of 
porphyrin accumulation may be a result of porphyrin catalysed 
photoinactivation of uroporphyrinogen decarboxylase by uro- and 
coproporphyrin (Batlle, 1986; Day, 1986) 
Incidence of cutaneous features 
The incidence and severity of the photocutaneous features of VP seem 
to vary with the geographic location. The South African experience 
suggests that men and women are similarly affected, 60-70% of our 
cases exhibiting cutaneous lesions (Bales, 1963; Bales et al, 1980). This 
figure is not truly representative in that it excludes subjects who in all 
probability have VP but do not show an unequivocal porphyrin 
excretory pattern. The number of entirely asymptomatic patients 
could therefore be large (Bales, 1961; Mustajoki, 1978; Day, 1986). 
Indeed, a systematic study of 45 patients in Finland revealed that half 
had no skin disease at all (Mustajoki and Koskela, 1976). On the other 
hand the South African figure of approximately 70% with skin 
involvement may be an accurate figure and may simply be higher 
because of more frequent and severe sun exposure. Of the Finnish 
group the half that did exhibit cutaneous involvement were only mildly 
affected, almost certainly because of the lower exposure to sunlight 
than that experienced by South African patients (Mustajoki, 1978; 
Muhlbauer et al, 1982). 
Treatment of the skin lesions 
Treatment of the cutaneous lesions in VP is generally of a prophylactic 
nature. Patients should be advised to minimise skin trauma and to 
avoid sun exposure wherever possible, particularly in the middle part 
of the day. This includes the use of protective clothing, hats etc. and 
application of opaque sun barrier creams containing zinc oxide or 
titanium dioxide. Good skin care must · be vigorously encouraged. 
More recently, activated charcoal has proved to be of value in the 
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treatment of the cutaneous manifestations of congenital 
erythropoietic porphyria (Pimstone et al, 1987). However, a twelve 
week trial designed to study the effect of charcoal treatment 
specifically in VP , failed to elicit a favourable response in seven VP 
patients with active skin lesions (Hift et al, 1989b). 
Biochemical description of VP 
Porphyrin and porphyrin precursor excretion 
Detailed description of porphyrin and porphyrin precursor excretion 
patterns in urine, and porphyrin patterns in stool, blood and other 
tissues has led to recognition of a characteristic biochemical profile of 
VP (Mustajoki, 1978; Day, 1986). This typical porphyrin excretory 
profile of VP is summarised in table 2.2 and examples of TLC tracings 
from VP patients are shown in figure 2.3. 
The most striking feature is an elevated faecal concentration of 
protoporphyrin and, to a lesser extent, of coproporphyrin. (Other 
helpful diagnostic markers are illustrated in figure 2.3). It is important 
to stress that since only the reduced porphyrinogens are metabolized 
in haem synthesis (until the formation of protoporphyrin by 
protoporphyrinogen oxidase ), it can be assumed that excesses of 
protoporphyrinogen and coproporphyrinogen must exist 
intracellularly. It is probably only once these intermediates are being 
excreted or have been excreted by the cell that spontaneous oxidation 
to their porphyrin form is facilitated. The environment within the cell 
is such as to facilitate reduction; that within the mitochondrion, where 
excess protoporphyrinogen would first be formed, even more so. 
Indeed, porphyrinogens have been measured in excreta of porphyric 
patients (Bloomer and Straka, 1988) confirming that porphyrinogens 
do accumulate in at least some of the porphyrias. 
The above features are present both during remission and in the acute 
attack. During the acute attack the concentrations of proto- and 
coproporphyrin are further increased and are accompanied by 
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Table 2.2: Main biochemical features in VP as generally experienced Reference 1, Moore 
et al, 1987; Reference 2, Bloomer and Straka, 1988. Various authors place 
differing emphases on these features as well as on other characteristic d~talls 
not presented in this table. 
REFERENCE 1 REFERENCE 2 
Re1J7ission Relapse 
URINE 
ALA Raised in Normal Moderately 
attack increased 
PBG Raised in Normal Moderately 
attack increased 
Uroporphyrin Usually raised Normal Moderately 
in attack increased 
Coproporphyrin Usually raised Normal or Markedly 
in attack mildly increased 
increased 
STOOL 
Coproporphyrin Raised Mildly Moderately 
increased increased 
Protoporphyrin Raised Moderately Markedly 
increased increased 
increases in the more proximal porphyrin intermediates, in particular 
uroporphyrin. In addition the acute attack is invariably associated with 
grossly elevated concentrations of ALA and PBG in the urine. 
The varied clinical and biochemical findings in VP have given rise to 
terms such as "latent VP", "silent VP", "prepubertal VP" and "dual 
porphyria" (Day, 1986). Two terms are used in this thesis, "quiescent 
VP" and "acute VP". These require definition. Quiescent VP will be 
used to describe subjects in whom porphyrin metabolic abnormalities 
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Figure 2.3: Typical TLC tracing obtained in the stool from a quiescent VP patient (A). A porphyrin 
excretion profile representing the normal population (8) is included for comparison. 
Protoporphyrin level in A calculated to 147 4 nmol/g dry weight and coproporphyrin to 207 nmol/ 
g dry weight. B's levels were 181 and 13 nmol/g dry weight respectively. The peak marked 
"pseudo" (pseudo-pentacarboxylic porphyrin) is a useful diagnostic marker of VP. It appears to 
be present in approximately 83% of VP cases in our laboratory and is thought to be an 
hydroxylated dicarboxylic porphyrin (Day, 1986 and personal communication, Smith SG, Day 
RS, Moore MR). 8COOH, uroporphyrin; 7COOH, heptacarboxylic porphyrin; 6COOH, 
hexacarboxylic porphyrin; 5COOH, pentacarboxylic porphyrin; 4COOH, coproporphyrin; 
3COOH, harderoporpyhrin; 2COOH, protoporphyrin. 
are present in the stool, plasma and sometimes urine; photocutaneous 
clinical features may be present but there is no clinical evidence of an 
acute attack.Acute VP will be used to describe patients in whom there 
are clinical features of an acute attack accompanied by pronounced 
increases in urine, stool and plasma porphyrin concentrations as well 
as marked elevation of urinary ALA and PBG. 
Further detailed comment on our experience of porphyrin excretion 
patterns is given in Appendices 13 and 14 ( to which the reader will be 
referred in Chapter 7). 
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The primary enzymatic "block" in VP 
Most studies indicate that a deficiency of protoporphyrinogen oxidase 
activity is the primary enzyme defect in VP. Although a 50% reduction 
in ferrochelatase activity in VP was reported and could explain the 
preponderance of stool protoporphyrin in this condition (Viljoen et al, 
1979), other workers have reported normal ferrochelatase activity in 
a variety of tissues from VP patients (Pimstone et al, 1973; Becker et 
al, 1977; Siepker and Kramer, 1985). In addition, a deficiency in 
ferrochelatase is unequivocally associated with EPP, a porphyria which 
is biochemically and clinically distinct from VP (Bonkowsky et al, 1975; 
De Goeij et al, 1975; Bottomley et al, 1975). 
In contrast, an approximately 50% decrease in activity of 
protoporphyrinogen oxidase has consistently been reported in all VP 
tissues studied to date. These include fibroblasts (Brenner and 
Bloomer, 1980a), lymphocytes (Deybach et al, 1981), Epstein-Barr 
virus transformed lyrnphoblasts (Meissner et al, 1986) and leukocytes 
(Viljoen et al, 1983; Boyle et al, 1986) in VP. A defect in 
protoporphyrinogen oxidase would result in accumulation chiefly of 
protoporphyrinogen which would be evident in the stool in its oxidised 
form, protoporphyrin. The elevation of coproporphyrin can be 
ascribed to "backing up" of the substrates immediately prior to 
protoporphyrinogen. It is of interest that cultured fibroblasts from VP 
patients have been shown not to accumulate protoporphyrin, 
purportedly as a result of the "exclusive" hepatic expression of VP, yet 
protoporphyrinogen oxidase has been shown to be decreased in 
fibroblasts (Brenner and Bloomer, 1980a). 
Other haem biosynthetic enzymes in VP 
The activities of the more proximally situated haem synthetic enzymes 
have not been systematically investigated in any large series of VP 
patients. Some information on ALA synthetase and PBG dearninase 
activity in VP is nevertheless available. 
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Leucocyte ALA synthetase activity was significantly raised in six cases 
of quiescent VP whereas erythrocyte PBG deaminase activity was 
normal (Moore et al, 1980). Another study has reported raised hepatic 
ALA synthetase activity in one patient with quiescent VP (Dowdle et 
al, 1967). Erythrocyte PBG deaminase activities have been reported 
to be normal in patients with quiescent VP. Close examination of these 
reports reveal that PBG deaminase levels lie towards the lower limit 
of the quoted normal range (Magnusson et al, 197 4; Brodie et al, 1977a; 
Doss and Von Tiepermann, 1978) and, in some cases, slightly below 
the normal range of PBG deaminase activity (Mustajoki, 1976; McColl 
et al, 1985). PBG deaminase activity is most certainly never raised. 
In the light of the above it is apparent that VP is one of the lesser 
studied porphyrias, no doubt due to its relative rarity. The remainder 
of this thesis is concerned with the formulation and testing of two 
linked hypotheses aimed at understanding the underlying mechanisms 
which may result in elevated concentrations of ALA and PBG 
associated with the acute attack of VP. 
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Chapter Three 
Formulation of the hypothesis 
One of the most fascinating areas in VP is the increase in ALA and 
PBG concentrations associated with the acute attack. Indeed, all three 
of the acute porphyrias have elevated ALA and PBG concentrations 
during acute attacks. The increase in ALA and PBG is easily explained 
in AIP (where there is diminished PBG deaminase activity) but not in 
HCP and VP where the enzyme defects ( coproporphyrinogen oxidase 
and protoporphyrinogen oxidase) involve the distal portion of the 
haem biosynthetic pathway. The consistent finding of elevated 
concentrations of ALA and PBG in the acute porphyric attack plus the 
evidence suggesting that these precursors may be involved in the 
pathogenesis of the acute attack underline the need for understanding 
why they should be increased during the acute attack of VP. This 
chapter reviews the current explanations for the increased ALA and 
PBG found during the acute VP attack and formulates the hypothesis 
which forms the basis of this thesis. 
Current explanations 
Damming up of intermediates proximal to the enzyme block 
This theory is based on the assumption that precursor excretion in VP 
results from a single distally situated, inherited enzyme block at the 
level of protoporphyrinogen oxidase. It therefore implies that there is 
sequential damming up of intermediates prior to the block, which, 
during the acute attack extends to include ALA and PBG. 
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There are a number of arguments against this. Increased 
concentrations of ALA and PBG are not found in PCT where large 
amounts of uroporphyrinogen, the haem intermediate only one step 
distal to PBG, accumulate as a result of a defect in uroporphyrinogen 
decarboxylase (Pimstone, 1982; Mascaro et al, 1986). Secondly, there 
is little precedent for this in other pathways of intermediary 
metabolism, the effects of a partial block in a pathway normally only 
resulting in build up of intermediates one to two, and never to six steps 
behind the block. 
PBG deaminase as a second rate limiting enzyme 
There is universal agreement that ALA synthetase. has the lowest 
relative activity and is rate limiting for the haem biosynthetic pathway. 
PBG deaminase appears to exhibit the second lowest activity in the 
pathway and clearly differs from all the other haem synthetic enzymes 
which possess far greater activities than either ALA synthetase or PBG 
deaminase (see table 1.2). 
ALA synthetase, however, is highly "inducible", at least in the liver. 
Under these circumstances PBG deaminase becomes rate limiting. 
Thus induction of ALA synthetase would result in accumulation of 
ALAandPBG. 
It appears logical that ALA synthetase should be slightly derepressed 
at all times in all so-called "haem deficiency" porphyrias since 
provision of additional substrate might be expected to maintain haem 
synthesis. Indeed, ALA synthetase activity has been shown to be 
increased in all types of porphyria (Brodie et al, 1977a; Meyer and 
Schmid, 1978; Moore et al, 1980; Elder, 1982). Since PBG deaminase 
is probably rate limiting in all of the "haem deficiency" porphyrias any 
further decrease in its activity might be expected to have a profound 
influence on ALA and PBG concentrations. 
It is of course important to bear in mind that haem synthetic regulation 
differs in various tissues. While the primary enzyme deficiency in the 
inherited porphyrias is thought to be present in all cells types, the 
compensatory changes in ALA synthetase activity and substrate 
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overproduction may be restricted to certain tissues (Elder, 1982). 
Although the excess haem synthetic intermediates observed in VP are 
believed to originate mainly in the liver, it is interesting to note that 
increased ALA synthetase activity in quiescent VP has been measured 
in both liver (Dowdle et al, 1967) and in leucocytes (Brodie et al, 1977a; 
Moore et al, 1980). Thus excess intermediates could conceivably 
originate from extrahepatic tissue. Also, there is evidence to suggest 
that excess intermediates in quiescent and acute VP are synthesised in 
the kidney (Day et al, 1981; Day andEales, 1982)while the excess stool 
porphyrins may originate in the intestinal tract (Day et al, 1980). Thus 
the regulation of haem biosynthesis and the resultant substrate 
acGumulation in various tissues is complex and is not well understood. 
If PBG deaminase is important in explaining the increased ALA and 
PBG seen in the acute porphyrias, the absence of such accumulations 
in PCT, EPP and CEP also requires attention. In these porphyrias, 
PBG deaminase never appears to be rate-limiting in spite of reported 
increases in leucocyte ALA synthetase in all three (Moore et al, 1980) 
and hepatic ALA synthetase in clinically "active" PCT (Dowdle et al, 
1967). In EPP and CEP the explanation could involve their erythroid 
expression. But PCT, an "hepatic" porphyria, remains anomalous in its 
behaviour, assuming the haem pathway is subject to the same synthetic 
demands as in the acute porphyrias. Some workers have suggested that 
PBG deaminase is increased in these conditions but such increases are 
small and not present in all patients. Alternatively differences in 
permeability of the hepatocyte to different haem substrates has been 
suggested (Elder, 1982). If true, a particular substrate could be 
confined to a small space so that a relatively small increase could drive 
the cycle and restore/maintain haem synthesis. 
The Hypothesis 
The hypothesis which this thesis sets out to examine is that the primary 
defect in VP, a decrease in the activity of protoporphyrinogen oxidase, 
results in an accumulation of distal haem pathway intermediates which 
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in turn inhibit PBG deaminase. When the pathway is relatively 
quiescent this inhibition is marginal. However, any further increase in 
ALA synthetase activity would increase the accumulation of distal 
pathway intermediates and have an increased effect on PBG 
dearninase until a point is reached where ALA and PBG accumulate. 
Thus PBG deaminase activity should be slightly decreased in quiescent 
VP and secondly, the obligate haem substrates proto- and 
copropo,phyrinogen which accumulate in VP should inhibit PBG 
deaminase activity. Equally important, the substrate predominantly 
increased in PCT (ie. uroporphyrinogen) should not effect PBG 
dearninase. 
Protoporphyrinogen Oxidase and PBG Deaminase in VP 
Chapter Four 
Protoporphyrinogen oxidase and 
Porphobilinogen deaminase in 
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T his chapter describes the studies which examine the first part of the 
hypothesis outlined in the previous chapter. 
Objectives of the study 
D To confirm that VP is characterised by a reduction of 
protoporphyrinogen oxidase activity. 
D To test the hypothesis that PBG deaminase activity is also reduced 
in VP. 
Choice of a tissue system in which to assay 
protoporphyrinogen oxidase and PBG deaminase 
While it would obviously be preferable to study the haem synthetic 
enzymes in hepatocytes from normal and VP subjects, this would 
involve invasive procedures which are clearly unacceptable. However, 
since VP is likely to arise from a defect encoded by a single gene and 
has previously been shown to be expressed in tissues other than the 
liver (see Chapter 2), a tissue culture system should afford a 
convenient opportunity for pursuing the above objectives. 
Protoporphyrinogen oxidase activity has been measured in 
lymphocytes and leucocytes and has been shown to be decreased in 
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these cell types in VP patients (Deybach et al, 1981; Boyle et al, 1986). 
PBG deaminase has been measured in many different tissue types, 
including Epstein-Barr virus transformed lymphoblasts derived from 
control and AIP subjects (Sassa et al, 1978). We therefore considered 
it reasonable to investigate the use of Epstein-Barr virus transformed 
lymphoblasts as a "model" tissue. The use of transformed tissue, 
however, required validation in order to be certain that the 
transformation process did not alter the relative expression of the 
enzymes of interest in this study. 
Methods 
Preparation and culture of Epstein-Barr virus transformed 
lymphoblasts and choice of VP patients 
Approximately 18X106 lymphocytes were isolated from 20ml of 
heparinised blood from each subject by centrifugation over a ficoll 
gradient ("Histopaque", Sigma Chemical Company). These were 
incubated in a medium containing Epstein-Barr virus to effect 
transformation according to previously described procedures 
(Nilsson, 1971; Bird et al, 1981; Van der Westhuizen et al, 1984). 
Transforming medium was prepared from semi-confluent cultures of 
the Epstein-Barr virus producing marmoset cell line B95/8 (Miller and 
Lipman, 1973). Full details on the transformation and maintenance of 
the cell lines in culture is given in Appendix 6. Once a secondary 
culture and sufficient numbers of viable cells were available, 
protoporphyrinogen oxidase and PBG deaminase could be assayed. 
Generally this point was reached when 60ml of suspension culture 
containing approximately 5X106 cells/ml of 80% viability, as 
determined by trypan blue exclusion, were available. 
Epstein-Barr virus-transf armed lymphoblasts are hereafter ref erred to as 
"lymphoblasts". 
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Successful Epstein-Barr virus transformations were obtained in 86% 
of cultures. Failures were ascribed to super-infection, to a failure to 
maintain cultures at a density appropriate for successful growth and in 
three cases the virus just did not "take". Optimal growth rate occurred 
at a cell density of 1-5X106 cells/ml. Healthy lymphoblasts could be 
distinguished by their characteristic clustering (figure 4.1); they often 
appeared to have "tails" and a greenish tinge when viewed under a 
phase contrast microscope. Protein concentration was determined in 
a l.5ml sonicate by the Lowry method (Lowry et al, 1951), cell density 
by a Coulter counter and viability using a trypan blue exclusion test in 
all cultures (Williams and Wilson, 1981). The protein concentration, 
cell density and viability immediately (lh) prior to preparation showed 
no appreciable variation from the sample mean (Table 4.1). 
Comparison of these parameters between the control and VP group 
showed no significant difference using the Students two-tailed T-test 
(Bailey, 1981) (p = 0.191, 0.194 and 0.692 respectively) 
Table 4.1: Mean protein concentration (mg/ml), cell density (cells/ml) and viability (%) as 
determined in lymphoblast cultures 1 h prior to preparation tor 
protoporphyrinogen oxidase or PBG deaminase assay. SD, standard deviation. 
Protein Cell Viability 
concentration density 
(mg/ml) (X106 cells/ml) (%) 
Controls (N = 27) 
Mean 0.71 5.27 89 
Median 0.71 5.26 89 
Range 0.64-0.80 4.78-5.89 83-96 
SD 0.04 0.33 4.1 
VP (N=27) 
Mean 0.70 5.25 89 
Median 0.69 5.24 90 
Range 0.59-0.79 5.32-6.01 83-95 
SD 0.05 0.35 3.4 
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Figure 4.1: Photomicrograph showing typical 
Epstein-Barr virus transformed lymphoblasts in 
suspension culture. Growing medium was Ham F-1 o (with L-glutamine) containing 10% foetal calf serum. 
Cells were best maintained at a density of 
approximately 1X106 cells/ml. 
Lymphocytes from 33 
normal control subjects 
and from 30 quiescent 
VP subjects yielded 54 
successful cultures, 27 
in · each group. The 
diagnosis of VP was 
based on the clinical 
and family data and on 
the demonstration of 
the characteristic "VP" 
pattern of porphyrins in stool, urine and plasma using a quantitative 
TLC technique (Day et al, 1978a). This technique is described in detail 
in Appendix 4 ). ALA and PBG concentrations were assayed using an 
ion-exchange method (Davis and Andelman, 1967) available in "kit" 
form (see Appendix 5). The main inclusion criterion was a stool 
protoporphyrin of concentrations greater than 200nmol/g dry weight. 
In most cases elevated concentrations of coproporphyrin and 
pentacarboxylic porphyrin and/or a porphyrin species running very 
closely to pentacarboxylic porphyrin which we have termed 
"pseudo-pentacarboxylic" porphyrin, were present (see figure 2.3). 
Urinary ALA and PBG concentrations indicated that none of the 
patients were in an acute attack. 
Assay of protoporphyrinogen oxidase 
Protoporphyrinogen oxidase was assayed using an adaptation of a 
previously described fluorometric assay (Poulson, 1976; Brenner and 
Bloomer, 1980b; Jacobs and Jacobs, 1982; Dailey and Karr, 1987). The 
adaptation was necessary to facilitate measurement of 
protoporphyrinogen oxidase in lymphoblasts. The optimization of pH, 
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the time course of the reaction and of reducing agents and detergents 
in the assay system are discussed below. Full details of the assay 
method are given in Appendix 7 and 8. 
In brief: Protoporphyrinogen solution (produced by treating 
protoporphyrin with 4% sodium amalgam) was added at 5 different 
concentrations, to a lymphoblast sonicate, and reaction buffer. The 
0 
reaction was allowed to proceed in the dark for lh at 37 C. 
Protoporphyrin concentrations were measured by direct fluorometry. 
Non-enzymatic production of protoporphyrin was controlled for by 
measuring the amount of protoporphyrin produced under similar 
conditions but without active sample solution. The rate of 
non-enzymatic oxidation of protoporphyrinogen was subtracted from 
the enzymatic rate. Apparent V max and Km* values for 
protoporphyrinogen oxidase were determined from double-reciprocal 
Lineweaver-Burk plots. All assays were performed in duplicate. 
Optimal conditions for protoporphyrinogen oxidase 
* 
The influence of pH was studied using potassium phosphate, Tris-HCl 
and sodium borate buffers in 50mM concentrations ranging from pH 
6.8 to 9.4. Activity was maximal around pH 8.6 and was affected 
minimally by using different buffers (figure 4.2). 
The linearity of the rate of enzymatic protoporphyrin production was 
ascertained by measuring activity every 15min up to 60min and at 
30min intervals up to 150min. There was good linearity between 15 
and 90 minutes after a slight "lag" in the initial production of 
protoporphyrin (figure 4.3). Non-enzymatic auto-oxidation of 
substrate (protoporphyrinogen) never exceeded 18% of the total 
measured oxidation of protoporphyrinogen (figure 4.3). 
The term "apparent" is used as the enzymes' V max and Km determined in sonicated 
preparations of lymphoblasts may not reflect the true V max and Km of the enzyme under 
investigation. The true V max and Km would only be reflected were the enzyme in a pure state. 
Although the term "apparent" will not be used hereafter, it is implied. ,. 
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Figure 4.2: Effect of pH on human lymphoblast protoporphyrinogen oxidase. Activity (nmol 
protoporphyrin/mg protein/h) was determined as described over a pH range of 
6.8 to 9.4 using 50mM potassium phosphate, Tris-HG! or sodium borate buffers. 
Individual data points represent the mean activities assayed in 3 normal control 
lymphoblast cultures. 
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Figure 4.3: Time course of protoporphyrinogen oxidation by lymphoblast 
protoporphyrinogen oxidase (PPO). Protoporphyrin production (nmol/mg 
protein) was linear with respect to time to 90min after a "lag" phase of 
approximately 15min. Curves A and Care included to illustrate how PPO activity 
(curve B) was arrived at. Curve C represented protoporphyrin production by the 
non-enzymatic controls. This was considered as auto-oxidation of the 
protoporphyrinogen substrate and subtracted from the total protoporphyrin 
produced by the sonicated lymphoblasts (curve A) to give enzymatic production 
of protoporphyrin due to PPO. Data points represent the mean of 3 iidentical 
experiments. 
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Table 4.2: Effects of various reducing agents on the enzymatic and non-enzymatic formation 
of protoporphyrin from protoporphyrinogen. Standard assay conditions were 
used except for the variation in type and concentration of reducing agent. Values 
are the result of the mean of identical runs in 2 normal control cultures. 
REDUCING AGENT 
Control 
Glutathione (1 mM) 
Glutathione (5mM) 
Dithiothreitol (1 mM) 
Dithiothreitol (3mM) 
Dithiothreitol (5mM) 
B-Mercaptoethanol (3mM) 
PROTOPORPHYRIN FORMATION (nmol) 
Enzymatic Non-enzymatic 
1.16 0.15 
1.19 0.15 
1.15 0.12 
1.17 0.14 
1.17 0.08 
0.91 0.05 
1.15 0.11 
The effects of various concentrations of glutathione, dithiothreitol and 
.B-mercaptoethanol on the enzymatic and non-enzymatic formation of 
protoporphyrin were determined (table 4.2). The most effective of 
these reducing agents was 3mM dithiothreitol; auto-oxidation of the 
substrate was minimised and neither inhibition nor stimulation of the 
enzyme was apparent in the presence of 3mM dithiothreitol. 
The amount of fluorescence emitted from protoporphyrin in solution 
was found to depend on the amount of tissue present, the greater the 
amount added, the more fluorescence was emitted (table 4.3). This 
was independent of the amount of porphyrin present. 
Table 4.3: Enhanced fluorescence quantum yield accompanying increasing amounts of 
sample protein. Fluorescence readings were performed using 1 and 10 µM 
protoporphyrin solutions in the standard reaction mixture, including 1% Brij 35. 
AMOUNT OF LYMPHOBLAST 
PROTEIN ADDED (mg) 
0.25 
0.50 
1.00 
2.00 
FLUORESCENCE UNITS 
(on a X10 and a X1 scale) 
[Protoporphyrin] 
1 µM 10µM 
46 44 
61 64 
91 92 
148 150 
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It has been reported that this effect can be minimised and the 
fluorescence quantum yield increased by addition of a detergent, such 
as Tween-20, to the reaction mixture (Brenner and Bloomer, 1980b). 
It has been suggested that this enhancement of fluorescence may occur 
because protoporphyrin is maintained in monomeric form by the 
detergent (Brenner and Bloomer, 1980b). We therefore compared 
Triton XlOO, Tween 20 and Brij 35 by adding each to the assay mixture 
to yield a final 1 % detergent concentration. Brij-35 was the most 
beneficial as it increased fluorescence quantum yield by approximately 
4-fold (figure 4.4). 
Figure 4.4 also shows that the measured fluorescence was proportional 
to the protoporphyrin concentration up to l2µM a concentration 
which includes the entire range of protoporphyrin concentrations 
actually encountered in the assay. 
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Figure 4.4: The effect of different detergents (in a 1% concentration) on fluorescence of 
protoporphyrin (measured at excitation wavelength of 405nm, emission of 
630nm). 1% Brij 35 maximised the fluorescence quantum yield. Data points 
represent the mean of 3 identical experiments. 
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Figure 4.5: Protoporphyrinogen oxidase activity as a function of the amount of lymphoblast 
protein. Activity is expressed as nmol of protoporphyrin generated enzymatically 
per h. Assays were performed under standard conditions. Data points represent 
the mean of 2 identical experiments in triplicate. The lower limit of reproducibility 
is indicated by an arrow. 
The rate of protoporphyrin production by lymphoblast 
protoporphyrinogen oxidase was linear with respect to the amount of 
lymphoblast protein present in the assay reaction mixture up to 
approximately 1.Smglassay tube ie. approximately 3mglml (figure 4.5). 
The lower limit of reproducibility was approximately 0.3mg of 
protein/assay tube. This was established by running two identical 
experiments which measured protoporphyrinogen oxidase activity 
with amounts of protein ranging between O and 2.Smglassay tube, in 
triplicate. 
Assay of porphobilinogen deaminase 
PBG dearninase activity in lymphoblasts could be measured by 
minimal adaptation of previously described methods for measuring 
erythrocyte and lymphocyte PBG dearninase activity under conditions 
of substrate excess (Piepkorn et al, 1978; Sassa et al, 1978; Ford et al, 
1980; Anderson and Desnick, 1982). Appropriate conditions for the 
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enzyme in our system were examined. The method, like that of 
protoporphyrinogen oxidase, is a fluorometric one. The rate of 
production of uroporphyrinogen from PBG can be determined by 
incubating lymphoblast sonicates in the presence of excess PBG at 
37° C in the dark, stopping the reaction with trichloroacetic acid (TCA), 
allowing oxidation of the uroporphyrinogen to uroporphyrin, and 
measuring fluorescence directly. Full detail of the method is given in 
Appendix 9. All assays were performed in duplicate. Since this method 
has been used in lymphoblasts before, in depth studies used for 
optimisation of the assay were not necessary. Studies measuring PBG 
deaminase activity as a function of pH, of time and of protein 
concentration were however performed in order to confirm that the 
method worked in our system. 
Optimal conditions for PBG deaminase 
The influence of pH was examined using O. lM citrate phosphate, 
potassium phosphate, Tris-HCl or sodium borate buffer over a pH 
range from 6.0 to 9.4. The pH optimum was from 8.2-8.4, no activity 
was measured below pH 6.2 (figure 4.6) and there was slight loss of 
activity in the presence of sodium borate buffer. 
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Figure 4.6: Effect of pH on human lymphoblast porphobilinogen deaminase. Enzymatic activity 
(pmol uroporphyrin/mg protein/h) was determined as described in the methods 
section except that the pH was varied between 6.8 to 9.4. Individual data points 
represent the mean activities assayed in 2 control /ymphoblast sonicates. 
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PBG deaminase activity was measured at lSmin intervals from O to 
. 0 
120min. The assay was linear from approximately 5 to 75min at 37 C 
(figure 4.7). Activity was apparent at 20°C but was reduced to 19% of 
0 
that measured after lh at 37 C. 
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Figure 4.7: Linearity of PBG deaminase assay with respect to time at 37°C and at 20°c. 
Uroporphyrin production (pmol/mg protein) was linear between 5 and 75min at 
37°C and until approximately 90min at 20°C. 
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Figure 4.8: Porphobilinogen deaminase activity as a function of the amount of lymphoblast 
protein. Activity is in pmol of uroporphyrin generated enzymatically per h. Assays 
were performed under standard conditions. Data points represent the mean of 3 
identical experiments. The lower limit of reproducibilty is indicated by an arrow. 
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The rate of uroporphyrin production by lymphoblast PBG deaminase 
was directly proportional to the amount of lymphoblast protein 
present in the assay reaction mixture up to concentrations of 
approximately 2.0mg/assay tube ie. approximately 2.2mg/ml (figure 
4.8). The lower limit of reproducibility, as in the case of 
protoporphyrinogen oxidase, was approximately 0.3mg of 
protein/assay tube. 
Evaluation of transformed lymphoblasts for assay of 
protoporphyrinogen oxidase and PBG deaminase 
Having established that both lymphoblast protoporphyrinogen 
oxidase and PBG deaminase activities were within the linear portion 
of the assays as described, the suitability of lymphoblasts as a model in 
which to study protoporphyrinogen oxidase and PBG deaminase was 
assessed. 
Firstly four normal control lymphoblast lines had protoporphyrinogen 
oxidase and PBG deaminase assayed at three 10 day intervals to assess 
the variation in activity in culture over a fairly long period ( table 4.4 ). 
Both enzymes showed remarkably constant activity over this period. 
Reproducibility of the assays was verified by measuring the enzymes 
in triplicate, in the same tissue batch on two separate occasions 
separated by 2h. Proteolysis was assumed to be minimal over this time 
period. The results did not differ by more than 14% (table 4.5). 
Table 4.4: Protoporphyrinogen oxidase (PPO) and porphobilinogen deaminase (PBGD) 
activities in culture was constant. Activity was assayed at three 10 day intervals 
in 4 control · lymphoblast cultures by the methods described. The mean result 
(±SD) is given as all 4 behaved similarly. 
Day 30 (ie. 30 days post-transformation) 
Day40 
Day50 
PPO 
(nmol/mg/h) 
0.95 (±0.1) 
0.91 (±0.1) 
0.94 (±0.1) 
PBGD 
(pmol/mg/h) 
21 .2 (±1.4) 
22.4 (±1.2) 
21 .9 (±1.1) 
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Table 4.5: Reproducibility of the protoporphyrinogen oxidase (PPO) and porphobilinogen 
deaminase (PBGD) assays. 
PPO PBGD 
(nmol/mg/h) (pmol/mg/h) 
Time o (fissue batch L74) 0.95 21.2 
0.92 20.4 
0.98 21 .8 
Time +2 (fissue batch L74, 2h later) 0.84 19.6 
0.94 20.8 
0.90 19.9 
The effect of transformation on protoporphyrinogen oxidase 
and PBG deaminase activity 
Secondly, any stimulatory or inhibitory effects of the transformation 
process on protoporphyrinogen oxidase and PBG deaminase were 
assessed by comparing activities of these two enzymes after 3, 4, 5, 7, 
14, 21 and 28 days after initiation of the transformation process. These 
results ( obtained from identical experiments in five control cell lines) 
are shown in figure 4.9. 
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Figure 4.9: Effect of transformation on protoporphyrinogen oxidase activity (nmol/mg 
protein/h) and PBG deaminase activity (pmol/mg protein/h). Assays were carried 
out at 3, 4, 5, 7, 14, 21 and 28 days after initiating transformation. After an initial 
maximal stimulation both enzymes displayed a consistent level of activity. 
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Both protoporphyrinogen oxidase and PBG deaminase activity 
appeared to fluctuate similarly over this period. Maximal activities 
were measured at 7 days (4-fold increases). Thereafter both enzyme 
activities dropped to a steady level approximately twice the baseline 
value. This stimulatory effect of transformation is probably due to a 
general increase in metabolic activity in the transformed cells. 
Evidence that the assumed VP defect in protoporphyrinogen 
oxidase activity is carried through into culture 
Finally, in a comparative experiment designed to validate . the 
lymphoblast cultures as a model of the assumed inherited deficiency 
in VP, protoporphyrinogen oxidase was assayed in fresh lymphocytes 
isolated from 500ml of blood from3 normal controls and 3 VP subjects. 
Epstein-Barr virus transformed lymphoblasts from the same controls 
and VP subjects had previously been established and were sufficiently 
populous for the assay. Thus protoporphyrinogen oxidase V max and 
Km of transformed lymphoblasts and lymphocytes originating from the 
same subjects could be compared. The results are shown in table 4.6. 
The VP protoporphyrinogen oxidase defect appeared to have been 
maintained through the transformation procedure and into secondary 
culture. 
Table 4.6: Presence of an approximate 50% decrease in protoporphyrinogen oxidase Vmax 
activity (nmol/mg protein/h) was apparent both prior to and after transformation of 
lymphoblasts originating from the same VP subject. There was no significant 
variation in Km (µM) between the two groups. Values given represent the mean of 
3 subjects in each group. 
LYMPHOCYTES TRANSFORMED 
LYMPHOBLASTS 
Vmax Km Vmax Km 
Controls 0.28 0.98 0.79 1.01 
VP 0.14 1.06 0.35 1.02 
% Difference -50% -55.7% 
·. 
; 
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Data analysis 
Results 
Units of expressionforprotoporphyrinogen oxidase activity were nrnol 
of protoporphyrin/mg protein/h and for PBG deaminase, nrnol 
uroporphyrin/mg protein/h. Where applicable data are presented as 
mean ±standard deviation (SD). Enzyme activities of transformed 
lymphoblasts from the group of VP patients were compared to the 
results obtained in normal controls and statistical significance was 
assessed with the Student T-test for comparing the means of two 
population samples (Bailey, 1981). Significance was gauged from the 
probability (p) value. 
Protoporphyrinogen oxidase activity in VP 
The protoporphyrinogen oxidase mean V max activity for the normal 
control group of cultures was 0.82±0.lOnrnol protoporphyrin/mg 
protein/h (N = 27) and that for the VP cultures 0.39±0.08nmol 
protoporphyrin/mg protein/h (N =27) (figure 4.10). This represented 
a 52% decrease in mean activity which was statistically significant (p<0.001). The mean protoporphyrinogen oxidase apparent Km for 
the normal control cultures was 1.06±0.28µM and that for the VP 
cultures 1.00±0.27µM which was not significantly different (p = 0.505). 
PBG deaminase activity in VP 
The mean activity of PBG deaminase in cultures from the normal 
control subjects was 19.4±0.14pmol uroporphyrin/mg protein/h and 
that in the cultures from the VP subjects 15.0±0.18pmol 
uroporphyrin/mg protein/h (figure 4.11). This represents a 24% 
decrease in activity and is statistically significant (p<0.001). 
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Figure 4.10: Human lymphoblast protoporphyrinogen oxidase Vmax (nmol/mg protein/h) was 
decreased by an average of 52% in a group of 27 VP lymphoblast cultures. Km 
values were not significantly different. The "T" bars represent one standard 
deviation. 
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Figure 4.11: Human lymphoblast porphobilinogen deaminase apparent Vmax (pmol/mg 
protein/h) was decreased by an average of 24% in a group of 27 VP lymphoblast 
cultures. The "T" bars represent one standard deviation. 
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Family study 
Enzyme activity was measured in affected and non-affected members 
of 3 generations of a VP family. The data obtained from these 14 
subjects are presented as a simplified family tree in figure 4.12. All 
subjects in whom protoporphyrinogen oxidase activity was decreased 
by more than 2 standard deviations from the control mean activity also 
exhibited a decrease in PBG deaminase activity greater than 2 
standard deviations below control mean activity. One asymptomatic 
and biochemically normal subject had a protoporphyrinogen oxidase 
activity of 0.57nmol/mg/h which lay between the porphyric and the 
control group. His PBG deaminase was normal. 
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Figure 4.12: Pedigree of the VP family studied. Protoporphyrinogen oxidase and PBG 
deaminase activities are given in nmol/mg protein/h and pmol/mg protein/h 
respectively. Hatched symbols denote decreased protoporphyrinogen oxidase 
and PBG deaminase activity by more than 2 standard deviations below the mean 
control activity. Asterisks denote the presence of typical VP porphyrin excretory 
profiles. All patients with unequivocally decreased protoporphyrinogen oxidase 
appeared to demonstrate typical porphyrin profiles as well. 
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Discussion 
Firstly, some comment regarding the use of lymphoblasts to examine 
protoporphyrinogen oxidase and PBG deaminase in VP is 
appropriate. 
Lymphoblast cultures 
The use of Epstein-Barr virus transformed lymphoblasts in the study 
of haem biosynthetic enzymes was attractive since it appeared to offer 
several advantages. Cells could be obtained with little inconvenience 
to the donor subjects (10-20ml of peripheral blood is required) and 
this compared favourably to more invasive procedures such as skin or 
liver biopsy. A long-lived cell line is produced which can be stored with 
minimal loss of viability (Bird et al, 1981; Van der Westhuizen, 1984 
and our results). This is of particular advantage where large surveys 
are undertaken. Thus the cultures allow for simultaneous assay of 
relatively large numbers of subjects but are also available for repeat 
assays, further experimentation and inter-laboratory transport. Finally 
large numbers of cells can be produced when required. 
Protoporphyrinogen oxidase and PBG deaminase assay in 
lymphoblasts 
Assays of both PBG deaminase and protoporphyrinogen oxidase in the 
lymphoblast preparations proved to be relatively easy using the 
methods described. Because of the time required to produce sufficient 
cells, transformation followed by enzyme measurement is not 
recommended as a routine diagnostic laboratory procedure. It is 
important to use cultures with more than 80% viability. We found that 
our results became inconsistent and irreproducible when the 
proportion of viable cells diminished to below this level. We found 
(figures 4.2-4.8 and tables 2 and 3) that the conditions previously 
described for the assay of both of these enzymes in other tissues were 
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applicable to our lyrnphoblasts. Thus, those laboratories with existing 
assays could easily adapt these for use in lymphoblast cultures. 
The characteristics of protoporphyrinogen oxidase in our system were 
similar to those reported (Brenner and Bloomer, 1980b; Jacobs and 
Jacobs, 1982). The pH optimum of 8.6 (figure 4.2) is similar to that 
reported for rat liver mitochondria (Brenner and Bloomer, 1980b), 
and for purified murine (Dailey and Karr, 1987) and bovine (Siepker 
et al, 1987) liver protoporphyrinogen oxidase. In keeping with other 
reports we found it difficult to obtain good activity at substrate 
concentrations above 30µM and concentrations in excess of SOµM 
were inhibitory (Camadro et al, 1985; Siepker et al, 1987). The initial 
lag in the generation of protoporphyrin (figure 4.3) has also previously 
been documented (Brenner and Bloomer, 1980b) although the reasons 
for this remain unclear. However, after 15min, generation of 
protoporphyrin was linear for up to 90min. The V max activity of 
protoporphyrinogen oxidase in lymphoblasts was about a third of that 
reported in untransformed human lymphocytes (Deybach et al, 1981). 
The reason is unclear but since the results were so consistent, this was 
felt to be acceptable. The use of a "kinetic" as opposed to an end-point 
assay allowed us to determine V max and Km values. Though these are 
"apparent" V max and Km values, they are nevertheless valid for making 
direct comparisons between control and VP groups. 
The characteristics of PBG deaminase in our system are also similar 
to those reported previously (Anderson and Desnick, 1982). The 
activity oflyrnphoblast PBG deaminase was within the range reported 
elsewhere for human lymphoblasts and lymphocytes (Sassa et al, 1978; 
Anderson and Desnick, 1982). 
The effect of transformation on protoporphyrinogen oxidase 
and PBG deaminase 
Mitogen-stimulated lymphocytes demonstrate striking increases in 
metabolic activities related to DNA, RNA and protein synthesis. It was 
thus likely that enzymes in lymphoblasts would also show a degree of 
increased activity when compared to unstimulated precursor 
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lymphocytes (Sassa et al, 1978). Sassa et al previously measured the 
activities of ALA synthetase, ALA dehydratase, uroporphyrinogen 
synthetase (PBG deaminase) and catalase in phytohemagglutinin 
(PHA)- and pokeweed mitogen (PWM)-stimulated lymphocytes from 
normal and AIP subjects (Sassa et al, 1978). ALA synthetase, ALA 
dehydratase and catalase activities were increased two- to three-fold 
by mitogen treatment for 4 days in all cells, whereas a 10-15 fold 
induction of PBG deaminase was observed in control (normal) 
mitogen-stimulated lymphocytes and an approximately 30-fold 
induction in mitogen-stimulated AIP lymphocytes. 
Our results show that control lymphoblast cultures in the presence of 
Epstein-Barr virus demonstrate an approximately 4-fold increase in 
PBG deaminase activity after 7 days (figure 4.9). After 4 weeks, 
however, PBG deaminase activities levelled off at mean levels of 1.5 
to 2 times those found in the untreated lymphocytes. 
Protoporphyrinogen oxidase behaved almost identically (figure 4.9). 
Our data would therefore appear to show no difference in the relative 
response of PBG deaminase and protoporphyrinogen oxidase. While 
this may appear to differ from the previously mentioned study (Sassa 
et al, 1978) it is important to note that that study did not measure 
protoporphyrinogen oxidase while ours did not measure ALA 
synthetase or ALA dehydratase. Furthermore the two studies included 
certain methodological differences including the method of 
stimulation and the times at which PBG deaminase activity was 
determined. It is conceivable that we would have found significantly 
more stimulation of PBG deaminase activity (and possibly 
protoporphyrinogen oxidase as well) at an earlier point in the 
transformation process. This would have explained our apparently 
discrepant results. Whatever the explanation, in . our hands 
lymphoblasts (after 4 weeks in culture) showed similar increases in 
PBG deaminase and protoporphyrinogen oxidase. 
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Confirmation of the protoporphyrinogen oxidase activity 
defect in VP 
85 
In this study of 27 lymphoblast cultures from quiescent VP subjects, 
lymphoblast protoporphyrinogen oxidase V max activities were found 
to be decreased by approximately 50% (figure4.10). This data is similar 
to that obtained by others (Brenner and Bloomer, 1980a; Deybach et 
al, 1981; Viljoen et al, 1983; Boyle et al, 1986) and suggests that 
decreased protoporphyrinogen oxidase activity may be the underlying 
defect in VP. 
The similar Km of protoporphyrinogen oxidase in lymphoblasts in 
control and VP lymphoblasts appears to favour the suggestion that 
protoporphyrinogen oxidase in VP is not structurally mutant; only 
activity from the enzyme produced by the normal allele is being 
measured. Either the abnormal inherited allele is producing no 
enzyme or it is producing an enzyme with a markedly increased Km. It 
must however be emphasised that we have determined an apparent 
Km using unpurified enzyme. Thus caution must therefore be 
exercised in basing any conclusions regarding protoporphyrinogen 
oxidase structure on our data. 
Perpetuation of protoporphyrinogen oxidase activity through 
transformation into culture. 
VP lymphoblasts exhibited the same diminution of 
protoporphyrinogen oxidase activity as untransformed lymphocytes 
derived from the same VP patient when compared to the equivalent 
normal control cultures (table 4.6). The deficiency in 
protoporphyrinogen oxidase activity thus appeared to be carried 
through the transformation process and into secondary culture. 
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Evidence that PBG deaminase activity is also decreased in 
lymphoblasts from subj¢cts with VP 
This was a most significant finding in terms of the development of the 
hypothesis outlined in Chapter 3 of this thesis; the mean lymphoblast 
PEG deaminase activity in the VP cultures, including those from the 6 
affected members of the VP family, was reduced by approximately 25 % 
(p<0.001) (figure 4.11). The significance of this difference has not 
been fully documented previously. This is probably due in part to the 
fact that most studies measuring PBG deaminase in VP have used 
erythrocytes (Magnusson et al, 1974; Brodie et al, 1977\ Doss and Von 
Tiepermann, 1978) and in part to the small numbers invloved in these 
studies. In one larger study (16 VP patients) a modest decrease of 
erythrocyte PBG deaminase was apparent although neither statistical 
comparisons nor comment was made (Mustajoki, 1976). 
The significance of diminished PBG deaminase activity in VP 
We would like to suggest that the association of a low PBG deaminase 
activity with diminished protoporphyrinogen oxidase activity may be 
significant. This we believe might explain some of the features 
characteristic of VP. Thus the elevation in later ( distal) porphyrin 
intermediates found in VP (mainly protoporphyrin and 
coproporphyrin) is in keeping with the decreased protoporphyrinogen 
oxidase activity and the increased concentrations of ALA and PBG 
found under conditions of increased haem synthetic drive, namely 
during acute attacks, could be due to the decrease in PBG deaminase 
activity which we have observed. Presumably the flux through the 
pathway in the quiescent phase of VP is not sufficient to stress the 
modest diminution in PBG deaminase activity. 
Why is PBG deaminase activity diminished in VP? 
The cause of the decreased porphobilinogen deaminase activity in VP 
is not obvious. While the exact site of the gene coding for 
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protoporphyrinogen oxidase is unknown there is evidence that it is 
encoded for on chromosome 14 (Bissbort et al, 1988), far removed 
from that encoding PBG deaminase on chromosome 11 (Meisler et al, 
1980, 1981; Wang et al, 1981). There is thus little evidence or precedent 
to favour the genes for these haem synthetic enzymes being close to 
one another. Thus, assuming the enzymes are on different 
chromosomes, an inherited mutation of PBG deaminase should be 
passed on independently of any defect in protoporphyrinogen oxidase 
and our family study should have revealed some subjects with one or 
the other deficiency alone. Yet none were detected. Thus simple 
genetic linkage would appear not to be an explanation and it might 
therefore be more appropriate to consider the decreased PBG 
deaminase activity as a secondary phenomenon linked in some way to 
the primary inherited protoporphyrinogen oxidase defect. This is the 
suggestion examined in the following chapter. 
Conclusions 
D Epstein-Barr virus transformed lymphoblasts appear to be a valid 
model in which to study protoporphyrinogen oxidase and PBG 
deaminase. 
Epstein-Barr virus transformed lymphoblasts appear to retain their 
haem synthetic enzyme activity in that both protoporphyrinogen 
oxidase and PBG deaminase are present and can be assayed. (Previous 
workers have also demonstrated active ALA synthetase and ALA 
dehydratase in Epstein-Barr virus-stimulated lymphocytes). Although 
the transformation process results in a mild stimulation of 
porphobilinogen deaminase and protoporphyrinogen oxidase 
activities, neither appears to be selectively stimulated. Finally, 
decreased activity of protoporphyrinogen oxidase was demonstrated 
in lymphocytes from the same VP subjects before and after 
transformation with Epstein-Barr virus. 
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D There is a 50% decrease in protoporphyrinogen oxidase activity 
lymphoblasts from VP subjects. 
This study represents the largest series of VP subjects to have 
protoporphyrinogen oxidase activities measured to date. 
D Lymphoblasts from VP subjects demonstrate a modest but significant 
decrease in PBG deaminase activity. 
This decrease of roughly 25 % appears to coexist with the decrease in 
protoporphyrinogen oxidase activity. We suggest that the porphyrin 
and porphyrin precursor accumulation observed in VP can be 
explained on the basis of the enzyme alterations described above. In 
particular, our data suggest an explanation for the elevations of ALA 
and PBG seen in the acute phase of VP. A constriction in the form of 
partially diminished PBG deaminase activity may well contribute to 
the elevations of proximal haem intermediates in acute VP. The idea 
of a second "constriction" or control point in haem biosynthesis 
(Brodie et al, 1977a; Moore et al, 1980; Doss, 1978) would thus appear 
to offer a potential explanation for elevated concentrations of ALA 
and PBG in VP. We suggest that the decrease in PBG deaminase 
activity is not due to a separate autosomal dominant mutation since 
genetic linkage seems improbable. 
The possibility that the reduction in PBG deaminase activity is a 
consequence of the protoporphyrinogen oxidase defect is examined in 
the following chapter. 
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Chapter Five 
PBG Deaminase kinetics in VP and 
kinetic effects of haem 
intermediates on PBG deaminase 
* 
The data presented thus far point to intriguing questions regarding 
the cause of the diminished PBG dearninase activity in VP. Having 
dismissed the simultaneous genetic transmission of two enzyme 
defects ( Chapter 4) we turn to the second part of the hypothesis 
outlined in chapter 3. Our hypothesis suggested that PBG dearninase 
is directly influenced by an "external" factor. Because PBG dearninase 
activity appears to be linked to the presence of decreased 
protoporphyrinogen oxidase activity it would seem logical to include 
those intermediates which accumulate as a result of the decreased 
protoporphyrinogen oxidase activity in the list of putative inhibitors of 
PBG dearninase. Further, if the mechanism envisaged is to be more 
generally operative and hence to be extrapolated to HCP too, it must 
in some way be linked to a deficiency in coproporphyrinogen oxidase 
as well. Conversely any explanantion would have to account for the 
lack of accumulation of ALA and PBG in PCT, EPP and CEP. 
We thus hypothesise that raised concentrations of proto- · and 
coproporphyrinogen but not of uroporphyrinogen act as negative 
allosteric effectors* resulting in inhibition of PBG dearninase activity. 
Thus conditions such as VP and HCP, where elevated concentrations 
The term allosteric is used in the sense that PBG deaminase is inhibited by certain factors other 
than the catalytically active substrate (Atkinson, 1970). 
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of proto- and coproporphyrinogen are assumed to exist intracellularly, 
could well be expected to demonstrate decreased PBG deaminase 
activity, or at the least a PBG deaminase that would not be able to 
increase it.s activity to cope with the haem synthetic demands under 
certain conditions. On the other hand conditions such as PCT in which 
uroporphyrinogen accumulate should not be associated with a 
decrease in PBG deaminase activity. 
Objectives 
D To compare the basic kinetic profiles of PBG deaminase in VP and 
control lymphoblasts. 
D To examine the effects of various porphyrinogens and porphyrins 
on PBG deaminase activity and its kinetic behaviour. 
D To establish whether normal V max activity of the enzyme in VP 
lymphoblasts could be restored by removal of any endogenously 
occurring allosteric inhibitors. 
Study design 
D PBG deaminase activity was assayed in sonicates of Epstein-Barr 
virus transformed lymphoblasts obtained from each of 12 patients 
with quiescent VP and 12 normal control subjects. The kinetic 
characteristics of PBG deaminase in each group were compared. 
D The effects of different concentrations of added porphyrinogens 
and porphyrins on PBG deaminase were assessed. Here 
. protoporphyrin, protoporphyrinogen, coproporphyrin, 
coproporphyrinogen, uroporphyrin and uroporphyrinogen were 
added to sonicates of lymphoblasts from both the control and VP 
group. 
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D In a further set of experiments endogenous porphyrinogens and 
porphyrins were removed from VP lymphoblast preparations prior 
to the kinetic assay of PBG deaminase. 
Methods 
Lymphoblasts 
Lymphoblasts were prepared from both VP and control subjects as 
described previously (see Chapter 4, Methods and Appendix 6 and 7). 
PBG deaminase assay 
PBG deaminase activity was assayed using the method described in 
Chapter 4 (Methods) and Appendix 9 with the following modification: 
Each assay was performed with substrate (PBG) concentrations of 
1.25, 2.5, 5, 10 and 20µM and a substrate versus velocity curve obtained. 
PBG concentrations were selected to straddle the reported Km of PBG 
deaminase. 
Each experiment was controlled for non-enzymatic porphyrin 
production (which is normally negligible), by subtracting the 
fluorescence produced in matching assay tubes containing all reaction 
ingredients except the PBG deaminase, from the fluorescence 
obtained in equivalent tubes containing enzyme. 
Protein concentrations were determined in all cases using Biorad 
protein dye solution (see Appendix 12) according to the "Bradford" 
technique for microgram quantities of protein (Bradford, 1976). 
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Potential difficulties associated with assaying PBG 
deaminase in the presence of additional porphyrins or 
porphyri nogens 
1. PBG deaminase assay against a high background of 
porphyrin fluorescence 
We were concerned that the PBG deaminase assay might be 
confounded by the addition of exogenous porphyrins, which might 
themselves provide too much fluorescence to allow accurate 
determination of that resulting from the enzymatic production of 
uroporphyrin from PBG. Similarly added porphyrinogens, once 
oxidised, might also result in a high background fluorescence. We 
evaluated this potential problem as follows: 
The assay was performed in six control lymphoblast lines in the 
presence of an added mixture resulting in lOµM uroporphyrin, 
coproporphyrin and protoporphyrin in the incubation mixture. This 
created a fluorescence background even higher than that anticipated 
in the proposed experiments. The fluorescence ultimately resulting 
from enzymatic production of uroporphyrin and the added porphyrins 
was determined by total fluorescence determination of a 1/10 dilution 
(in order to exclude the effects of fluorescence quenching) of reaction 
mixture by direct fluorometry using an excitation wavelength of 405nm 
and an emission wavelength of 595nm. Fluorescence in control assay 
tubes containing all reaction ingredients except the PBG deaminase 
was subtracted from fluorescence in the enzyme-containing tubes. 
This resulted in positive readings. Thus some additional porphyrin, 
presumed to be uroporphyrin, had been produced from PBG by PBG 
deaminase. 
We verified that the increased fluorescence was indeed due to 
uroporphyrin by performing 1LC analysis of all porphyrin species 
present before and after assay in a parallel experiment using aliquots 
of the same six control lymphoblast preparations (Table 5.1). This 
served a useful dual purpose by yielding further data with which to 
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Table 5.1: Integrated peak fluorescence readings of porphyrins present in TLC traces of 
reaction mixture pre- and post-PBG deaminase assay. Added porphyrins were 
contrived to give reaction mixture concentrations of 1 OµM for each of uro-, copra-
and protoporphyrin. Results are expressed in arbitrary fluorescence units and 
represent the mean ( ±SD) of 6 control lymphoblast cell lines, each performed in 
duplicate. Note that the quantum fluorescence yield of 
proto<copro<uroporphyrin; hence equivalent quantities of these 3 porphyrins 
give correspondingly variable readings on fluorscanning. ( *significantly 
different, p<0.001). 
Pre-assay Post-assay 
(Fluorscence Units) (Fluorescence Units) 
Uroporphyrin 124 (±18) * 169 (±20) 
Coproporphyrin 116 (±19) 110 (±15) 
Protoporphyrin 95 (±15) 93 (±16) 
calculate PBG deaminase activity and which could be compared with 
results obtained using the direct "total fluorescence" method. 
The latter experiments were accomplished by setting up and running 
the assays as described. After 30min, however, the reaction was 
terminated by addition of 3ml of ethyl acetate:acetic acid (3:1, v/v) 
instead of TCA. Any protein precipitate was removed by 
centrifugation (10000Xg, 10min) and any porphyrinogens present 
(including reaction product, uroporphyrinogen) oxidized to their 
porphyrin form by exposure to longwave ultraviolet and white 
fluorescent light for 30min. Any porphyrins present in the assay 
mixture at this stage ( endogenous, reaction product or additions) were 
analysed on TLC by esterification, extraction, separation and 
quantitation as already described (Appendix 4). 
The first method of assay ( direct fluorometry of a 1/10 dilution of 
reaction mixture) yielded a mean PBG deaminase V max of 
26.2( ±4.1 )pmol/mg protein/h and the second method ( extraction and 
quantitative porphyrin TLC) gave a mean V max of 28.0( ±2.1 )pmol/mg 
protein/h. A comparison of these two methods showed a marginally 
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lower V max with a slightly larger scatter using the first method although 
the two results were not statistically different (p = 0.230, N = 6). 
Furthermore, TLC analysis indicated similar quantities of copra- and 
protoporphyrin both before and after assay, whereas the amount of 
uroporphyrin was increased post-assay (Table 5.1). It was concluded 
that the assay as described, using a single fluorescence reading on a 
diluted aliquot of reaction mixture was acceptable as uroporphyrin 
product was able to be ascertained even against a high background of 
porphyrin fluorescence. Thus the potentially more accurate ( certainly 
more visible), but tedious, alternative extraction and TLC procedure 
offered no significant advantage and was thus only used to verify the 
assay described above. 
2. Preparation and stability of porphyrinogens 
The second potential problem related to the known instability of 
porphyrinogens. Because testing of the hypothesis demanded that 
porphyrinogens be investigated it was necessary to examine the 
stability of various porphyrinogens under assay conditions. An 
experiment to ascertain the relative stability of proto-, copra- and 
uroporphyrinogen under PBG deaminase assay conditions was 
performed; 5ml of a 50µM solution of the appropriate porphyrin was 
reduced to the porphyrinogen using 4% sodium amalgam as described 
for the preparation of protoporphyrinogen ( Chapter 4 and Appendix 
8). The reduced solution was filtered and the pH adjusted to 8.2 with 
glacial acetic acid. 2ml of this was added to 8ml of PBG deaminase 
assay buffer and the solution incubated in a 37°C shaking water bath 
in the dark for 2h. A 1ml aliquot was removed every 15min and its 
fluorescence measured in a fluorometer. In this way the likely rate of 
re-oxidation of porphyrinogens under assay . conditions was 
determined. After 2h any . porphyrinogen present in the remaining 
volume was re~oxidised by adding 50µ1 of a 0.005% (w/v) aqueous 
iodine solution and a small crystal of cysteine added to decolourise the 
excess iodine (Fuhrhop and Smith, 1975). This confirmed that 
porphyrinogens were still present after 2h and that there was no 
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Figure 5.1: Rate of auto-oxidation of 10µM proto-, copra- and uroporphyrinogen under 
standard assay conditions over a 2h period. At time zero the porphyrinogens were 
100% reduced as judged by the complete absence of fluorescence. 
Auto-oxidation was followed by fluorescence readings eve,y 15 minutes. After 2h 
chemical re-oxidation of any remaining porphyrinogens was stimulated by 
addition of iodine. 
significant porphyrin destruction/modification due to the reduction 
process. 
The results of this experiment are shown in figure 5.1. Oxidation of 
these porphyrinogens as judged by reappearance of porphyrin 
fluorescence was negligible over the first 30rnin and very slight over 
the next 90rnin, the rates of re-oxidation of the 3 porphyrinogens being 
slightly different. Protoporphyrinogen was the least stable, 
uroporphyrinogen most stable. It was concluded that the stability of 
the porphyrinogens under investigation was acceptable under the 
proposed assay conditions. 
3. Oxidation of porphyrinogens 
It was important to ensure that porphyrinogens could be completely 
oxidised to the corresponding porphyrins since it is these that are 
measured. Thus VP lyrnphoblasts were sonicated, lOOµM proto-, 
Table 5.2: Three experiments illustrating re-oxidation of 100µM proto-, copra- and 
uroporphyrinogen in the presence of lymphoblast sonicates using exposure to 
ultraviolet light and vigorous shaking in air. These conditions encouraged 
spontaneous re-oxidation of the porphyrinogens and was judged over 2h by 
appearance of porphyrin fluorescence. Results were expressed as a % of total 
porphyrin fluorescence measured prior to reduction. 
Protoporphyrinogen Coproporphyrinogen Uroporphyrinogen 
(100µM) (100µM) (100µM) 
Relative Relative Relative 
TIME (min) Fluorescence Fluorescence Fluorescence 
Pre-oxidation 
0 
15 
30 
45 
60 
75 
90 
105 
120 
100 100 100 
0 0 0 
35 27 26 
56 50 48 
67 63 62 
75 72 70 
82 80 77 
88 86 83 
92 90 89 
94 91 90 
copro- or uroporphyrinogen added and the preparation exposed to 
longwave ultraviolet and white light while being vigorously shaken. 
Porphyrin fluorescence was monitored every lSmin for 2h. Table 5.2 
indicates that exposure to these oxidising conditions for 2h resulted in 
94% re-oxidation of protoporphyrinogen, 91 % re-oxidation of 
coproporphyrinogen and 90% of uroporphyrinogen. 
Analysis of kinetic data comparing VP and control 
lymphoblast PBG deaminase 
Data obtained from assays of PBG deaminase reaction velocity at 
different substrate concentrations using lymphoblasts derived from 12 
quiescent VP and 12 control subjects were initially treated by 
application of the Michaelis-Menten equation (Bergmeyer, 1978) in 
Kinetics of PEG Deaminase 97 
order to obtain V max and Km. Data which did not conform to the 
Michaelis-Menten rate law were examined using the Hill equation 
(Van Holde, 1971). This equation is normally used to analyse 
cooperative interactions. A non-linear, least squares grid search 
procedure computed the following parameters from the Hill equation 
which were used for comparative purposes: V max, Ko.5 and the Hill 
coefficient, n. V max is the maximal catalytic rate (velocity) for PBG 
deaminase, Ko.sis the substrate concentration at which half-maximal 
velocity is achieved. The Hill coefficient describes the extent of 
cooperativity for ligand binding processes, or the extent to which 
multiple ligand-binding sites interact. The coefficient, n, is always less 
than the actual number ofligand-binding sites (Hammes, 1982). Thus 
for single site substrate binding processes displaying perfect 
hyperbolic Michaelis-Menten behaviour the Hill coefficients will 
approximate to 1. For hyperbolic behaviour Km, as obtained from the 
Michaelis-Men ten equation is identical to Ko.s. For processes not 
following Michaelis-Menten behaviour the Km per se is meaningless 
and an equivalent parameter, in this case termed Ko.s, is more 
informative. Appendix 10 gives detail of the Hill equation. A Hill plot, 
logv/(Vmax -v) versus log[S] (where vis the initial velocity at the given 
substrate concentration and [SJ is the substrate concentration), will 
have a slope of approximately 1 where the binding is independent and 
a slope approaching n where there is cooperativity. However, the 
binding is rarely so highly cooperative as to yield a straight line with 
slope n l over a wide range of log[S]. A more detailed analysis shows 
that the graph will approach a slope of unity near the extremes and 
have a maximum slope of <n. Numerically the Hill coefficient is always 
less than the actual number of ligand (substrate) binding sites. 
Comparisons were assessed for statistical significance using the 
Student's T-test. 
Addition of porphyrins and porphyrinogens 
Varying concentrations of pro to-, copra- and uroporphyrin and pro to-, 
copra- and uroporphyrinogen were added to control lymphoblasts and 
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to VP lymphoblasts. Data were analysed using the Hill equation and 
compared to those obtained in control or VP lymphoblasts without 
added test substances. The porphyrinogens were produced by 
reduction with sodium amalgam (Appendix 8) immediately prior to 
use. All test substances were added to the incubation mixture in final 
concentrations of 1, 5 and lOµM 5min prior to the start of the assay. 
The effect of varying the time between the addition and initiation of 
the PBG deaminase reaction was also examined by pre-incubating 
with porphyrins and porphyrinogens for times ranging from 5 to 60min. 
There was no significant change in the value of any of the determined 
parameters between 5 and 60min (see Results and figures 5.7 and 5.9). 
Separation of porphyrin(ogen)s from PBG deaminase in VP 
lymphoblasts 
1. Sephadex G25 chromatography 
After sonication of VP lymphoblasts Sephadex G25 chromatography 
was used to separate the low molecular weight endogenous 
porphyrin( ogen)s from fractions containing PBG deaminase activity. 
Fractions containing PBG deaminase were used for subsequent 
kinetic studies. 
In order to validate the separation of porphyrins and PBG deaminase 
a mixture of 0.5mM uro-, copra- and protoporphyrin was added to 
lOOOOXg supernatants of control lymphoblast sonicates. Additional 
porphyrins were added to ensure visible porphyrin fluorescence in the 
resulting porphyrin containing fractions eluted from the column. PBG 
deaminase activity was found to elute in the G25 void while porphyrins 
eluted at 3.2-3.4X the void volume (figure 5.2). 
Next supernatants (lOOOOXg) of sonicated VP lymphoblasts were 
applied to a 1.5X10cm Sephadex G25 column, equilibrated with O. lM 
Tris-HCl buffer (pH 8.2) and eluted, with the same buffer, at a flow 
rate of 40ml/h. Fractions containing PBG deaminase activity were 
pooled, concentrated on Centricon-30 (Amicon) columns through a 
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Figure 5.2: Elution profile of a mixture of porphyrins and lymphoblast PBG deaminase on 
Sephadex G25. Those fractions containing PBG deaminase activity were clearly 
separated from those containing porphyrins. 
P30 membrane and assayed for protein content pnor to PBG 
deaminase assay. 
·2. Oxidation of intracellular porphyrinogens 
If porphyrinogens are exerting an effect on PBG deaminase then their 
"removal" should be facilitated by subjecting lymphoblast 
preparations to oxidising conditions. VP lymphoblast sonicates were 
thus subjected to the "oxidising" conditions described above for 2h and 
PBG deaminase assayed in an aliquot both before and after 
porphyrinogen oxidation. 
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Results 
PBG deaminase kinetics in control and VP lymphoblasts 
Lymphoblast sonicate PBG deaminase from the 12 control subjects 
gave a mean Vmax of 25.2(±1.7)pmol/mg protein/h and a mean 
Michaelis constant (Km) of 8.1(±0.7)µM when fitted to the 
Michaelis-Menten equation and evaluated by double-reciprocal 
substrate versus velocity (Lineweaver-Burk) plots. Linearity of the 
Lineweaver-Burk plot and of the rate/substrate concentration versus 
rate (Eadie) plot confirmed the adherence of "control" PBG 
deaminase to the Michaelis-Menten rate law (figure 5.3). Application 
of the Hill equation to the same data gave mean values for V max of 
28. 7( ± 1.8)pmol/mg protein/h and Ko.s of 8.5( ±0.8)µM which were not 
significantly different from those obtained using the 
Michaelis-Menten equation. As expected, the Hill coefficient of 0.83 
was close to 1. 
X 10' 
1.6 
'.2 t 1.2 
..... 
0 
E 
C. 
: 0.8 
~ 
a: 
0.4 
0.4 0.8 1.2 1.6 X10 1 
[PBG] (µM) 
Figure 5.3: Substrate-velocity plot of PBG deaminase in control lymphoblast sonicates (mean 
of 12 sonicates). Michaelis-Menten kinetics were obeyed as illustrated by the 
straight lines obtained in the Lineweaver-Burke plot (inset 1) and the Eadie plot 
(inset 2). 
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x10' 
Identical experiments in sonicates of lymphoblasts from 12 VP 
subjects yielded substrate-velocity data that did not conform to 
Michaelis-Menten kinetics. Non-hyperbolic behaviour was 
demonstrated by failure of the data to produce a straight line with 
either the Lineweaver-Burk or Eadie plots (figure 5.4). (The Eadie 
plot is particularly suitable for showing lack of adherence to 
Michaelis-Menten kinetics.) Hence Vmax and Km could not be 
assessed by this method. The Hill equation, however, did allow these 
determinations. Control and VP results are contrasted table 5.3. 
Lymphoblast V max values were decreased by a mean of 26% in the VP 
group, a figure similar to the decrease in V max observed in the 
conventional substrate excess assay described in the Chapter 4. The 
mean substrate-velocity plot of the group of VP lymphoblasts was 
sigmoidal (figure 5.5). The Hill plot had a maximum slope equal to the 
Hill coefficient but approached unity near the extremes. 
1.6 4 
x10' 
1.6 
~ 1.2 
a, 
..§ 
0 
E 
2 0.8 
w 
~ 
a: 
0.4 
4 
0 .80 0 .88 0 .96 1.04 1. 12 1.20 1.26 
RATE/ [PBG] 
Figure 5.4: PBG deaminase in VP lymphoblast 
sonicates (mean of 12 sonicates) showed lack of 
conformity to the Michae/is-Menten rate equation as 
demonstrated by non-linearity of the. Eadie plot. 
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Figure 5.5: Sigmoidal substrate-velocity plot of VP 
lymphoblast PBG deaminase. The curve was drawn 
by fitting the data to the Hill equation. The Hill plot is 
shown in the inset. 
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Table 5.3: Kinetic parameters for control and VP lymphoblasts when analysed by the Hill 
equation. Vmax was significantly decreased in the VP cells. Ko.5 values were not 
significantly altered but the Hill coefficients of the 2 groups were different. 
Vmax Ko.s Hill 
(pmol/mg/h) (µM) coeffcient 
Controls 28.7 ±1.8 8.5 ±0.8 0.83 ±0.07 · 
VP 21.2 ±2.0 7.4 ±0.7 1.78 ±0.17 
% Difference 26% Not 
(p<0.001) Significant 
(p=0.424) 
Addition of porphyrins to control lymphoblast sonicates 
The addition of 1, 5, or lOµM proto-, copra- or uroporphyrin had no 
effect on the kinetic behaviour of PBG deaminase in 12 control 
lymphoblast sonicates. It was hoped that this range would approximate 
that found in the various phases of VP in vivo. Figure 5.6 shows the 
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Figure 5.6: Substrate-velocityplots of PBG deaminase in control lymphoblast sonlcates after 
5min pre-incubation In the presence of 10µM protoporphyrin ( o-a ), 10µM 
coproporphyrin ( o····O ) and 10µM uroporphyrin ( 1::r-- -c. ). There were no 
differences between these plots and that obtained without additional porphyrins 
(figure 5.3). Kinetic data derived from these curves are given in table 5.4. 
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mean substrate-velocity plots oflymphoblast PBG deaminase after the 
addition of lOµM proto-, copra- and . uroporphyrin which were 
pre-incubated for 5rnin before substrate (PBG) was added. Table 5.4 
lists the results obtained with 1, 5 and lOµM concentrations of the 
corresponding porphyrin series. 
Pre-incubating lymphoblast preparations with lOµM proto-, copro-
and uroporphyrin for periods of time up to lh before assaying PBG 
deaminase (figure 5.7) shows that these longer periods of 
pre-incubation did not alter PBG deaminase behaviour. 
Table 5.4: Control PBG deaminase kinetic parameters in the absence and in the presence 
of 1, 5 and 10/tM proto-, copro- and uroporphyrin. The porphyrins were added 
to the incubation mixture 5min prior to the start of the assay. Results were obtained 
by fitting substrate-velocity data to the Hill equation and are expressed as the 
mean of the 12 control lymphoblast preparations used in the study (±SD). No 
systematic or significant trends or differences were obseNed. 
Control lymphoblasts 
No additions 
+ 1µM Proto 
+ 5µM Proto 
+ 10µM Proto 
+ 1µM Copro 
+ 5µM Copro 
+ 10µM Copro 
+ 1µM Uro 
+ 5µ M Uro 
+ 10µM Uro 
Vmax 
(pmol/mg/h) 
28.7 ±1.8 
28.4 ±2.9 
28.4 ±1.7 
29.3 ±1.6 
30.2 ±2.1 
31 .2±1 .3 
30.8 ±1.6 
28.8±1.3 
34.5 ±3.3 
30.9 ±2.0 
Ko.s 
(µM) 
8.5 ±0.8 
8.4 ±1.1 
8.3 ±0.9 
8.0 ±1.0 
8.8 ±1.9 
8.9 ±1.2 
9.5 ±0.9 
9.0±1.0 
8.5 ±1.3 
8.7 ±1.3 
Hill 
coeffcient 
0.83 ±0.07 
0.89 ±0.10 
0.90 ±0.09 
0.87 ±0.10 
0.86 ±0.10 
0.89 ±0.05 
0.88 ±0.07 
0.95 ±0.11 
0.78 ±0.1 6 
0.82 ±0.08 
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Figure 5. 7: Effect of length of pre-incubation period in the presence of 10µM proto-, copro-
and uroporphyrin on PBG deaminase rate (A) and Ko.5 (8). No systematic or significant 
changes are observed. 
Addition of porphyrinogens to control lymphoblast sonicates 
1, 5 and lOµM concentrations of protoporphyrinogen all displayed a 
striking ability to alter the kinetic behaviour of control lymphoblast 
PBG deaminase, resulting in reduced V max activity and sigmoidal 
substrate-velocity plots resembling those observed in VP 
lymphoblasts. Figure 5.8 illustrates these effects and table 5.5 
summarises the data obtained from the Hill equation in each case. 
Compared to the values obtained in the absence of additional 
porphyrinogen, Vma.'< was decreased by an average of 41% (p<0.001) 
while the Ko.s was unaltered (p = 0.361). Vmax tended to decrease as 
the concentration of protoporphyrinogen increased, but this did not 
achieve statistical significance. The Ko.s obtained in the presence of 
lOµM protoporphyrinogen was greater than that obtained with 5µM 
protoporphyrinogen which was in turn greater than that in the 
presence of lµM protoporphyrinogen. As in the case of V max, variation 
of Ko.s within the group didn't achieve significance. 
As the concentration of protoporphyrinogen was increased over a 
ten-fold range, the Hill coefficient increased to approach a value of 4 
in the limit. 
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Figure 5.8: Substrate-velocity plots of PBG deaminase in control lymphoblast sonicates after 
5min incubation in the presence of 1( o--a ), 5( o--o) and 10µM( L:!:-6) 
protoporphyrinogen. There were striking differences between these curves and 
that obtained with no addition ( o---o ). Each data point on each curve 
represents the mean of observations carried out in 12 control lymphoblast 
preparations. Kinetic data corresponding to these curves are given in table 5.5. 
Table 5.5: Control PBG deaminase kinetic parameters in the absence and in the presence 
of 1, 5 and 10µM protoporphyrinogen. Results were obtained by fitting 
substrate-velocity data to the Hill equation and are expressed as the mean of the 
12 control lymphoblast preparations used in the study (SD). 
Control lymphoblasts 
No additions 
+ 1µM Proto'gen 
+5µM Proto'gen 
+ 10µM Proto'gen 
Vmax 
(pmol/mg/h) 
28.7 ±1.8 
17.7 ±1 .3 
16.4 ±1.7 
16.1 ±1.6 
Ko.s 
(µM) 
8.5±0.8 
7.7±1.1 
8.9 ±1.1 
10.9 ±2.1 
Hill 
coeffcient 
0.83 ±0.07 
2.89 ±0.43 
3.05 ±0.47 
3.61 ±0.45 
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Figure 5.9: Effect of period of pre-incubation in the presence of 10µM protoporphyrinogen 
on PBG deaminase rate and Ko.5. The kinetic changes as determined by the Hill 
equation apparent at 5min were not further enhanced or diminished over 1h. 
Longer periods of pre-incubation in the presence of 
protoporphyrinogen appeared to exert no further alterations on the 
kinetic behaviour of control lymphoblast PBG deaminase (figure 5.9). 
The effect of pre-incubation times under 5min were not determined. 
Addition of 1, 5 and lOµM concentrations of coproporphyrinogen had 
a similar but less impressive effect on control lymphoblast PBG 
deaminase. Vmaxwas decreased by an average of 27% (p<0.001) and 
the Hill coefficients appeared to approach 3 (in the limit) as 
coproporphyrinogen concentrations were increased over a ten-fold 
range. The mean of the Ko.s values between the lymphoblasts with 
additions and those without were not significantly different 
(p = 0.247). The distinctive sigmoidal substrate-velocity plot was once 
again observed as were the trends in Vmax and Ko.s (figure 5.10 and 
table 5.6). Longer periods of pre-incubation in the presence of 
coproporphyrinogen showed no further changes to those measured 
after 5min of pre-incubation ( data not shown). 
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Figure 5. 1 O: Substrate-velocity plots of PBG deaminase in control lymphoblast sonicates after 
5min incubation in the presence of 1( o--o ), 5( o--o ) and 10µM( fr-"6) 
coproporphyrinogen. There were significant differences between these curves 
and that obtained with no addition ( o-- --0 ). Each data point on each curve 
represents the mean of observations carried out in 12 control /ymphoblast · 
preparations. Kinetic data corresponding to these curves are given in table 5.6. 
Table 5.6: PBG deaminase kinetic parameters in the absence and in the presence of 1, 5 
and 10µM coproporphyrinogen. The experiments were performed and results 
obtained exactly as for the protoporphyrinogen additions. 
Control lymphoblasts 
No additions 
+ 1µM Copro'gen 
+5µM Copro'gen 
+ 10µM Copro'gen 
Vmax 
(pmol/mg/h) 
28.7 ±1.8 
21.8 ±1 .8 
21.5 ±2.2 
19.5 ±1.9 
Ko.s 
(µM) 
8.5 ±0.8 
8.5 ±2.3 
9.8 ±1.3 
10.3 ±1.4 
Hill 
coeffcient 
0.83 ±0.07 
1.67 ±0.51 
1.96 ±0.33 
2.51 ±0.38 
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In contrast to the striking effects noted on the addition of proto- and 
coproporphyrinogen, uroporphyrinogen failed to influence the kinetic 
behaviour of control lyrnphoblast PBG dearninase. There were no 
significant differences in V max, Ko.s, the Hill coefficient (p>0.05 in all 
cases) or in the shape of the substrate-velocity plot (figure 5.11 and 
table 5.7). 
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Figure 5.11: Substrate-velocity plots of PBG deaminase in control lymphoblast sonicates after 
5min incubation in the presence of 1( o-o ), 5( O··· ·O ) and 10µM( t:r--6.) 
uroporphyrinogen. Each data point on each curve represents the mean of 
observations carried out in 12 control lymphoblast preparations. Kinetic values 
in table 5. 7. 
Table 5.7: PBG deaminase kinetic values in the absence and in the presence of 1, 5 and 
10µM uroporphyrinogen. The experiments were performed and results obtained 
exactly as for the protoporphyrinogen additions. 
Control lymphoblasts 
No additions 
+ 1µM Uro'gen 
+ 5µM Uro'gen 
+ 10µM Uro'gen 
Vmax · 
(pmol/mg/h) 
28.7 ±1.8 
30.1 ±1.5 
28.7 ±2.4 
29.0 ±1.6 
Ko.s 
(µM) 
8.5 ±0.8 
7.8 ±1.2 
8.7 ±1.0 
8.4 ±1.1 
Hill 
coeffcient 
0.83 ±0.07 
0.79 ±0.26 
0.93 ±0.11 
0.89 ±0.13 
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An identical series of experiments was then carried out using 
lymphoblast sonicates from 12 VP subjects. 
Addition of porphyrins to VP lymphoblast sonicates 
The addition of 1, 5, or lOµM proto-, copro- or uroporphyrin had no 
additional effect on the already anomalous kinetic behaviour of PBG 
deaminase in 12 VP lymphoblast sonicates. Figure 5.12 shows the 
mean substrate-velocity plots of VP lymphoblast PBG deaminase after 
the addition of lOµM proto-, copro- and uroporphyrin while table 5.8 
details these results and the results obtained with 1 and 5µM 
concentrations of the same porphyrin series. Longer periods of 
pre-incubation in the presence of the various porphyrin additions did 
not result in any additional effects on VP PBG deaminase behaviour ( data not shown). 
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Figure 5.12: Substrate-velocity plots of PBG deaminase in VP lymphoblast sonic ates after 5min 
incubation in the presence of 10µM protoporphyrin (0-,J), 10µM coproporphyrin ( O···O) and 10µM uroporphyrin (L::,.---c) . There were no apparent differences 
between these plots and that obtained in VP lymphoblasts without additional 
porphyrins (figure 5.5). See table 5.8 for kinetic data. 
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Table 5.8: VP PBG deaminase kinetic parameters in the absence and in the presence of 1, 
5 and 10µM proto-, copro- and uroporphyrin. Experiments were carried out as for 
the addition of porphyrins to control lymphoblasts. There was no systematic 
variation or significant differences in any of the values. 
VP lymphoblasts 
No additions 
+ 1µM Proto 
+ 5µM Proto 
+10µM Proto 
+ 1µM Copra 
+ 5µM Copra 
+10µM Copra 
+ 1µM Ura 
+ 5µM Ura 
+ 10µM Ura 
Vmax 
(pmol/mgf h) 
21.2 ±2.0 
19.2 ±2.8 
20.0 ±1.6 
18.8±1.4 
19.8 ±1 .8 
19.3 ±2.2 
21 .1 ±1 .9 
17.9 ±1 .5 
20.4 ±2.3 
18.1 ±1.5 
Ko.s 
(µM) 
7.4 ±0.7 
10.1 ±1.2 
9.2 ±1.9 
7.6 ±2.2 
7.5 ±1 .6 
8.5 ±1.8 
8.4 ±1 .7 
7.4 ±1.4 
7.1 ±1.0 
8.9 ±1.3 
Hill 
coeffcient 
1.78 ±0.17 
1.97 ±0.20 
1.91 ±0.21 
1.82 ±0.16 
1.83 ±0.25 
1.72 ±0.18 
1.93 ±0.21 
1.87 ±0.30 
1.92 ±0.31 
1.88 ±0.29 
Addition of porphyrinogens to VP lymphoblast sonicates 
Addition of proto- and coproporphyrinogen to VP lymphoblast 
sonicates (figures 5.13 and 5.14, table 5.9) resulted in an exaggeration 
of the kinetic changes already present. Once again 
protoporphyrinogen appeared to have a greater effect than 
coproporphyrinogen. V max values were not decreased further than the 
decreased levels induced by addition of equivalent amounts of proto-
or coproporphyrinogen to control lymphoblasts. Similarly, the Hill 
coefficients never tended to a value greater than 4 in any of the cases 
examined. 
As in the control lymphoblasts, uroporphyrinogen failed to exert any 
additional effect on VP PBG deaminase kinetic behaviour (figure 5.15 
and table 5.9). 
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Figure 5.13: Substrate-velocity plots of PBG deaminase in VP lymphoblast sonicates in the 
presence of 1( t:,.---6. ), 5( o·····O ) and 10µM( [)--{] J protoporphyrinogen. 
Each data point on each curve represents the mean of observations carried out 
in 12 VP lymphoblast preparations. The curve obtained with no additions is 
included for reference ( <>-·-·-0 ). The kinetic alterations observed in VP 
lymphoblasts were further enhanced by addition of protoporphyrinogen. 
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Figure 5.14: Substrate-velocity plots of PBG deaminase in VP lymphoblast sonicates in the 
presence of 1(t:,,...-t:,.), 5(0···0) and 10µM(o--a) coproporphyrinogen. Each data 
point on each curve represents the mean of observations carried out in 12 VP 
lymphoblast preparations: The curve obtained with no additions is included for 
reference (<>-<>). Kinetic values in table 5.9. 
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Table 5.9: VP PBG deaminase kinetic parameters In the absence and in the presence of 1, 
5 and 10µM proto-, copro- and uroporphyrinogen. Kinetic anomalies already 
present in the VP lymphoblasts were further enhanced by addition of 
VP lymphoblast 
No additions 
+ 1µM Proto'gen 
+5µM Proto'gen 
+ 1 OµM Proto'gen 
+ 1µM Copro'gen 
+5µM Copro'gen 
+ 1 OµM Copro'gen 
+ 1µM Uro'gen 
+5µM Uro'gen 
+ 10µM Uro'gen 
--.i:::. 
...... 
Ol 
E 
...... 
0 
E 
.s 
w 
~ 
a: 
x10 1 
1.6 
1.2 
0.8 
0 .4 
0 
Vmax 
(pmol/mg/h) 
21.2 ±2.0 
17.7 ±1.8 
17.3±1.5 
16.6 ±1.3 
19.0 ±1.5 
18.5 ±2.0 
18.3 ±1 .8 
20.4 ±1.4 
19.5 ±1 .3 
21 .3 ±2.2 
Ko.s 
(µM) 
7.4 ±0.7 
7.2 ±1.0 
8.5 ±1 .2 
8.7 ±1.1 
8.5 ±1.1 
7.9 ±2.2 
8.9 ±1.4 
7.5 ±1.6 
9.4 ±1.8 
7.6 ±0. 
O 0.4 0.8 1.2 1.6 x10 1 
[PBG] 
Hill 
coefficient 
1.78 ± 0.17 
2.25 ±0.40 
2.64 ±0.49 
3.22 ±0.42 
1.88 ±0.31 
2.01 ±0.33 
2.05 ±0.31 
1.75 ±0.19 
1.75 ±0.18 
1.83 ±0.20 
Figure 5.15: Substrate-velocity plots of PBG deaminase in VP /ymphoblast sonicates after 
5min incubation in the presence of 1(0--0 ), 5( er---6 ) and 10µM(o····o) 
uroporphyrinogen. These curves were not significantly different to those obtained 
from VP lymphoblasts in the absence of uroporphyrinogen additions. Kinetic 
values corresponding to these curves are given in table 5.9. 
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Sephadex G25 chromatography 
Sephadex 025 allowed separation of fractions containing PBO 
deaminase activity and those containing porphyrins ( and presumably 
porphyrinogens) (see Methods, figure 5.2). Application of control 
lymphoblast preparations to this column resulted in the same kinetic 
profile before and after Sephadex 025 chromatography ( data not 
shown). In striking contrast, application of VP lymphoblast 
preparations to this column resulted in fractions containing PBO 
deaminase activity which after pooling and concentrating displayed 
kirietic characteristics identical to those of control lyrnphoblasts 
(figure 5.16 and table 5.10). 
Oxidation of intracellular porphyrinogens 
The results of an experiment designed to convert any endogenous 
porphyrinogens to their corresponding porphyrin forms and thus to 
restore normal kinetic behaviour to VP lymphoblast PBO deaminase 
are summarised in table 5.11. The kinetic profile of VP PBO 
deaminase was unchanged after exposure to oxidising conditions for 
2h. 
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Figure 5.16: VP lymphoblast PBG deaminase substrate-velocity plots before ( _._......_ ) and 
after ( 6 .. , .. ,-6_) Sephadex G25 chromatography. "Normal" kinetic behaviour was 
apparently restored to PBG deaminase. 
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Table 5.10: Kinetic parameters for VP /ymphoblast PBG deaminase before and after 
Sephadex G25 chromatography. All parameters as determined by the Hill 
VP: Pre-Sephadex 
VP: Post-Sephadex 
Vmax 
(pmo!Jmg/h) 
19.9 ±1 .9 
30.8 ±1 .6 
Ko.s 
(µM) 
7.9 ±1 .2 
6.7 ±2.9 
Hill 
coefficient 
1.78 ±0.21 
0.82 ±0.33 
Table 5.11: Effect of 2h of oxidising conditions on VP lymphoblast PBG deaminase. Kinetic 
values determined by the Hill equation appeared unaffected by this treatment. 
The data quoted represents the mean of'} separate experiments using 4 different 
VP cell lines. 
VP: Pre-oxidation 
VP: Post-oxidation 
Discussion 
Validity of methods 
Vmax 
(pmo/Jmg/h) 
21.0 ±1.7 
20.1 ±1 .6 
Ko.s 
(µM) 
7.3 ±1.5 
7.5 ±1 .6 
Hill 
coefficient 
1.84 ±0.30 
1.79 ±0.29 
Substrate-velocity data for PBG deaminase were obtained by 
measuring the rate of formation of uroporphyrinogen at 5 substrate 
concentrations. Ideally these concentrations should fall both above 
and below the Km for the enzyme (Van Holde, 1971) so as to cover a 
wide range of the V max. The literature reports Km values ranging 
between 6 and 22µM (Sancovich et al, 1969; Sassaet al, 1978; Anderson 
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and Desnick, 1980, 1982; Fumagalli, 1985) and our data indicated a 
Km ( or the equivalent Ko.s using Hill analysis) of approximately 8µM 
for lymphoblast PBG deaminase originating from healthy control 
subjects. Thus the choice of PBG concentrations of 1.25, 2.5, 5, 10 and 
20µM appears to be justified since these substrate concentrations 
cover a range from 13 % to 73 % of V max. 
Analysis of the data obtained in control lymphoblasts by the 
Michaelis-Menten equation yielded a Vmax of 25.2 ±1.7 pmol/mg/h 
and a Km of 8.1 ±0.7 µM. There are only two previous reports of the 
measurement of PBG deaminase activity in lymphoblasts. One (Anderson and Desnick, 1982) gives an activity of llpmol/mg 
protein/h for human lymphoblast lines but it is unclear whether these 
were Epstein-Barr virus-transformed lymphoblast lines, and another 
(Sassa et al, 1978) 40 and 68pmol/mg protein/h for PHA or PWM 
stimulated lymphocytes and Epstein-Barr virus transformed 
lymphoblasts respectively. It must be noted that reported erythrocyte 
PBG deaminase activities show a large range which underscores the 
need to establish control values for each individual laboratory and 
method (Kreimer-Birnbaum et al, 1980). Our control lymphoblast 
results appear to be of the same order as those in other reports and 
were thus considered a valid standard for the purposes of this study. 
We were concerned that addition of exogenous porphyrins to the assay 
system would result in inaccuracies in the "standard" PBG deaminase 
assay. We therefore examined this possibility by quantifying all 
porphyrins, including reaction product, with an analytical TLC 
technique. This enabled us to gauge precisely the types and quantities 
of porphyrin present at time zero and at the completion of the assay 
reaction. The rate of uroporphyrin production determined using the 
"standard" assay (26.2 ±4.1 pmol/mg protein/h) agreed favourably 
with that obtained by the TLC approach (28.0 ±2.1 pmol/mgprotein/h) 
although it gave marginally less consistent results (SD= 4.1 as opposed 
to 2.1 using the TLC approach). It therefore appeared satisfactory to 
continue using the "standard" PBG deaminase assay method. (Note, 
however, that we did dilute aliquots of the assay mixture tenfold prior 
to fluorometric determination to reduce any possible quenching.) 
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The stability of the porphyrinogens used in the study was also an area 
of concern. Had significant auto-oxidation occurred during the 
pre-incubation and assay periods it would have been difficult to ascribe 
any change in PBG deaminase behaviour to the presence of 
porphyrinogen. Fortunately all 3 porphyrinogens used displayed less 
than 6% re-oxidation over lh under conditions of the PBG deaminase 
assay (figure 5.1). Protoporphyrinogen was the most labile and 
approximately 18% had re-oxidised by 2h. This agrees with the 
experience of other workers (Brenner and Bloomer, 1880b; Jacobs and 
Jacobs, 1982; Personal communication, Camadro JP). 
To assess whether there was any appreciable degradation or 
inter-conversion of porphyrins as a result of the reduction process, we 
assessed the recovery rate following chemical re-oxidation at 2h. After 
iodine treatment there was virtually complete recovery of the original 
fluorescence of uro- or coproporphyrin and approximately 90% that 
of protoporphyrin (figure 5.1). The slight loss of protoporphyrin might 
result from reduction of the vinyl side-chains by sodium amalgam 
(Fuhrhop and Smith, 1975) or by iodine attack on the vinyl groups 
(Sano and Granick, 1961). However, we were satisfied that virtually 
complete reduction of the porphyrins could be achieved without 
damage to the porphyrin side-chains of copra- and uroporphyrin, and 
little, if any, to those of protoporphyrin. 
Differences in kinetic behaviour of VP and control 
lymphoblast PBG deaminase 
Comparison of kinetic behaviour of VP lymphoblast PBG deaminase 
with that of control lymphoblasts yielded the unprecedented 
observation that whereas normal ( control) PBG deaminase exhibited 
kinetic properties associated with a hyperbolic substrate-velocity 
curve involving enzyme substrate interaction at a single ligand-binding 
site, VP PBG deaminase did not. 
while the mechanism of action of PBG deaminase remains a subject 
of research activity and debate (Jordan and Berry, 1981; Jordan and 
Warren, 1987; Battersby, 1988; Scott et al, 1988. See Chapter 1), it is 
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generally assumed that in most cases the appearance and rate of 
production of uroporphyrinogen from PBG by the enzyme follows the 
Michaelis-Menten rate law. There are, however, reports of 
non-Michaelian behaviour from one group (Sancovich et al, 1969; 
Llambias and Batlle, 1970; Fumagalli et al, 1985. See Chapter 3). 
In our study, in impure preparations, PBG deaminase from control 
lymphoblasts exhibited classic Michaelis-Menten behaviour. This was 
borne out by the linearity of the Lineweaver-Burk plot (1/Rate versus 
1/[Substrate]) and the Eadie plot (Rate/[Substrate] versus Rate) (figure 5.3). 
The Hill equation (Von Holde, 1971 and Appendix 10) can also be 
used for determining kinetic data. Under conditions where there is a 
hyperbolic substrate-velocity relationship, the Hill coefficient 
approaches 1 and should yield V max and Ko.s values equivalent to the 
Michaelis-Men ten V max and Km. This was the case for control 
lymphoblast PBG deaminase. 
The Hill equation is typically used to analyse the number of 
ligand-binding sites . and their interdependence of macromolec:ular 
species such as proteins. The macromolecule as a whole may be either 
multimeric or monomeric, but with · more than one possible 
ligand-binding site. A Hill coefficient close to 1 (in this case 0.83) 
implies that the enzyme has only one binding site or that multiple sites, 
if present, are identical and that the binding at any site is independent 
of the occupation of other sites. It is generally accepted that PBG 
deaminase exists in monomeric form and, that there is only one 
substrate (ligand)-binding site (Sassa et al, 1978; Anderson and 
Desnick, 1979; Jordan and Berry, 1981. See Chapter 3). However, 
closer kinetic examination of the pure enzyme in one case (Llambias 
and Batlle, 1970; Fumagalli et al, 1985) suggests that there may be two. 
The substrate-velocity data for VP lymphoblast PBG deaminase does 
not fit the Michaelis-Menten equation (figure 5.4). The most striking 
difference was a sigmoidal substrate-velocity plot. However, the data 
fitted the Hill equation well. 
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Using the Hill equation, Vmax in the VP cells gave a mean value of 
21.2 ±2.0 pmol/mg protein/b, a significant 26% decrease over that of 
control cells (table 5.3). This is consistent with our earlier observation 
of decreased PBG deaminase activity in VP lymphoblasts when we 
used a single saturating substrate concentration for the assay (figure 
4.11). Comparison of the Ko.s values obtained in the VP and control 
groups showed no significant alterations. This implies that there was 
no major difference in the thermodynamics of ligand binding by PBG 
deaminase in the two groups. It is thus unlikely that the different 
behaviour of the two groups is due to a major strnctural defect. 
A sigmoidal substrate-velocity curve implies the presence of more 
than one cooperative ligand-binding site. The substrate-velocity plot 
of VP lymphoblast PBG deaminase yielded a Hill coefficient of 1.78 
±0.17 (ie.<2). The data thus suggest that PBG deaminase is converted 
from a form displaying independent substrate binding in the control 
lymphoblasts to one which displays multiple cooperative binding sites 
in the VP lymphoblasts. In this case, there appears to be two interacting 
substrate-binding sites. Furthermore, this form of PBG deaminase 
exhibits a reduced V max. 
These findings may support the suggestion that monomeric PBG 
deaminase possesses more than one substrate-binding site only one of 
which is available under normal circumstances for binding, while the 
others are blocked either by some . controlling factor or by 
conformational exclusion. Alternatively PBG deaminase may possess 
only one ligand-binding site, but in VP a number of PBG deaminase 
monomers are somehow brought into close proximity to form a 
cooperative multimeric structure with decreased catalytic ability. 
Addition of porphyrinogens to control lymphoblast PBG 
deaminase preparations 
In contrast to the various porphyrins which failed to influence PBG 
deaminase kinetics, addition of proto- and coproporphyrinogen to 
control lymphoblasts produced a marked alteration in the PBG 
deaminase substrate-velocity behaviour. Indeed, addition of proto-
I _.,.,., 
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and coproporphyrinogen resulted in PBG deaminase kinetics which 
closely resemble those observed in "native" VP lymphoblasts. 
1. Addition of protoporphyrinogen 
Figure 5.8 illustrates both a decreased V max and a change in the form 
of the substrate-velocity plot to a sigmoidal form when 
protoporphyrinogen was added. V max was decreased most by lOµM 
protoporphyrinogen and least by lµM protoporphyrinogen (table 
5.5). Although there was an inverse relationship between Vmax and 
protoporphyrinogen concentration this did not appear to be directly 
proportional. Possibly the effect is already maximal at a concentration 
of 5 or lOµM, or the impurity of PBG deaminase in the lymphoblast 
preparations is such that small trends in activity are not accurate 
reflections on the true behaviour. 
Secondly, there was a uniform increase in the Hill coefficient which 
ranged between 2.89 and 3.61. This implied that, in response to 
additional protoporphyrinogen, PBG deaminase exhibits up to four 
ligand-binding sites, and not just the two observed in "native" VP 
lymphoblasts. Either protoporphyrinogen mediates the aggregation of 
up to four monomeric units, or that of alternative schemes such as two 
dimeric units, or it in some way removes blocking factors present on 
other, hitherto unsuspected, binding sites. 
Thirdly, addition of protoporphyrinogen resulted in a small, although 
statistically insignificant, trend in Ko.s, its value increasing with an 
increase in the concentration of protoporphyrinogen. As in VP PBG 
deaminase this indicates no major change to the overall 
thermodynamics of ligand-binding by PBG deaminase. 
2. Addition of coproporphyrinogen 
Addition of coproporphyrinogen to control lymphoblast preparations 
produced effects similar to those observed after addition of 
protoporphyrinogen. The changes in shape of the substrate-velocity 
curve and the diminution Vmax activity were less marked than those 
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produced by protoporphyrinogen. For 1 and 5µM coproporphyrinogen 
the Hill coefficient approached 2 and for lOµM coproporphyrinogen, 
3. Presumably coproporphyrinogen influenced PBG deaminase in the 
same way as protoporphyrinogen, but is less "potent" an inhibitor. This 
may be due to the difference in side-group composition. 
3. Addition of uroporphyrinogen 
Thus far the data supports the thesis that proto- and 
coproporphyrinogen, presumably present in higher intracellular 
concentrations in VP lymphoblasts than in control lymphoblasts, alter 
PBG deaminase in such a way that there is a partial inhibition of 
activity and the appearance of cooperativity with multiple 
substrate-binding sites. Further support of this thesis is lent by the 
failure of uroporphyrinogen to alter the kinetic behaviour of PBG 
deaminase. Though it is highly likely that intracellular concentrations 
of uroporphyrinogen are elevated in PCT, there is no evidence to 
suggest altered PBG deaminase functioning; ALA and PBG 
concentrations are never elevated in PCT and certainly no acute 
attacks have ever been described for this condition. The lack of effect 
ofuroporphyrinogen on PBG deaminase may explain this (figure 5.11 
and table 5.7). 
Addition of porphyrinogens and porphyrins to VP 
lymphoblast PBG deaminase preparations 
Analysis of PBG deaminase substrate-velocity data in VP lymphoblast 
soriicates by the Hill equation yielded Hill coefficients (table 5.3). 
Greater degrees of change were induced in control lymphoblasts to 
which 1, 5 and lOµM concentrations of proto- and coproporphyrinogen 
were added. It should therefore be possible to enhance the anomalous 
behaviour of VP lymphoblast PBG deaminase by addition of further 
proto- and coproporphyrinogen. Similarly, the addition of 
uroporphyrinogen, proto-, copro- and uroporphyrin would be 
expected to be without effect. This proved to be trne. 
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1. Addition of protoporphyrinogen 
Addition of 1, 5 and lOµM protoporphyrinogen to VP lymphoblast 
preparations did' indeed enhance the kinetic changes already noted 
(figure 5.13). The data obtained (table 5.9) indicated a similar 
minimum level of PBG deaminase activity and similar Ko.s values to 
those observed in control lymphoblasts to which proto- or 
coproporphyrinogen were added. The Hill coefficients, however, 
differed. 1 and 5µM protoporphyrinogen yielded Hill coefficients 
between 2 and 3, and lOµM protoporphyrinogen gave a Hill coefficient 
of 3.22 ( compare to table 5.5). The Hill coefficients in treated VP 
lymphoblasts never exceeded 4. Thus the addition of 
protoporphyrinogen to VP lymphoblasts indeed appeared to 
aggravate an existing alteration in the behaviour of PBG deaminase. 
2. Addition of coproporphyrinogen 
Addition of coproporphyrinogen to VP lymphoblast preparations 
resulted in changes similar to those described above (figure 5.14). 
However, the coproporphyrinogen data differ from the addition of 
protoporphyrinogen in one respect. Whereas protoporphyrinogen 
induced increasing degrees of enhancement with increasing 
concentration, 1, 5 and lOµM coproporphyrinogen all produced a very 
similar degree of enhancement (figure 5.14 and table 5.9). It thus 
appeared that the kinetic changes induced in VP lymphoblasts by 
coproporphyrinogen were already at a maximum when lµM additional 
coproporphyrinogen was present. This was not so in control 
lymphoblast PBG deaminase. 
3. Addition of uroporphyrinogen and porphyrins 
Uroporphyrinogen, like the porphyrins, failed to influence the kinetics 
of PBG deaminase in VP lymphoblasts (figure 5.15, table 5.9 and 
figure 5.12, table 5.8). This was consistent with the finding in control 
lymphoblasts. 
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Further comment on the data thus far discussed 
Decreasing the number of carboxyl groups on the porphyrinogen 
appeared to enhance the effect of the porphyrinogen on PBG 
deaminase: Uroporphyrinogen had no effect, while the effect of 
coproporphyrinogen was less than that of protoporphyrinogen. This 
suggests that steric and/or hydrophobic effects may be import in the 
phenomenon observed. Secondly, the lack of influence of porphyrins 
on PBG deaminase may be due to the strongly aromatic nature of these 
compounds, in contrast to the unconjugated macrocyclic ring system 
of the porphyrinogens. In the porphyrins the conjugated :n:-electron 
systems lie above and below the whole tetrapyrrolic macrocycle and 
may shield the porphyrin from potential interaction with the enzyme 
molecule. The porphyrinogens, on the other hand are aliphatic and the 
aromaticity is confined to the individual pyrrolic "corners" (Bonnett, 
1981). This means that the interpyrrolic methylene groups are more 
accessible. 
These data give no direct clue as to the nature of the interaction 
between proto- and coproporphyrinogen and PBG deaminase. It is 
thus only possible to theorise: Presumably the binding may involve 
hydrogen bonding, hydrophobic interaction or covalent attachment. 
The maximum of 4 possible ligand-binding sites would imply that up 
to 4 molecules of PBG deaminase ( assuming PBG deaminase to 
possess a single substrate-binding site) may be brought together by the 
porphyrinogen. This may result in a randomly stacked complex or 
perhaps an ordered complex arranged around a single molecule of 
porphyrinogen. Thus the porphyrinogen, being a tetrapyrrole, may 
possess 4 similar areas of potential interaction and may therefore bind 
4 molecules of PBG deaminase, resulting in a Hill coefficient, n<4 
However, a random stacking arrangement might allow a larger 
number than 4 PBG deaminase molecules to stack together in a 
multimeric, or even polymeric, unit. The Hill data suggest that this 
does not happen, possibly because of thermodynamic instability, or 
because the association is not via a random stacking. 
Furthermore, PBG deaminase requires a covalently bound 
dipyrromethane cofactor (Jordan and warren, 1987; Scott et al, 1988) 
' ..... ·-
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which facilitates binding of substrate (PBG) and directs synthesis of 
the linear tetrapyrrole hydroxymethylbilane. The porphyrinogens and 
dipyrromethane exhibit structural similarity; in very broad terms 1 
porphyrinogen = 2X dipyrromethane. This may lead to the PBG 
deaminase binding to an analogous structural area in . the 
porphyrinogens rather than to the dipyrromethane cofactor. There 
are, however, several objections to this speculation. The side groups 
possessed by dipyrromethane are exactly analogous to those on 
uroporphyrinogen, and less to those on copra- or protoporphyrinogen 
( table 1.1 and figure 1.5). Yet uroporphyrinogen has no effect on PBG 
deaminase. It has also been suggested that the dipyrromethane 
cofactor binds before folding of the PBG deaminase polypeptide takes 
place, and that it remains resident for "life" (Scott et al, 1988). It must 
therefore be stressed that the above suggestion is purely speculative. 
That elevated intracellular concentrations of proto- and 
coproporphyrinogen lead to altered behaviour of PBG deaminase 
appears therefore to be true, at least in the lymphoblast system used 
in this study. This would be further supported if the removal of 
protoporphyrinogen and/or coproporphyrinogen from VP 
lymphoblasts resulted in restoration of normal function to PBG 
deaminase. 
Removal of porphyrin(ogen)s from VP lymphoblasts restored 
a normal kinetic profile to PBG deaminase 
One method of "removing" porphyrinogens is by their conversion to 
the corresponding porphyrins, which do not inhibit PBG deaminase. 
However, when VP lymphoblast sonicates were treated in oxidising 
conditions (light, atmospheric oxygen) for up to 2h prior to the assay, 
there was no significant change in the substrate-velocity behaviour or 
V max ( table 5 .11 ), even though in a separate experiment, it was shown 
that approximately lOOµM proto- copra- and uroporphyrinogen could 
be almost fully oxidised under identical conditions (table 5.2). There 
are several possible explanations: PBG deaminase might be 
irreversibly affected by the oxidation, the porphyrinogens interacting 
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with PBG deaminase were "locked" into position, 2h was not long 
enough for the effect to be reversed, or the observed phenomenon was 
not due to porphyrinogens at all. 
Thus a different approach was taken. VP lymphoblast cytosolic 
preparations were subjected to molecular sieving by Sephadex G25 
chromatography. This was intended to remove all porphyrin( ogen)s 
from the solution containing PBG deaminase. This might allow for the 
dissolution of any bound porphyrinogens from PBG deaminase 
because of the resultant negative equilibrium. In a pilot experiment it 
was established that fractions containing PBG deaminase activity and 
those containing porphyrins were well separated by Sephadex G25 
chromatography (figure 5.2). It was assumed that porphyrinogens 
would be equally well separated. Single passage of VP lymphoblast 
cytosolic preparations down a Sephadex G25 column resulted in a 
restoration of "normal" kinetic behaviour to PBG deaminase. 
Although it was possible that Sephadex G25 had removed some other 
factor(s) responsible for alteration of PBG deaminase behaviour the 
removal of protoporphyrinogen and, possibly coproporphyrinogen, 
appeared the most likely cause as previous experiments had shown 
them to be directly implicated in the alteration of PBG deaminase 
kinetic behaviour. 
Conclusions 
0 VP lymphoblast PBG deaminase exhibits different ldnetic properties 
to that of normal lymphoblast PBG deaminase. 
The kinetic profile of control lymphoblast PBG deaminase is 
consistent with that of a monomeric Michaelis-Menten type enzyme 
with a single substrate-binding site whereas that in VP lymphoblasts 
is consistent with an allosteric, cooperative, multimeric structure. 
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D Addition of proto- and coproporphyrinogen in contrast to 
uroporphyrinogen or any of the porphyrins resulted in a striking 
transformation of the "normal" kinetics to a kinetic profile resembling 
that displayed by PBG deaminase in VP lymphoblasts. 
Addition of these porphyrinogens to VP lymphoblasts further 
enhanced the observed anomalous kinetic behaviour. 
D . Sephadex G25 chromatography resulted in restoration of "normal" 
kinetics to VP lymphoblast preparations. 
This was presumed to be due to removal of proto- and 
coproporphyrinogen from the VP cells. 
The above observations lend considerable support to the hypothesis 
that the "defect" in PBG deaminase observed in VP is linked to the 
primary defect of protoporphyrinogen oxidase and that the haem 
synthetic intermediates likely to accumulate in response to this block, 
proto- and coproporphyrinogen, may exert a negative allosteric effect 
on PBG deaminase in VP. This concept is strengthened by the 
occurrence of acute attacks in HCP, where elevated concentrations of 
coproporphyrinogen may occur, and the lack of acute attacks in PCT 
where excessive concentrations of uroporphyrinogen predominate. It 
may be possible to extrapolate the concept to EPP and CEP as well, 
but the predominant erythropoietic expression of these diseases could 
require a different explanation for the lack of acute attacks in these 
conditions. 
A further point of definite interest would be to establish whether the 
behaviour of purified PBG deaminase in the presence of these haem 
pathway intermediates is similar to that of the unpurified preparations. 
This is explored in the following chapter. 
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Chapter Six 
Kinetic effects of 
protoporphyrin(ogen) on purified 
PBG deaminase 
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T his section sets out to examine whether the inhibition of PBG 
deaminase by proto- and coproporphyrinogen is due to a direct 
interaction with the enzyme, or is mediated by an indirect mechanism 
such as an interaction with some endogenous factor present in the cell? 
Purified PBG deaminase was used in order to address this question. 
Objectives 
D To purify human PBG deaminase. 
D To compare the kinetic profile of purified PBG deaminase with 
that of unpurified lymphoblast PBG deaminase. 
D To determine whether the addition of proto- or 
coproporphyrinogen to the pure enzyme would result in similar 
anomalous behaviour to that observed in lymphoblasts. 
This chapter describes the purification of PBG deaminase and the 
determination of kinetic data as determined in the presence and 
absence of porphyrinogen or porphyrin. 
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Methods . 
Purification of PBG deaminase 
There are a number of reported methods for the purification of PBG 
deaminase (Sancovich et al, 1969; Frydman and Frydman, 1970; Davies 
and Neuberger, 1973; Jordan and She min, 1973; Higuchi and Bogorad, 
1975; Miyagi et al, 1979; Anderson and Desnick, 1980; Fumagalli et al, 
1985). Many use erythrocytes as a convenient source of the enzyme. 
Since there appears to be good inter-tissue homology of PBG 
deaminase we chose to use erythrocyte PBG deaminase in our study. 
The purification procedure was adapted from two previous methods 
(Anderson and Desnick, 1980; Fumagalli et al, 1985). Briefly, 
erythrocytes were lysed and haemoglobin was removed by specific 
denaturation. The cytosol was subjected to ammonium sulphate 
fractionation and heat treatment, Sephadex G25 and G 100 
chromatography, DEAE cellulose chromatography, 
chromatofocusing over a 7 to 4 pH gradient and finally hydrophobic 
interaction chromatography on a phenyl-Sepharose column. The 
method is outlined in figure 6.1 and full detail is given in Appendix 11 
together with related methodologies. Activity was followed 
throughout the purification by assaying 1001tl aliquots of sample for 
PBG deaminase activity as described in Appendix 9. Protein 
concentrations were determined using the "Bradford" technique of 
protein-dye binding (Bradford, 1976 and Appendix 12). 
Addition of porphyrinogen and porphyrin 
Substrate-velocity data were obtained over a 1.25-20µM PBG 
concentration range ( as used in the previous experiments), at 
protoporphyrinogen concentrations of 0.01, 0.05, 0.1, 0.5, 1, 5 and 
lOµM. Protoporphyrin was assessed for its effects in 0.1, 1 and lOµM 
concentrations. 
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Figure 6.1: Main steps of the purification procedure for PBG deaminase. Using this procedure 
460ml of blood yielded approximately 100µg of PBG deaminase purified 
7115-fold. 
The activity of PBG deaminase in the presence of added 
protoporphyrinogen or protoporphyrin was assayed at a single, 
substrate saturating concentration using the methods described 
previously (see Chapter 4 and Chapter 5, Methods and Appendix 9). 
All enzyme assays were performed in duplicate. 
Kinetic analysis 
All substrate-velocity data shown below represents the mean of three 
experiments. All substrate-velocity data were analysed with the Hill 
equation (see Chapter 5, Methods and Appendix 10) and Vmax, Ko.s 
and the Hill coefficient values were obtained for comparative 
purposes. 
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Results 
Purification of PBG deaminase 
Table 6.1: 
Table 6.1 summarises the purification of human erythrocyte PBG 
deaminase from 460ml of blood. The enzyme was purified 
approximately 7000-fold. 
The elution traces (protein absorbance at 280nm and corresponding 
PBG deaminase activity) for the Sephadex GlOO and 
chromatofocusing runs are shown in figures 6.2 and 6.3. The peak of 
activity for the final phenyl-Sepharose was sharp and well defined, but 
a reliable continuous protein absorbance trace was not obtained since 
the ethylene glycol in which it was run interfered with this. Protein 
concentrations were measured only in the regions containing PBG 
deaminase activity. An SDS-PAGE of an aliquot of the final 
post-phenyl Sepharose PBG deaminase fractions (after concentration 
and exchange into O.OSM Tris-HCl buffer, pH 7.4) is shown in figure 
6.4. The clear single protein band obtained with silver staining was 
estimated to have a molecular weight of 41200 (±2300). 
This solution (pure PBG deaminase in Tris-HCl buffer) served as the 
source of PBG deaminase for all subsequent kinetic experiments. 
Purification of PBG deaminase from 190ml of human erythrocytes. Protein 
concentration, mg/ml; Volume, ml; Specific activity, nmol of uroporphyrin 
framed/mg protein/h; Purification, -told. 
Step [Protein] Volume Specific Purification 
activity 
1. Erythrocytes 231 190 0.034 1 
2. Supernatant from dialysis 22 90 0.94 28 
3. Post Sephadex G25 17 106 1.11 33 
4. Post Sephadex G100 38.5 22.5 1.20 35 
5. Post DEAE cellulose 0.88 7.5 20.80 614 
6. Post chromatofocusing 0.058 6 150.00 4425 
7. Post phenyl Sepharose 0.018 4 241.20 7115 
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Figure 6.2: Elution profile from Sephadex G100 column (2.5X100cm), the second of the 
chromatography steps in the purification procedure followed. The column was 
equilibrated and the protein eluted with 0.05M Tris-HG/, pH7.4. The dashed peak 
corresponds to PBG deaminase activity and is expressed as arbitrary 
fluorescence units/50µ1 aliquot of the fractions tested. The main protein peak has 
been broken at the points marked(~). PBG deaminase eluted from this column 
represented an approximate 35-fold purification. 
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Figure 6.3: Elution profile from chromatofocusing on PBE 94 column (0.9X30cm). The 
column was equilibrated with 0.025M imidazole-HCI, pH7.4 and the protein eluted 
with a 7.4 to 4 pH gradient using "Polybuffer 74". The dashed peak corresponds 
to PBG deaminase activity and is expressed as arbitrary fluorescence units/50µ/ 
aliquot of the fractions tested (axis not shown). The pl-I gradient is also shown. 
PBG deaminase eluted from this column represented an approximate 4400-fold 
purification. 
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Figure 6.4: SOS-PAGE of PBG deaminase post phenyl-Sepharose stained with silver stain. 
PBG deaminase appeared as a single protein band of molecular weight 41200 
(±2300) when compared to molecular weight markers indicated below. 
Molecular weights are given in Daltons. 
Kinetics of pure PBG deaminase 
A simple substrate-velocity plot (figure 6.5) of pure PBG deaminase 
yielded a hyperbolic curve with a V max of 249 ( ±36) nmol/mg/h, a Ko.s 
of 8.9 (±1.5) µM and a Hill coefficient of 0.93 (±0.14). 
Lineweaver-Burk and Eadie plots yielded linear plots. 
Addition of 0.1, 1 and lOµM concentrations of protoporphyrin had no 
effect on pure PBG deaminase. This is illustrated by the 
substrate-velocity plots in figure 6.6 and the kinetic data given in table 
6.2. Remarkably consistent curves were obtained at all protoporphyrin 
concentrations. 
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Figure 6.6: Addition of 0.1, 1 and 1 Op.M protoporphyrin had no effect on the kinetics of punfied PBG deammase. 
Table 6.2: Addition of protoporphyrin had no effect on the kinetics as ascertained by 
application of the Hill equation. Figures represent the mean of three experiments 
in each case. Proto, protoporphyrin. 
Vmax 
(nmo!/mg/h) 
Ko.s 
(µM) 
Hill 
coefficient 
Purified control PBG deaminase 
No additions 249 ±36 
264 ±48 
246 ±44 
235 ±41 
8.9 ±1.5 
8.2 ±1.1 
8.6 ±1.2 
8.1 ±1.0 
0.93 ±0.14 
0.85 ±0.12 
0.95 ±0.16 
0.96 ±0.17 
+0.1µM Proto 
+1µM Proto 
+ 10µM Proto 
Addition of protoporphyrinogen over a 1000-fold range of 
concentrations (0.01 to lOµM) resulted in the striking transformation 
of the hyperbolic substrate-velocity curve obtained in the absence of 
protoporphyrinogen to sigmoidal curves similar to those displayed by 
impure PBG deaminase in the presence of 1, 5 and lOµM proto- and 
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coproporphyrinogen (figure 6.7, table 6.3). 0.0lµM 
protoporphyrinogen had a negligible effect on pure PBG deaminase. 
There was an inverse relationship · between V max and the 
protoporphyrinogen concentration, the lowest V max values being 
recorded at the highest protoporphyrinogen concentration. V max in 
the presence of lOµM protoporphyrinogen was 169 ( ±28) nmol/mg/h, 
which was 32 % lower than that in the absence of protoporphyrinogen. 
The Hill coefficients appeared to approach 4 in the limit and Ko.s was 
essentially unaltered. This was unlike the behaviour of impure PBG 
deaminase where there was a small non-significant systematic 
variation. 
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Figure 6.7: Addition of 0.01 to 10µM protoporphyrinogen to pure PBG deaminase resulted 
in sigmoidal substrate-velocity plots with decreased Vmax activity and a Hill 
coefficient that approached 4 in the limit. 
A plot of V max and the Hill coefficient versus protoporphyrinogen 
concentration (figure 6.8) shows a single exponential growth 
relationship in the case of the Hill coefficient and a single exponential 
decay for V max, Single exponential analysis reveals that the 
protoporphyrinogen concentration at which the Hill coefficient is half 
its estimated maximum is 0.2µM and the concentration at which V max 
is half its estimated maximum inhibition is 0.19µM. 
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Table 6.3: Addition of various concentrations of protoporphyrinogen resulted in altered PBG 
deaminase kinetics as ascertained by application of the Hill equation. Figures 
represent the mean of three identical experiments in each case. Proto'gen, 
protoporphyrinogen. 
Vmax 
(nmol/mg/h) 
Purified control PBG deaminase 
No additions 249 ±36 
+0.01µM Proto'gen 246 ±37 
+0.05µM Proto'gen 235 ±42 
+ 0.10µM Proto'gen 221 ±40 
+ 0.50µM Proto'gen 190 ±48 
+ 1.00µM Proto'gen 186 ±46 
+ 5.00µM Proto'gen 178 ±39 
+ 1 O.OµM Proto'gen 169 ±28 
Vmax (nmol/mg/h) 
250 
230 
+ 
210 
190 
170 
Ko.s 
(µM) 
8.9 ±1.5 
8.9 ±1 .0 
9.5 ±1.5 
9.8 ±1.1 
9.1 ±1.9 
9.7 ±1.6 
9.7 ±1.4 
9.7 ±1 .6 
HILL COEFFICIENT 
Hill 
coeficicient 
0.93 ±0.14 
0.96 ±0.09 
1.19±0.14 
1.58 ±0.20 
2.27 ±0.16 
2.66 ±0.16 
3.02 ±0.11 
3.49 ±0.19 
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Figure 6.8: Relationship between added protoporphyrinogen (µM) and Vmax and the Hill 
coefficient. 
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Discussion 
Our purification procedure, judged by silver staining of SDS-PAGE, 
yielded apparently homogeneous PBG deaminase (figure 6.4). The 
final specific activity of 24 lnmol uroporphyrin formed/mg/h is 
intermediate between the approximately 2300nmol/mg/h (Anderson 
and Desnick, 1980) and the 68nmol/mg/h (Fumagalli et al, 1985) 
reported by the two groups on whose methods our method was based. 
This represented an approximately 7100-fold purification which, again 
lies between the 3400-fold (Fumagalli et al, 1985) and 42000-fold 
(Anderson and Desnick, 1980) reported by the two methods followed. 
The product ran on SDS-PAGE as a single unit of molecular weight 
41200 (±2300). We did not detect the five distinct peaks reported to 
correspond to native enzyme and its four enzyme-substrate 
intermediates, the mono-, di-, tri- and tetrapyrroles (Anderson and 
Desnick, 1980). These intermediates are normally observed when a 
final step based on charge-separation (such as DEAE cellulose 
chromatography) is employed. 
Our purification procedure itself behaved similarly to the other 
reported methods, except for the DEAE cellulose chromatography 
where we found that PEG deaminase eluted as a single peak in the 
latter part of the breakthrough peak, rather than well into the sodium 
chloride gradient. 
Although ethylene-glycol is effective in eluting PEG deaminase from 
a phenyl-Sepharose column it is difficult to remove (by dialysis) and 
this resulted in substantial losses. Other methods of elution were tried 
without much success, hence we continued to employ this method. 
The kinetic experiments carried out in the presence of 
protoporphyrinogen are most illuminating. Firstly, purified PEG 
deaminase, in the absence of added porphyrinogen, behaved as a 
Michaelian enzyme with a single substrate binding site (figure 6.6, 
table 6.2). We could find no evidence that purified erythrocyte PEG 
deaminase from control subjects possessed more than one binding site 
in its "native" state. 
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Secondly, the purified PBG deaminase responded to 
protoporphyrinogen in a similar fashion to the non-pure lymphoblast 
PBG deaminase preparation. The substrate-velocity curve became 
sigmoidal, V max was decreased and the Hill coefficient approached 4 (figure 6.8, table 6.3). Thus, once again, PBG deaminase appeared to 
be transformed into a cooperatively behaving unit, with up to 4 
interacting binding sites. Both V max and the Hill coefficient were 
maximally affected at lOµM protoporphyrinogen and tenuously 
affected at O.OlµM. Single exponential analysis of both V max and the 
Hill coefficient against protoporphyrinogen concentration (figure 6.8) 
revealed that the concentrations at which the effects were half 
"maximal" were almost identical. It can therefore be concluded that 
the property of protoporphyrinogen which causes inhibition of V max 
appears also to be that which causes the increase in cooperativity. 
There was no significant variation in Ko.s. The "mini trend" apparent 
in ·non-pure PBG deaminase preparations was absent. The lack of 
change in Ko.s is strong evidence that protoporphyrinogen exerts a 
direct effect on PBG deaminase and that the disturbed kinetics in the 
VP PBG deaminase are not due to a structurally mutant enzyme. This 
suggests that PBG deaminase is normal in VP subjects, but exhibits 
anomalous behaviour in the presence of protoporphyrinogen. 
Addition of protoporphyrin had no effect on the kinetics of PBG 
deaminase. This is wholly consistent with the observations in the 
lymphoblast sonicates. Kinetic experiments have not yet been 
performed in the presence of copra- and uroporphyrin( ogen), but it is 
probably fair to extrapolate the findings in the lymphoblasts to the 
purified enzyme since the effects of porphyrinogen and 
protoporphyrin are entirely concordant. 
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Conclusions 
* 
0 The kinetic profile of pure erythrocyte PBG deaminase is analogous 
to that of the non-pure enzyme in lymphoblast sonicates. 
D · Addition of protoporphyrinogen but not of protoporphyrin to pure 
PBG deaminase results in anomalous kinetics with an inhibited 
Vmax and apparent cooperativity with respect to substrate binding. 
It appears therefore, invoking Occam's razor*, that neither 
endogenously occurring blocking or stimulatory agents ( other than 
proto- and coproporphyrinogen), nor complex in vivo effector 
mediated mechanismsn nor the presence of a structurally mutant 
enzyme are required to explain the non-hyperbolic, cooperative 
kinetics of VP PBG deaminase. Protoporphyrinogen ( and 
coproporphyrinogen) appear to exert a direct allosteric effect on PBG 
deaminase which, in their absence, is capable of functioning normally. 
William of Occam's (1280-1349) dictum - Entia non sunt multiplicanda practer necessitatem. 
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Chapter Seven 
Urinary ALA and PBG 
concentrations in VP 
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T he data presented in chapters 4 to 6 appear to favour the hypothesis 
under examination in this thesis. Firstly, partially diminished PBG 
deaminase activity has been measured in lymphoblasts and secondly 
it has been shown that both protoporphyrinogen and, to a lesser extent 
coproporphyrinogen, exert negative allosteric effects on PBG 
deaminase, resulting in decreased activity and sigmoidal 
substrate-velocity behaviour. 
If the hypothesis is true it may be argued that VP patients who exhibit 
elevated concentrations of protoporphyrin, and often coproporphyrin 
as well, will have decreased PBG deaminase activity and should 
demonstrate mildly elevated levels of PBG (and possibly ALA) during 
both the quiescent and acute phases of VP. 
Indeed a few authors have noted urinary ALA and PBG 
concentrations to be mildly elevated in quiescent VP. However, this 
has attracted little attention (Mustajoki, 1976; Muhlbauer, 1982). We 
therefore considered it important to examine the concentration of 
ALA and PBG in the urine of 1mequivocal cases of quiescent VP and 
to compare these with those observed in normal subjects. 
Objectives 
D · To characterise a large group of quiescent VP subjects with respect 
to urinary ALA and PBG concentrations. 
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D To confirm the diagnosis of quiescent VP by measuring the levels 
and patterns of porphyrin excretion in the stool, urine and plasma. 
Methods 
Porphyrin precursor and porphyrin quantitation 
The method used for determination of urinary ALA and PBG is given 
in Appendix 3.2. This method for quantifying urinary ALA and PBG 
appeared to be accurate at both high and low concentrations of ALA 
and PBG ( table 7 .1 ). This was verified by measuring standard solutions 
of known precursor concentration ranging from 0.5 to lOOOµmol/1. The 
lower limit of reliable determination (based on repeat experiments) 
for ALA lay between 1 and Sµmol/1 and that of PBG was approximately 
lmol/1. Urine samples subjected to repeated testing over a period of 
two days showed a 6% variability in ALA concentration and an 8% 0 
variabilityinPBG concentration. Storage of urines (at4 C, in the dark) 
for a period not exceeding two days thus appeared acceptable. 
Table 7 .1 :Comparison of standard ALA and PBG concentrations to measured 
concentrations using ''ALA Test kits" (Bio-Rad). !RR: Irreproducible. 
ALA concentration PBG concentration 
(µmo!//) (1tmol/l) 
Real Measured Real Measured 
(Mean of 3) (Mean of 3) 
0.5 1.2 (IRR) 0.5 0.6 
1.0 1.4 1.0 1.1 
5.0 6.2 5.0 5.2 
10.0 13.3 10.0 10.5 
50.0 57.8 50.0 49.1 
100.0 105.0 100.0 96.3 
500.0 491 .0 500.0 486.0 
1000.0 950.0 1000.0 911 .0 
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For diagnostic purposes porphyrins were analysed and quantified by 
the 1LC method referred to in Chapter 4 (Methods) and described in 
detail in Appendix 3.1. The method was also assessed for reliability 
and sensitivity. Stool porphyrins measured on repeated occasions 
demonstrated a 19% variability in total porphyrin concentration. The 
lower limit of reproducible sensitivity in stool was approximately 
O.Snmol/dry g although concentrations down to O. lnmol/dry g were 
detectable. These are approximate figures as the limits varied 
according to the precise type of porphyrin in question, the 
fluorescence quantum yield of the different porphyrin species varying 
over an approximate twofold range. Similar experiments in urine 
demonstrated a 15 % variability; the lower limit of reproducible 
sensitivity was approximately 0.9nmol/l though, once again 
concentrations considerably less than this could be detected. Although 
the limits of sensitivity should allow determination of most plasma 
porphyrin concentrations, as verified in a previous report (Day, 1978a), 
accurate figures were difficult to obtain as readings often fell at the 
lowest levels of sensitivity. Furthermore, 1LC was often hampered by 
the presence of unknown factor( s) that retarded the migration of the 
porphyrins on the plate and appeared to interfere with the 
fluorometric readings. 
Any process involving extraction of porphyrins can be expected to 
involve some losses. Using the system described standard porphyrin 
mixtures of known concentrations (0.5-lOOOnmol/l) were tested for 
loss after esterification and extraction. Recovery ranged from 96% (low concentrations) to 83% (concentrations 500nmol/l). 
We have used 1LC in this study as the method has been successfully 
employed in our laboratories for some 15 years. We have found the 
method to be as sensitive as any HPLC method we have experimented 
with. HPLC methods for separation and quantitation of porphyrin 
esters tried by us (Seubert and Seubert, 1982; Chiba and Sassa, 1982; 
Lim et al, 1983) appear not to be as reproducible as 1LC owing, in 
large part, to quantities of porphyrin sticking to the column, in spite of 
experimentation with different solvent mixtures. These methods were 
inconsistent and a "noisy" baseline resulted in inaccuracies and loss of 
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identification of small porphyrin peaks. This may be due to unknown 
perturbing factors present in biological samples. 
Diagnosis of VP 
All urinary, stool and plasma porphyrin data of the patients included 
in the study are tabulated and further comment given in Appendices 
6.1 and 6.2. These results, representing a large number of patients, are 
presented in order to add useful information to the overall descriptive 
profile of VP, apart from giving confirmatory evidence of the diagnosis 
of VP in these patients. 
Subjects were considered to have VP where typical VP porphyrin 
excretory profiles were evident. All patients had elevated stool 
protoporphyrin of concentrations greater than 200nmol/dry g, the 
mean stool protoporphyrin concentration being 992nmol/dry g, and 
elevated concentrations of coproporphyrin greater than 50nmol/dry g 
in 89% of cases. 
"Secondary" diagnostic criteria were also used and were as follows: 
Approximately 85% of the stool analyses revealed pentacarboxylic 
porphyrin and/or a porphyrin species running very closely to 
pentacarboxylic porphyrin which we have termed 
"pseudo-pentacarboxylic" porphyrin. It was not always possible to 
differentiate the two, or to assign a single peak to one or the other. The 
significance of "pseudo-pentacarboxylic" porphyrin is that it is an 
extremely useful marker of VP; elevated porphyrins in the 
pentacarboxylic porphyrin retention region appearing extremely 
infrequently in normal stools or in other types of porphyria (Day, 1986; 
Personal experience). "Pseudo-pentacarboxylic" porphyrin has 
previously been identified by two-dimensional TLC as a hydroxylated 
dicarboxylic porphyrin and presumably originates from spontaneous 
conversion of excess protoporphyrin or protoporphyrinogen (Moore 
et al, 1987; Personal communication Smith SG, Day RS and Moore 
MR). 
Secondly, a common feature of abnormal porphyrin metabolism in the 
stool of VP patients was the presence of porphyrin fluorescence 
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remaining at the origin after the TLC plate was developed (92% of the 
VP cases). Previous workers have termed this fraction porphyrin X. 
Porphyrin X is thought to consist of hydrophilic porphyrin-peptide 
complexes and has been the subject of much investigation and 
speculation (Rimington et al, 1968; Grosser et al, 1971 and 1972; 
Moore et al, 1972; Elder et al, 1974). While not considered diagnostic 
of VP any longer (Bales et al, 1980; Day, 1986) it yielded useful 
confirmatory evidence of VP in most cases. 
Unfortunately data describing the exact incidence of clinical 
symptoms in the complete group of VP patients can not be 
forthcoming because adequate clinical information was not supplied 
for all patients. 
Patients and samples 
Laboratory data obtained over a 5 year period (April 1984 - April 
1989) of all patients who were unequivocally diagnosed as having VP 
were included in the ALA and PBG analysis. Random urine samples, 
30-SOml, 5-lOg stool samples and where possible 10ml of heparinised 
blood had been sent to the laboratory for full porphyrin and porphyrin 
precursor analysis when a diagnosis of porphyria had been considered. 
The subjects were drawn from the Cape Province of South Africa and 
Namibia and comprised all sections of the Southern African social and 
ethnic spectrum. Samples were received within 24h and were usually 
wrapped in opaque material to exclude light. All specimens were 
initially screened for the presence of PBG and porphyrins, quantitative 
urinary ALA and PBG concentrations determined immediately where 
possible ( or stored for no longer than 2 days in the dark at 4 C) and 
TLC analysjs of porphyrin profiles performed thereafter. 
In the final analysis, urinary ALA and PBG concentrations in 225 VP 
and 93 control subjects were compared. ALA and PBG data were not 
available in 24 of the original 249 urines from subjects with the 
unequivocal diagnosis of VP over the 5 year period because of 
technical problems in the laboratory on two occasions. Often only 
urine and stool were received for investigation. In 34% of cases we 
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received plasma as well. Where a stool specimen was not received, the 
urine was only included in the analysis if the patient had previously 
been proven to have VP. 4 of the 225 patients were diagnosed as being 
in an acute attack at the time of investigation; ALA and PBG levels 
were grossly elevated and there were definitive clinical symptoms of 
the acute attack. These 4 were analysed separately from the quiescent 
VP subjects. 
Control data was obtained by analysis of 93 normal subjects 
demonstrating no evidence of porphyria. 
Data recording and statistical analysis 
Results 
Urinary ALA and PBG concentrations are expressed as mol/lOmmol 
creatinine and porphyrins as nmol/lOmmol creatinine. This takes into 
account variability in urinary concentration and renders urine results 
comparable. Plasma concentrations are expressed as nmol/1 of plasma 
and stool porphyrins as nmol/g of dry stool. 
The data were recorded and entered into a computer spreadsheet 
(Lotus 123) to facilitate statistical analysis. Where applicable, the 
significance of the difference between the mean of the VP and control 
group was calculated using the Wilcoxon rank sum test for two 
non-parametric, independent population groups (Bailey, 1981). 
Significance was gauged from the probability (p) value where 
necessary. 
Urinary ALA and PBG concentrations in quiescent VP 
In this group (N = 221) there was a statistically significant increase in 
the mean ALA and PBG concentrations when compared to the normal 
control group (N = 93, p< 10-6). The means were increased 2.5- and 
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4.6-fold respectively. Table 7.2 gives the mean, the standard deviation 
and the range, and probability (p) value obtained from the statistical 
comparison of the two groups. Figure 7.1 depicts them graphically. 
Approximately 50% of the ALA and PBG values were more than two 
standard deviations above the mean of the control group (table 7.2, 
last column). It must be emphasised that these increases were noted 
despite the absence of any symptoms suggestive of the acute attack. 
Urinary ALA and PBG concentrations in acute VP 
In this group (N = 4) there was a dramatic increase in the mean ALA 
and PBG concentrations by 30-fold and 135-fold respectively (table 
7.2 and figure 7.1). These patients were exhibiting acute attack 
symptoms at the time of sampling. 
Table 7.2: Urinary porphyrin precursor data. Units of expression are µmol/10mmol 
creatinine. The small number of data points in the acute group disallows 
meaningful statistical comparisons. 
Mean SD p Proportion (%) 
(Range) >2 SD's above 
normal mean 
CONTROLS (93) 
ALA 12.85 5.7 5.5 
(0-35.8) 
PBG 3.4 2.3 4.4 
(0-15.4) 
QUIESCENT VP (221) 
ALA 32.4 26.3 <10-3 49.7 
PBG 
(3.2-158.4) 
<10-3 15.5 23.6 52.5 
(0.2-170.4) 
ACUTE VP (4) 
ALA 390.3 248.5 100 
(192-669) 
PBG 463.8 286.9 100 
(203-771) 
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Figure 7.1: Mean ALA and PBG concentrations in urine samples from 93 normal controls, 221 
non-acute VP's and 4 acute VP's. Refer to table 7.2 for detailed values and 
comparative parameters. A: [Concentration], B: Log[Concentration]. 
Discussion 
Urinary ALA and PBG concentrations 
Not much import appears to have been attached to the few reports of 
mildly elevated ALA and PBG in quiescent VP. Typical of the 
statements on this point are: "In VP the presence of elevated PBG is 
usually limited to the period of the acute attack" (Fromke et al, 1978). 
This type of statement implies that porphyrin precursors may be 
elevated during quiescent VP (Taddeini and Watson, 1968). Indeed, 
other reports are slightly more specific stating, for example: "The 
urinary porphyrin and precursor levels in this phase ( quiescent VP) 
are usually within the normal ranges although the precursors (ie. ALA 
and PBG), coproporphyrin, and, less frequently, the uroporphyrin 
levels may all become mildly elevated with no concomitant symptoms 
of the acute attack." (Day, 1986). Some have presented data showing 
normal precursor excretion in just about all quiescent VP cases (Dean 
and Barnes, 1959; Hamnstrom, 1967; Bales 1963; Bales et al, 1980; 
Day, 1986). Others have described data in which precursors are 
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definitely raised in quiescent VP (Mustajoki and Koskela, 1976; 
Muhlbauer, 1982), or at least, in certain individual patients (Bales et 
al, 1966; Wetterberg et al, 1968; Mustajoki, 1978). Values of ALA and 
PBG in relatively small VP populations ( ( cases) have been given, and, 
although overlapping with the given normal ranges of values, have 
mean values raised approximately twofold over the normal population (Mustajoki and Koskela, 1976; Muhlbauer, 1982). Because of the 
apparently variable precursor excretion in patients with quiescent VP, 
which is therefore considered of dubious value in establishing a VP 
diagnosis (Muhlbauer, 1982), very little discussion about these 
observations has ensued. Thus, most reports suggest that ALA and 
PBG concentrations are generally normal in VP except during the 
acute attack. 
This study shows clearly that increased porphyrin precursor output 
does occur in quiescent VP as well as in the acute attack. There were 
highly significant increases in both ALA and PBG concentrations by 
factors of 2.5 and 4.6 respectively in the urines of quiescent VP patients (figure 7.1, table 7.2). This increase appeared to be more consistent 
than is generally recognised. ALA fell more than two SD's above mean 
of normal in 110 of the 221 cases ( 49.7% ). The corresponding figure 
for PBG was 116 (52.5%). A further point of interest was that PBG 
was proportionately more increased than was the uroporphyrin 
concentration. (The mean uroporphyrin values were increased 
2.8-fold (see Appendix 6.1)). This observation lends additional 
indirect evidence of a "constriction" in the haem biosynthetic pathway 
at the level of PBG deaminase. 
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Conclusion 
D ALA and PBG in VP can be elevated to varying degrees, the highest 
concentrations being recorded during the acute attack. VP urine, 
however, often demonstrated significant increases in precursor 
concentrations without any accompanying clinical signs of the acute 
attack. 
Indeed, mean ALA and PBG levels in the non-acute VP group were 
increased 2.5- and 4.6-fold respectively. This is good supporting 
evidence of partially decreased PBG deaminase activity in quiescent 
VP. 
Lymphob/ast Porphyrins 
Chapter Eight 
Analysis of porphyrins present in 
Epstein-Barr virus transformed 
lymphoblasts derived from VP 
patients 
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In Chapter 4 we documented the suitability of lymphoblasts as a 
"model" VP tissue for the measurement of protoporphyrinogen 
oxidase and PBG deaminase activities. While the transformation 
process resulted in a mild stimulation of the activity both these 
enzymes, neither appeared to be selectively affected. Indeed, the 50% 
reduction in protoporphyrinogen oxidase activity present in 
lymphocytes from VP subjects persisted after transformation with 
Epstein-Barr virus. 
The presence of decreased protoporphyrinogen oxidase activity in VP 
lymphoblasts suggests that these cells should contain increased 
concentrations of intermediates immediately prior to the block. If 
PBG deaminase is indeed decreased by increased concentrations of 
proto- and coproporphyrinogen as our hypothesis demands, levels of 
these intermediates or their oxidised products should be elevated in 
VP lymphoblasts. Although cultured fibroblasts from VP patients have 
been shown not to accumulate protoporphyrin (Brenner and Bloomer, 
1980a), purportedly as a result of the "exclusive" hepatic expression of 
VP, we considered it justified to investigate the existence of altered 
porphyrin profiles in VP lymphoblasts. 
The feasibility of this study was supported by the fact that 
mitogen-stimulated and Epstein-Barr virus-transformed lymphocytes 
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have been previously shown to produce quantifiable amounts of 
porphyrin (Sassa et al, 1978). 
Objective 
D To determine whether the lymphoblast system used in this study 
exhibited evidence of increased concentrations of intermediates 
similar to that found in VP. 
We thus set out to determine whether native porphyrin production in 
lymphoblasts could be measured, both in the cells "resting" state and 
after incubation in the presence of ALA, which might stimulate 
porphyrin production (Sassa et al, 1978). Secondly, the effects of 
transformation on porphyrin production were assessed by comparing 
porphyrin concentrations (with and without ALA) at various stages 
during and after transformation. Finally, evidence of altered porphyrin 
production in the VP cultures both before and after ALA addition was 
sought by measuring porphyrin profiles and comparing those obtained 
for VP cells to those obtained from normal controls. 
Methods 
Control and VP lymphoblasts were cultured as previously described 
(Chapter 4, Methods and Appendix 3.3). To prepare the cells for 
determination of intracellular porphyrin content lymphoblasts were 
spun down at lOOOXg for 15min and washed twice in Hanks Balanced 
Salt Solution. 10ml of 5% sulphuric acid in methanol was added to the 
final cellular pellet, the mixture was vigorously agitated and heated, in 
0 
the dark, at 55 C for 8h. This ruptured the cells and esterified any 
porphyrin present. The mixture was centrifuged (2000Xg, 15min), the 
supernatant neutralised, the porphyrin esters extracted and 
quantitatively analysed by TLC and fluoroscanning as described in a 
previous section (Chapter 4, Methods and Appendix 3.1). 
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Results 
Stimulation of porphyrin production by ALA was evaluated as follows: 
Tue lymphoblasts were centrifuged down (lOOOXg, 15min) and 
washed twice in serum-free FlO medium. This medium has been 
shown to be rriore effective than a serum-containing medium in 
supporting the formation of porphyrins and inhibiting release of 
porphyrinsinto the growth medium (Sassaetal, 1974; Sassaetal, 1978). 
Cells were then suspended in serum-free Ham FlO medium containing 0 0.6mM ALA and incubated for 24h at 37 Cina 5% CO2 atmosphere. 
At the end of the incubation period the cells were spun down (850Xg, 
lOmin) and the porphyrins present esterified, extracted and analysed 
as described above. 
Porphyrin measurement in lymphoblasts 
Initial attempts to quantify porphyrins in the transformed 
lymphoblasts in their "resting" state were unsuccessful. It appeared 
that too few cells were present in these early attempts. When much 
larger numbers of viable cells were cultured, as in later experiments, 
porphyrins could just be detected using the TLC fluoroscanning 
technique described in the previous section. At least 500X106 cells (500ml of 1Xl06 suspension culture!) were required for reliable 
detection of porphyrins in our system. Figure 8.1 shows the total 
porphyrin level as a function of cell number and indicates the 
proportion of each different type of porphyrin species present. Results 
indicate that there was approximately 1.lpmol of total porphyrin/106 
cells. 
Porphyrin measurement in lymphoblasts after addition of ALA 
As shown in a previous study (Sassa et al, 1978), the amount of 
endogenous porphyrin produced could be significantly stimulated by 
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Figure 8.1: Total amounts (nmol) of different porphyrins present in "resting" lymphoblasts. 
By far the most abundant porphyrin species was protoporphyrin. Porphyrin 
quantitation below 0.2nmol was difficult and inaccurate, small amounts of 
coproporphyrin presumably present in the lower cell numbers were therefore 
undetectable. Results represent the mean of porphyrin estimations in 5 control 
lymphoblast cultures for experiments involving 2000X106 or less than 2000X106 
cells and the mean of 2 control cultures for experiments involving more than 
20oox106 cells. 
adding 0.6mM ALA to a serum-free Ham FlO medium in which the 
cells were maintained and incubating for 24h before extraction of 
endogenous porphyrin and analysis on TLC. Total porphyrin 
concentrations were increased 20-fold on average with this 
concentration of ALA (figure 8.2). 
The effect of transformation on porphyrin production 
Porphyrin determination in lymphoblasts was possible only when the 
cultures contained sufficient cells; that is, on days 7, 14, 21 and 28. It 
was necessary to stimulate porphyrin production by addition of ALA 
for 24h prior to measurement, as described above, in order to obtain 
meaningful results. Results obtained from identical experiments in 
five control cell lines are shown in figure 8.3. As with 
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Figure 8.2: Effect of 24h incubation in the presence of 0.6mM ALA on porphyrin production 
in control lymphoblasts. Porphyrin production was stimulated approximately 
20-fold when ALA was added to the growing medium. Amount of protoporphyrin 
is given as pmol/mg of lymphoblast protein. Note the LOG scale in (8) . 
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Figure 8.3: Effect of transformation on total porphyrin levels on days 7, 14 and 21 (ie. once 
the cells had proliferated sufficiently) . Stimulation of porphyrin production was 
high on day 7 but achieved a steady level over the ensuing 3 week period. 
Measurement of amount of total porphyrin was achieved by removing an aliquot 
of cells 24h prior to the due time and incubating in the presence of 6mM ALA. 
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protoporphyrinogen oxidase and PBG deaminase activities there was 
some fluctuation in porphyrin levels; the highest levels were measured 
on day 7 (see figure 4.9), but steady levels were measured over the 
ensuing 3 week period. 
Porphyrin production in VP cell lines 
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Figure 8.4(A) contrasts the porphyrin measurements in five normal 
control lymphoblasts with those in seven VP lymphoblasts. There was 
a significant increase of 20% (p<0.005) of the mean endogenous 
protoporphyrin in the VP cells; but copra- or uroporphyrin were not 
significantly increased, though there appeared to be a trend to a slight 
increase in coproporphyrin. 
When VP and control cell porphyrin productions were stimulated by 
addition of ALA and compared, the porphyrin profile of VP 
lymphoblasts differed similarly. After ALA stimulation, 
protoporphyrin was elevated by 30% (p<0.001) and coproporphyrin 
by 14% (p<0.005) in the VP lymphoblasts (figure 8.4(B)). 
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Figure 8.4: Differences in porphyrin production in control (normal) and VP lymphoblasts. 
(A) With no added ALA, protoporphyrin levels (pmol/mg lymphoblast protein) 
were significantly raised in a group of 7 VP cultures when compared to a group 
of 5 control cultures. In order to obtain these figures approximately 1000ml of a 
1-2X106 cell/ml suspension culture had to be prepared. 
(8) After ALA stimulation, protoporphyrin and coproporphyrin levels (pmol/mg 
/ymphoblast protein) were significantly raised by 30% and 14% respectively in a 
group of 12 VP cultures when compared to a group of 5 normal control cultures. 
"T" bars represent one standard deviation. 
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Discussion 
Porphyrin production in lymphoblasts 
Few previous studies have used transformed lymphoblasts for the 
study of porphyric disorders in man. One report shows that 
lymphocytes are capable of generating porphyrins from AI.A and that 
96h of incubation in the presence of phytohemagglutinin (PHA) 
considerably increased porphyrin production (Saillen et al, 1969). 
Another study showed that porphyrins are produced by human 
lymphocytes when incubated with AI.A for 48h and that PHA had no 
effect on porphyrin production up to 72h after stimulation (Josephson 
et al, 1972). Porphyrin measurements were not performed after 72h. 
The ability of transformed lymphoblasts to produce porphyrins from 
added AI.A in lymphocytes transformed by PHA as well as pokeweed 
mitogen (PWM) and Epstein-Barr virus has been more recently 
confirmed (Sassa et al, 1978). Our studies corroborate these findings 
and also show that lymphoblasts retain these characteristics in long 
term culture (figures 8.1 and 8.3). We are not aware of any previous 
report describing porphyrin production in Epstein-Barr virus 
transformed lymphoblasts at later stages of culture nor, indeed, in the 
absence of AI.A stimulation. These results, in lymphoblasts well 
established in culture, show porphyrin and haem pathway activity both 
in the "resting" cells and after pathway stimulation by addition of 
0.6mM AI.A (figure 8.2). 
Evidence of altered porphyrin metabolism in VP lymphoblasts 
It is of interest to compare porphyrin production in control 
lymphoblasts with that in VP lymphoblasts. VP cells showed a 
significant 20% increase in endogenous protoporphyrin 
concentrations (figure 8.4(A)). When porphyrin production was 
stimulated by addition of AI.A to the growing medium both 
protoporphyrin and coproporphyrin rose in the VP group, by 30% and 
14% respectively (figure 8.4(B) ). The similarity between the porphyrin 
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profile obtained in these cells and that found in the stool of VP patients 
is notable. 
This increase in concentrations of distal porphyrin intermediates in 
lyrnphoblasts from VP subjects has not previously been documented, 
and contrasts with the porphyrin production reported in VP 
fibroblasts, where no elevation of protoporphyrin was found (Brenner 
and Bloomer, 1980a). The authors of that study state that it is not clear 
why abnormal porphyrin metabolism is not apparent in fibroblasts 
despite a demonstrated decrease in protoporphyrinogen oxidase 
activity. They suggest that this may reflect varying activities of the 
haem biosynthetic pathway in different tissues and that it is only in the 
liver that protoporphyrinogen oxidase activity is sufficiently reduced 
for protoporphyrinogen to accumulate. Another study, however, 
points out that in 9 liver biopsy specimens from VP subjects no 
elevation of protoporphyrin was evident either (Day et al, 1980a). This 
would therefore appear to be a contentious issue. The accumulation 
of porphyrin in tissues would appear to depend on flux through the 
haem pathway and presumably may not be evident if haem synthesis 
was well within the V max activities of haem synthetic enzymes. Our 
data suggest that in transformed lymphoblasts the flux through the 
pathway may be high enough for a defect in protoporphyrinogen 
oxidase to declare itself by the accumulation of substrate. 
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Conclusions 
D Porphyrin production is apparent in trans/ ormed lymphoblasts and it 
is possible to stimulate this by incubation for 24h in the presence of 
ALA. 
D There are alterations ofporphyrin presence in lymphoblasts from VP 
subjects when compared to control lymphoblasts. 
The pattern of altered porphyrin production in VP lymphoblasts was 
consistent with a partial block in the distal portion of the haem 
biosynthetic pathway, as would be expected with a deficiency of 
protoporphyrinogen oxidase. 
Whatever the reason for demonstrably altered porphyrin 
concentrations in VP lymphoblasts, this data supports the validity of 
lymphoblasts as a "model" VP tissue on which to base conclusions 
pertaining to the hypothesis under examination in this dissertation. 
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Overview and implications of the 
present study 
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In the wake of the experimental work presented and discussed in this 
thesis, all that remains is to provide a concise synthesis of the data that 
has emerged from the present study and to examine its contribution 
to the established framework of knowledge concerning porphyria. 
Overview 
This study has concerned itself primarily with the study of PBG 
deaminase in VP. 
We have observed a decrease in PBG deaminase activity in 
lymphoblasts derived from subjects with quiescent VP. In contrast to 
normal lymphoblast PBG deaminase substrate-velocity curves which 
are hyperbolic and appear to obey Michaelis-Menten kinetic laws, VP 
lymphoblast PBG deaminase substrate-velocity curves are sigmoidal 
and do not conform to Michaelis-Menten kinetics. Addition of proto-
and coproporphyrinogen but not of uroporphyrinogen nor any of the 
porphyrins tested to control lymphoblasts resulted in substrate-velocity 
curves reminiscent of VP. Experiments designed to remove 
porphyrin( ogen)s from PBG deaminase derived from VP 
lymphoblasts restored PBG deaminase kinetics to normal. 
Similar kinetic alterations were observed using purified PBG 
deaminase with and without addition of proto- and 
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coproporphyrinogen. Uroporphyrinogen nor proto-, copro- or 
uroporphyrin failed to influence PBG deaminase. 
Further work showed that VP lymphoblasts appeared to exhibit 
altered porphyrin profiles with an increase in protoporphyrin ( and 
sometimes coproporphyrin) as compared to control cells. 
Additional evidence of partially inhibited PBG deaminase activity in 
VP was provided by finding a small but significant increase in urinary 
AlA and PBG concentrations in a large series of VP patients when 
compared to a series of normal controls. 
Implications 
The finding that proto- and coproporphyrinogen exert negative 
allosteric effects on PBG deaminase lend support to those who have 
observed that PBG deaminase is potentially rate-limiting in the haem 
biosynthetic pathway. In this regard our study provides a possible 
mechanism for the accumulation of the early haem precursors AlA 
and PBG during the acute attack of VP. 
In addition this study suggests a mechanism by which VP and HCP may 
be grouped with AIP as causes of "acute" porphyria. Our data would 
suggest that these are the only porphyric conditions in which PBG 
deaminase is an "affected" enzyme. In AIP, PBG deaminase deficiency 
is inherited. In VP and HCP the intermediates accumulating as a result 
of the inherited enzyme defect partially inhibit PBG deaminase. This 
we suggest results in accumulation of ALA and PBG when there is 
increased flux through the haem pathway. The finding that 
uroporphyrinogen exerted no influence on PBG deaminase is in 
keeping with our hypothesis since PCT is a non-acute porphyria and 
concentrations of ALA and PBG are not elevated in this condition. 
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Future work 
Firstly the work suggests that the Epstein-Barr virus lymphoblast may 
be a useful model system for the study of haem synthesis. At least some 
of the haem synthetic enzymes are able to be assayed in this system. 
Furthermore, any true inherited factors/deficiencies should be 
perpetuated thus providing a ready source of material for the study of 
inherited porphyrias in general. Epstein-Barr virus transformed 
lymphoblasts we believe should be considered as potential model 
system in which to study porphyria. Further, this system may provide 
a good model for studying the potential effects of drugs on haem 
biosynthesis in cells derived from porphyric subjects. 
If elevated intracellular concentrations of proto- and 
coproporphyrinogen do inhibit PBG deaminase then attempts to 
decrease the concentrations of these intermediates might have 
potential therapeutic benefits. Although no such methods are 
currently available the present study should give added impetus to 
efforts to achieve a reduction in porphyrin( ogen) accumulation, for 
example by the use of sorbent therapy such as the use of oral activated 
charcoal. 
This work might also be of use in the treatment of the acute attack per 
se. Again removal of excessive proto- and coproporphyrinogen by 
some means should provide a way of normalising apparent PBG 
deaminase activity to cope with the "switched-on" haem synthetic 
machinery and so avoid porphyrin precursor accumulation. 
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Because VP is traditionally considered as being mainly of hepatic 
expression, further work should be p6rformed to study whether 
hepatic haem synthesis is subject to the same potential mechanism of 
ALA and PBG build-up. This type of work could be feasible using 
cultured hepatocytes in which kine.tic experiments on PBG deaminase 
similar to those described here could be performed. 
Afterword 
* 
Many questions still surround the understanding of the porphyrias and 
in particular the pathogenesis of the acute attack of porphyria. While 
the present study has not been without its frustrations it has proved an 
exciting venture for me personally. In the words of the immunologist 
Peter Medawar: "Scientific discovery is a private event, and the delight 
that accompanies it, or the despair of finding it illusory does not 
* travel" . 
The apparently successful application of a basic science, such as 
enzyme kinetics, to a "clinically biochemical problem" has nevertheless 
provided much joy. It is my sincere hope that the new developments 
presented in this work will serve to advance the understanding of not 
only VP but the porphyrias generally. 
Hypothesis and Imagination (Peter Medawar, 1915-1987) 
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Appendix 1 
Materials and equipment 
Materials 
• Unless otherwise stated all chemicals and reagents were of analytical 
grade and obtained from Sigma Chemical Co., St. Louis, Missouri, 
USA and Merck, Darmstadt, West Germany respectively. 
• All porphyrins, porphyrin esters and porphyrin chromatographic 
markers were from Porphyrin Products, Logan, Utah, USA . 
• Acetic acid, acrylamide, ammonium persulphate, ammonium 
sulphate, bromophenol blue, ethanol, glutathione (reduced), 
glycerol, methanol and trypan blue were from BDH Chemicals Ltd, 
Poole, England. 
• Hanks balanced salt solution, HAM F-10 culture medium and foetal 
calf serum were from Gibco Ltd, Paisley, Scotland. 
• All column chromatographic media used for the purification of PBG 
deaminase and Sephadex G25 were from Pharmacia Fine 
Chemicals, Uppsala, Sweden. 
• ALA and PBG were quantified using Bio-Rad ALA columns (Bio-Rad, Munich, West Germany). 
• All tissue culture flasks and disposable pipettes were from Falcon 
Inc, Cockeysville, Maryland, USA. 
• Thin layer chromatographic plates were from Merck, Darmstadt, 
West Germany. 
• Centricon 30 microconcentrators were from Amicon, Danvers, 
Massachusetts, USA. 
• 0.45 and 0.22µm Millex HA filter units were from Millipore 
Corporation, Bedford, Massachusetts, USA 
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Equipment 
• A Vitatron TLD 100 scanning densitometer (Dieren, The 
Netherlands) interfaced to a Spectra Physics SP4270 recording 
integrator unit (San Jose, California, USA) was used for all 
quantitative fluoroscanning. 
• A Perkin Elmer 204A fluorescence spectrophotometer 
(Connecticut, USA) was used for all fluorometry . 
• A Sorvall RCSB refrigerated centrifuge (Du Pont Instruments, 
Connecticut, USA) and a Sigma 3E-1 benchtop centrifuge 
(Osterode, West Germany) were used for all centrifugation 
purposes . 
• Sonication was performed by a Heat Systems Ultrasonic Model 
W-10 sonicator (Plainview, New York) . 
• Absorbance spectrophotometry was performed on a Zeiss DM4 
dual beam spectrophotometer (Carl Zeiss, Oberkochen, West 
Germany) . 
• pH meter was a Radiometer AutoCal Model PHM83s (Radiometer, 
Copenhagen, Denmark) . 
• All tissue culture work was carried out in a laminar flow hood 
(Laminaire, Bino Instrumentation, Cape Town) and a water 
jacketed, CO2 incubator (Forma Scientific, Ohio, USA) was used for 
maintaining growth of cell cultures . 
• Where necessary data were analysed using a Bondwell AT IBM 
compatible computer system using the following software: DBase 
3-Plus®, Lotus 123®, Epistat©, Enzfitter© . 
• This thesis was produced on the above system using a Kyocera laser 
printer and the following software: Microsoft Word® (Version 5), 
Harvard Graphics® and Ventura® (Release 2). 
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Appendix 2* 
DRUG SAFETY IN PORPHYRIA 
* 
INTRODUCTION 
Drugs are the most common factor precipitating the acute attack of 
porphyria. Thus identification of potentially unsafe drugs in porphyria 
is vital. 
The list included here has been presented in two ways. Firstly, all 
commonly prescribed drugs on which there is information regarding 
that drug's porphyrinogenicity (ability to provoke an acute attack of 
porphyria) are listed alphabetically (by generic name). Secondly, the 
same drugs have been listed according to their specific therapeutic use. 
The information presented here has been obtained by combining and 
comparing data from several porphyria drug lists obtained from both 
local and overseas sources. The data regarding a drug's 
porphyrinogenicity is based upon experimental evidence ( either in 
tissue culture systems, animal models or human leukocytes), or upon 
the personal experience of doctors managing porphyric patients. Such 
information is by no means valid under all circumstances, and the list 
needs to be interpreted with caution. 
SUGGESTIONS FOR THE DOCTOR OR 
PHARMACIST 
We suggest strongly that porphyric patients do not receive medication 
unless it is felt to be absolutely vital. Most of the drug-related problems 
we encounter have involved medication which was not strictly 
necessary in the first place. Do not allow the patient to extract "a pill 
Extracted from Hift et al, 1989. Drug list and preamble compiled by Meissner PN 
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for every ill" from you. Secondly, avoid compound formulae -
particularly analgesics: though the paracetamol and codeine in them 
may be acceptable, often one of the "lesser" ingredients, such as 
meprobamate, is not. Thirdly, remember that these lists are only a 
guide. It is sometimes necessary to use a drug which is listed as possibly 
safe,probably unsafe or even unsafe, though, wherever possible, a safer 
alternative should be chosen. Even such potentially fatal agents as 
phenobarbitone have been used without precipitating an attack. 
However, such a step is_ never lightly undertaken. In such cases, our 
practice is to warn the patient what we are doing; to advise him to stop 
the drug and report back immediately he experiences any abdominal 
dis·comfort; to begin with low doses; and, where particular concern 
exists (as with the antituberculous agents or anticonvulsants) to 
monitor porphyrin and precursor production daily. If in doubt, do not 
hesitate to contact us for advice. Finally, always take a complai!).t of 
abdominal pain in a porphyric subject seriously, and regard any 
medication he may be taking as the cause until disproven. 
Note that this list is not exhaustive; also that new drugs are constantly 
being introduced. We have listed here only those drugs which are at 
all likely to be used at present. However, information is available from 
our Centre on a number of other agents ( older, experimental or 
uncommonly used) which have been omitted in the interests of brevity. 
You should therefore note that absence of a drug from this list does 
not necessarily mean that no information is available on it, still less 
that its safety can be assumed. Any patient given an agent where any 
doubt exists should be warned of the possible effects and instructed to 
stop it immediately any abdominal pain is experienced. 
Always remember that you, as the prescribing doctor, will bear the 
responsibility for a resultant acute attack. Therefore in every case 
weigh up the potential benefit of the drug against the harm which will 
result should an acute attack arise. 
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SUGGESTIONS FOR THE PERSON WITH 
PORPHYRIA 
169 
Avoid medication wherever possible. Do not force your doctor or 
pharmacist to prescribe something for every symptom you may 
experience: this may result in you becoming very ill with porphyria. Do 
not use any medication yourself except for paracetamol (Panado ). 
Should you at any stage, while on medication, experience abdominal 
pain or feel that your condition is deteriorating, stop your treatment 
immediately and check with your doctor. This is very important. 
USE OF THESE LISTS 
The following are the safety "status" terms that are used in the lists, 
together with a fuller explanation of their meaning: 
D S: Safe: Thought to be safe 
D U: Unsafe: Thought to be unsafe 
D C: Contentious: Drugs for which there is conflicting 
evidence 
D PS: Possibly Safe: There is conflicting evidence, but the 
drug is more likely to be safe than 
unsafe. 
D PU: Probably Unsafe: There is conflicting evidence, but the 
drug is more likely to be unsafe than 
safe. 
Although every effort has been made to ensure that these lists are 
correct, responsibility cannot be taken for errors or for any contrary 
experience that may be encountered. 
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ALPHABETICAL LISTING 
A cetazolamide . . S 
Actinomycin D . . S 
Acyclovir . . S 
Adrenaline . . . . . . S 
Alcuronium . . . . . U 
Allopurinol . . . . . PS 
Alpha-methyldopa . . . . U 
Alprazolam . . . . . . . U 
Amethocaine . . . . . . S 
Amiloride . . . . . . . S 
Aminocaproic acid . S 
Aminoglycosides . S 
Aminophylline . . . U 
Amiodarone . . . . . . U 
Amitriptyline . . PU 
Amoxycillin . . . . . . . . S 
Amphetamines . . .... PU 
Amphotericin . . . . . . S 
Ampicillin . . . . . . . .S 
Androgens . . . . . . . . PU 
Ascorbic acid . . . . . S 
Aspirin .. S 
Atenolol . . . . . . .. S 
Atropine . . . . . . . . ; . S 
Auranofin . . . . . . . . . U 
Aurothiomalate (gold) . . U 
Azathioprine . . . . . . . S 
B arbiturates . . . . . . . U 
Beclomethasone . . . . . . S 
Bendrofluazide . . . . . . C 
Benoxaprofen . . . . . . . U 
Benzothiazide . . . . . . . C 
Beta-blockers . ...... S 
Beta-carotene . . . . . . . S 
Biguanides . . . . . . . . . S 
Bromocriptine . . . . . . . U 
Bumetanide . . . . . . . . S 
Bupivacaine . . . . . . . . C . 
Buprenorphine . . . . . . S 
Busulphan . . . . . . . . . U 
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C aptopril . . . . . . U 
Carbamazepine . . . U 
Carbimazole S 
Cefuroxime . . . . . . PU 
Cephalexin . . . . . . PU 
Cephalosporins . . . . . PU 
Cephradine PU 
Chloral hydrate S 
Chlorambucil . . U 
Chloramphenicol U 
Chlordiazepoxide U 
Chlormethiazole C 
Chlormezanone . . . U 
Chloroform U 
Chloroquine . . . . C 
Chlorothiazide . . . PS 
Chlorpheniramine S 
Chlorpromazine . . S 
Chlorzoxazone . . . U 
Cimetidine . . . . . PU 
Cinnarizine . . . . U 
Cisplatin . . . . . . . . . S 
Clofibrate . . . . . . . . S 
Clomiphene citrate . . . S 
Clomipramine U 
Clonazepam C 
Clonidine . U 
Cloxacillin S 
Cocaine . . PU 
Codeine S 
Codeine phosphate S 
Colchicine . . . . . . . . S 
Corticosteroids . . . . . PS 
Corticotrophin (ACTH) S 
Co-trimoxazole . . . U 
Coumarin ........ S 
Crystal violet . . . . . . . U 
Cyclizine . . . . . . . . . S 
Cyclopenthiazide S 
Cyclophosphamide U 
Cyclopropane . . . S 
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Cycloserine . . . . . 
Cyclosporin . . . . . 
Cyproterone acetate 
. . U 
. . u 
.. PU 
D~xamethasone . .... S 
Dextropropoxyphene . . . U 
Dextrose .......... S 
Dia.morphine . . . . . . . S 
Diazepam ... C 
Diazoxide . . . . . . . S 
Diclofenac . . . U 
Dicyclomine . . . . S 
Diethyl ether . . . . S 
Diflunisal .... S 
Digitalis preparations . . . S 
Digoxin .... ....... S 
Dihydralazine . . . . U 
Dihydrocodeine . . . S 
Dihydroergotamine . U 
Diltiazem . PU 
Dimenhydrinate . U 
Dimethicone . . S 
Dinoprost . . . . . . . U 
Diphenhydramine . . . PU 
Dipyrone . . . . .. U 
Disopyramide . . . . . . . PS 
Domperidone . . . . . . . S 
Dothiepin . . . . . . . . . PS 
Doxorubicin . . . . . . S 
Doxycycline . . . . . . U 
Droperidol . . . . . . . . S 
Dydrogesterone . . . . . . U 
Enflurane ..... PU 
Ergometrine ... .. u 
.. .. u 
... u 
.. . U 
... PU 
... S 
Ergot compounds 
Ergotamine maleate 
Ergotamine tartrate 
Erythromycin 
Ethacrynic acid 
Ethambutol . . 
Ethanol 
Ethinyloestradiol 
Ethionamide 
..... s 
. .. u 
.. C 
. .. u 
Ethosuximide U 
Etomidate . . U 
F enfluramine U 
Fenoprofen . . . . . . S 
Fentantyl . . . . . . . . . S 
Flucloxacillin . . . , . . . PU 
Flucytosine S 
Flufenamic acid U 
Flunitrazepam U 
Flurazepam U 
Flurbiprofen S 
Fluroxene U 
FolicAcid S 
Fructose . . S 
Frusemide PU 
Fusidic acid PS 
Gentamicin S 
Glipizide S 
Glucagon . . . S 
Glucose S 
Glyceryl trinitrate . . S 
Griseofulvin U 
Guanethedine S 
Ha1operidol S 
Halothane . . . . C 
Haem arginate S 
Heparin S 
Hydantoins . . . . U 
Hydralazine . . . U 
Hydrochlorothiazide . . PU 
Hydrocortisone ... .. PS 
Hydroxyzine . . . . . . . U 
Hyoscine . . . . . . . . C 
Hyoscine butylbromide U 
Ibuprofen . . . . S 
Imipramine . . . . U 
Indomethacin . . PS 
Insulin . . . . . . S 
Iron preparations S 
Isoniazid . . . . . . PU 
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Ketamine . 
Ketoprofen 
... PS 
. .. s 
Labetalol . . . . . . . . . S 
Licorice .......... S 
Lignocaine . . . . . . . . . U 
Lithium salts . . . . . . . S 
Lofepramine . . . . . U 
Loj,eramide . . . . . . . . S 
Lorazepam . PS 
Lysuride maleate . U 
M agnesium sulphate . S 
Mebendazole . . . . . . PS 
Mefenamic acid . . . . . PU 
Megestrol acetate . U 
Melphalan . . . . . . . . . PS 
Mepivacaine . . . . . . U 
Meprobamate . . . . . .. U 
Mercaptopurine . . . . . . U 
Mestranol . . . U 
Metformin . . . S 
Methadone . . . S 
Methamphetamine . . . PU 
Methohexitone . . . . . . U 
Methotrexate . . . . . . . U 
Methotrimeprazine . . . PS 
Methoxyflurane . . . U 
Methsuximide . . . . . U 
Methylphenidate . . . S 
Methyluracil . . . . . . . S 
Methysergide . . . U 
Metoclopramide . PS 
Metoprolol Tartrate . S 
Metronidazole . U 
Metyrapone . U 
Mianserin . . . . . PS 
Miconazole . U 
Midazolam . . PS 
Minoxidil . . U 
Morphine .. S 
Nadolol 
Nalidixic acid 
.s 
.U 
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Naproxen .. 
N eostigmine 
Nifedipine 
Nitrazepam 
Nitrofurantoin 
Nitrous oxide 
Nortriptyline 
s 
s 
u 
u 
PU 
s 
PU 
O estrogens U 
Oral contraceptives PU 
Orphenadrine . . . U 
Oxazepam . . . . . PU 
Oxybuprocaine S 
Oxycodone . . . . . . . U 
Oxymetazolone . . . . . U 
Oxyphenbutazone U 
Oxytetracycline . . . . . U 
Oxytocin . . . . . S 
P ancuronium 
Paracetamol 
Paraldehyde . . . 
Penicillamine 
Penicillin ... .... . 
Pentazocine . . . . . . 
Pentobarbitone . . 
Perhexiline . . ..... . 
Pethidine ... . .. . 
Phenacetin 
Phenelzine 
Phenformin 
Phenoxybenzamine 
Phentolamine . . 
Phenylbutazone . . 
Phenytoin .. . .. . . . 
Pirenzipine 
Piroxicam 
Pivampicillin 
Prazosin .. 
Prednisolone 
Prilocaine 
Primaquine 
Primidone 
Probenecid 
PS 
s 
s 
s 
s 
u 
u 
u 
s 
u 
u 
s 
u 
s 
u 
u 
s 
u 
u 
PS 
s 
C 
s 
u 
PU 
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Probucol ... 
Procainamide 
Procaine ... 
Prochlorperazine 
Progestogens 
... . s 
.... S 
. . . . s 
Promazine ..... . 
.. s 
.PU 
.S 
. PU 
.PU 
.PS 
.PS 
.c 
.... s 
. ... s 
Promethazine . . . . . 
Propanidid . . . . . . . 
Propantheline bromide 
Propofol ... 
Propoxyphene 
Propranolol . . 
Propylthiouracil 
Prostigmine .. 
Pseudoephedrine . . . 
Pyrazinamide . ... 
Pyridoxine . . . . . . 
Pyrimethamine ... 
.. s 
.s 
.u 
.s 
.PS 
Q uinidine .S 
Quinine .S 
R anitidine . C 
Reserpine . S 
Rifampicin . . U 
S a1butamol .S 
Senna .S 
Spironolactone . U 
Stanozolol . . . . . . U 
Streptomycin . . . . S 
Succinyl Choline . S 
Sulphadoxine . . . . . U 
Sulindac . . . . . . . .S 
Sulphacetamide . . . . U 
Sulphamethoxazole . U 
Sulphasalazine . . . . . U 
Sulphonamides . U 
Sulphonylureas . U 
Suxamethonium . S 
T alampicillin 
Tamoxifen 
Tomazepam 
.s 
.u 
. . . . . s 
Tetracyclines 
Theophylline 
Thiazides 
Thiopentone 
Thioridazine 
Thyroxine 
Tiaprofenic acid 
Tilidine . .... 
Timolol 
Tocopherol acetate 
Tolbutamide . . . . 
Tranexamic acid . . 
Tranylcypromine 
Triamterene . . . 
Triazolam 
Trifluoperazine 
Trimethoprim 
Trimipramine 
Tubocurarine . 
V alproate 
Verapamil 
Vincristine 
Vitamins ... 
W arfarin . . 
Zinc preparations 
Zinc sulphate 
PS 
u 
C 
u 
u 
s 
s 
u 
s 
s 
u 
s 
u 
s 
C 
s 
u 
PU 
s 
PU 
u 
PS 
s 
s 
s 
s 
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LISTING BY USE 
D Cardiovascular 
Adrenaline . . . . . . . . . S 
Amiodarone . . . . . . . . U 
Atropine ......... . S 
Digitalis preparations . . . S 
Digoxin .... . ..... S 
Diltiazem . . . . . . . . . PU 
Disopyramide . . . . . . . PS 
Glyceryl trinitrate . . . . S 
Nifedipine . . . . . . . . . U_ 
Perhexiline . . . . . . . . U 
Procainamide . . . . . . . S 
Quinidine . . . . . . . . . S 
Verapamil . . . . . . . . . U 
D Diuretics 
Acetazolamide . . . . . . S 
Amiloride . . . . . . . . . S 
Bendrofluazide . . . . . . C 
Benzothiazide . . . . . . . C 
Bumetanide . . . . . . . . S 
Chlorothiazide . . . . . . PS 
Cyclopenthiazide . . . . . S 
Ethacrynic acid . . . . . . S 
Frusemide . . . . . . . . . PU 
Hydrochlorothiazide . . . PU 
Spironolactone . . . . . . U 
Thiazides . . . . . . . . . C 
Triamterene . . . . . . . . S 
D Antihypertensives 
(including 
. Beta-blockers) 
Alpha-methyldopa . . . . U 
Atenolol .... .. ... . S 
Beta-blockers . . . . . . . S 
Captopril . . . . . . . . . U 
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Clonidine . . . . . . . . U 
Diazoxide . . . . . . . . S 
Dihydralazine . . . . . . U 
Guanethedine . . . . . . S 
Hydralazine . . . . . . . U 
Labetalol . . . . . . . . S 
Metoprolol . . . . . . . S 
Minoxidil . . . . . . . . U 
Nadalol .. .. .. . .. S 
Phenoxybenzamine . . . U 
Phentolamine . . . . . . S 
Prazosin . . . . . . . . . PS 
Propranolol . . . . . . . S 
Reserpine . . . . . . . . S 
Timolol . .. . ... . . S 
D Anticoagulants and 
Fibrinolytics 
Aminocaproic acid . . . S 
Coumarin .... . ... S 
Heparin . . . . . ; . . . S 
Tranexamic acid . . . . . S 
Warfarin ..... . ... S 
Asthma 
Aminophylline U 
Beclamethasone S 
Hydrocortisone PS 
Salbutamol . . . . . . . . S 
Theophylline . . . . . . . U 
D Antihistamines 
Chlorpheniramine . . . . S 
Cyclizine . . . . . . . . . S 
Dimenhydrinate . . . . . U 
Diphenhydramine PU 
Hydroxyzine ....... U 
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D Sedatives and 
Major 
Tranquillisers 
Alprazolam . . . . . . . . U 
Chloral hydrate . . . . . . S 
Chlordiazepoxide . . . . . U 
Chlonnethiazole . . . . . C 
Chlormezanone . . . . . . U 
Chlorpromazine . . . . . . S 
Diazepam ......... C 
Droperidol . . . . . . . . . S 
Flunitrazepam . . . . . . U 
Flurazepam . . . . . . . . U 
Haloperidol . . . . . . . . S 
Lorazepam . . . . . . . . PS 
Meprobamate . . . . . . . U 
Methadone . . . . . . . . S 
Methotrimeprazine . . . PS 
Midazolam . . . . . . . . PS 
Nitrazepam . . . . . . . . U 
Oxazepam . . . . . . . . . PU 
Paraldehyde . . . . . . . . S 
Pentobarbitone . . . . . . U 
Promazine . . . . . . . . . S 
Promethazine . . . . . . . PU 
Temazepam . . . . . . . . S 
Thioridazine . . . . . . . . U 
Triazolam . . . . . . . . . C 
Trifluoperazine . . . . . . S 
D Antidepressants 
Amitriptyline . . . . . . . PU 
Clomipramine . . . . . . . U 
Dothiepin . . . . . . . . . PS 
Imipramine . . . . . . . . U 
Lithium salts . . . . . . . S 
Lofepramine . . . . . . . U 
Mianserin . . . . . . . . . PS 
Nortriptyline ....... PU 
Phenelzine . . . . . . . . . U 
Tranylcypromine . . . . . U 
Trimipramine . . . . . . PU 
D Anticonvulsants 
Barbiturates . . . . . . . U 
Carbamazepine . . . . . U 
Clonazepam . . . . . . . C 
Ethosuximide . . . . . . U 
Hydantoins . . . . . . . . U 
Magnesium sulphate . . S 
Methsuximide . . . . . . U 
Phenytoin . . . . . . . . U 
Primidone . . . . . . . . U 
Valproate . . . . . . . . . PU 
D CNS Stimulants and 
Anorectics 
Amphetamines PU 
Fenfluramine . . . . . . . U 
Methamphetamine . . . PU 
Methylphenidate S 
D Migraine 
Ergot compounds U 
Ergotamine maleate . . . U 
Ergotamine tartrate U 
Lysuride maleate . . . . U 
Methysergide . . . . . . U 
D Analgesics 
Buprenorphine . . . . . S 
Codeine . ...... .. S 
Codeine phosphate . . . S 
Dextropropoxyphene . . U 
Diamorphine . . . . . . S 
Dihydrocodeine . . . . . S 
Dipyrone ..... .. .. U 
Fentantyl . . . . . . . . . S 
Morphine ..... ... S 
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Oxycodone . . . . . . . . U 
Paracetamol . . . . . . . . S 
Pentazocine . . . . . . . . U 
Pethidine . . . . . . . . . S 
Phenacetin . . . . . . . . . U 
Propoxyphene . . . . . . . C 
Tilidine . . . . . . . . . ; . U 
D Ear, Nose and 
Throat 
Oxymetazolone . . . . . . U 
Pseudoephedrine . . . . . S 
D Non-steroidal 
Anti-inflammatory 
Aspirin .......... S 
Benoxaprofen . . . . . . . U 
Diclofenac . . . . . . . . U 
Diflunisal . . . . . . . . . S . 
Fenoprofen . . . . . . . . S 
Flufenamic acid . . . . . U 
Flurbiprofen . . . . . . . . S 
Ibuprofen . . . . . . . . . S 
Indomethacin . . . . . . . PS 
Ketoprofen . . . . . . . . S 
Mefenamic acid . . . . . . PU 
Naproxen .. ...... . S 
Oxyphenbutazone . . . . U 
Phenylbutazone . . . . . . U 
Piroxicam . . . . . . . . . U 
Sulindac .. ........ S 
Tiaprofenic acid . . . . . . S 
D Arthritis and Gout 
Allopurinol . . . . . . . . PS 
Auranofin . . . . . . . . . U 
Aurothiomalate ( Gold) . . U 
Colchicine . . . . . . . . . S 
Penicillamine . . . . . . . S 
Probenecid . . . . . . . . PU 
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D Antimicrobial Agents 
Acyclovir . . . . . . . . S 
Aminoglycosides S 
Amoxycillin . . . ; . . . S 
Amphotericin . . . . . . S 
Ampicillin . . . . . . . . S 
Cefurox:ime . . . . . . . . PU 
Cephalexin . . . . . . . . PU 
Cephalosporins . . . . . PU 
Cephradine . . . . . . . PU 
Chloramphenicol . . . . U 
Chloroquine . . . . . . . C 
Cloxacillin . . . . . . . . S 
Co-trimoxazole . . . . . U 
Cycloserine . . . . . . . U 
Dapsone ......... U 
Doxycycline . . . . . . . U 
Erythromycin . . . . . . PU 
Ethambutol . . . . . . . S 
Ethionamide . . . . . . U 
Flucloxacillin . . . . . . . PU 
Flucytosine . . . . . . . S 
Fusidic Acid . . . . . . . PS 
Gentamicin . . . . . . . . S 
Griseofulvin . . . . . . . U 
Isoniazid . . . . . . . . . PU 
Metronidazole U 
Miconazole . . . . . . . . U 
Nalidixic Acid . . . . . . U 
Nitrofurantoin . . . . . . PU 
Oxytetracycline . . . . . U 
Penicillin ... ...... S 
Pivampicillin . . . . . . U 
Primaquine . . . . . . . . S 
Pyrazinamide ...... U 
Pyrimethamine PS 
Quinine ........ . S 
Rifampicin . . . . . . . . U 
Streptomycin . . . . . . . S 
Sulphadoxine . . . . . . U 
Sulphacetamide . . . . . U 
Sulphamethoxazole . . . U 
Sulphonamides . . . . . U 
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Talampicillin . . . . . . . S 
Totracyclines . . . . . . . PS 
Trimethoprim . . . . . . . U 
D Gastro-intestinal 
and 
· Antispasmodics 
Cimetidine . . . . . . . . . PU 
Dicyclomine . . . . . . . S 
Hyoscine . ......... C 
Hyoscine butylbromide . . U 
Loperamide . . . . . . . . S 
Pirenzipine . . . . . . . . S 
Propantheline bromide . PS 
Ranitidine . . . . . . . . . C 
Senna ........... S 
Sulphasalazine . . . . . . . U 
D Anti-emetics 
Cinnarizine . . . . . . . . U 
Domperidone . . . . . . . S 
Metoclopramide . . . . . PS 
Prochlorperazine . . . . . S 
D Endocrine 
Bromocriptine 
Carbimazole 
... . .. u 
.... ... S 
Dinoprost . . . . . . . . . U 
Metyrapone . . . . . . . . U 
Propylthiouracil . . . . . . S 
Thyroxine . . . . . . . . . S 
D Antidiabetic Agents 
Biguanides . . . . . . . . . S 
Glipizide . . . . . . . . . S 
Metformin . . . . . . . . S 
Phenformin . . . . . . . . S 
Sulphonylureas . . . . . . U 
Tolbutamide . . . . . . . U 
D Steroids and 
Hormonal 
Preparations 
Androgens . . . . . . . . PU 
Beclomethasone . . . . . S 
Clomiphene citrate . . . S 
Corticosteroids . . . . . PS 
Corticotrophin (ACTH) S 
Cyproterone acetate PU 
Danazol ..... .. .. U 
Dexamethasone . . . . . S 
Dydrogesterone . . . . . U 
Ethinyl oestradiol . . . . C 
Glucagon .. ....... S 
Hydrocortisone ..... PS 
Insulin ........ . . S 
Megestrol acetate . . . . U 
Mestranol . . . . . . . . U 
Oestrogens . . . . . . . . U 
Oral contraceptives . . . PU 
Oxytocin ......... S 
Prednisolone . . . . . . . S 
Progestogens . . . . . . . PU 
Stanozolol . . . . . . . . U 
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D Cytotoxics and 
lmmunosuppressives 
Actinomycin D S 
Azathioprine . . . . . . . S 
Busulphan . . . . . . . . U 
Chlorambucil . . . . . . U 
Cisplatin ........ . 
Cyclophosphamide . . . 
Cy I . c.osponn ... .. . . 
Doxcrubicin ...... . 
Melphalan . .. ... . . 
Mercaptopurine . . . . . 
Methotrexate . . . . . . 
Methyluracil . . . . . . . 
s 
u 
u 
s 
PS 
u 
u 
s 
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Tamoxifen . . . . . . . . . U 
Vmcristine . . . . . . . . PS 
D Dermatology 
Beta-carotene ....... S 
Dimethicone . . . . . . . S 
D Drugs used in 
Anaesthesia 
Alcuronium . . . . . . . . U 
Chloroform . . . . . . . . U 
Cyclopropane . . . . . . . S 
Diethyl ether . . . . . . . S 
Enflurane . . . . . . . . . PU 
Etomidate . . . . . . . . . U 
Fluroxene . . . . . . . . . U 
Halothane . . . . . . . . . C 
Ketamine . . . . . . . . . PS 
Methohexitone . . . . . . U 
Methoxyflurane . . . . . . U 
Neostigmine ..... .. S 
Nitrous oxide . . . . . . . S 
Pancuronium . . . . . . . PS 
Propanidid . . . . . . . . . PU 
Propofol . . . . . . . . . . PS 
Prostigmine . . . . . . . . S 
Succinyl Choline . . . . . S 
Suxamethonium . . . . . S 
Thiopentone . . . . . . . U 
Tubocurarine . . . . . . . S . 
D . Local Anaesthetics 
Amethocaine . . . . . . . S 
Bupivacaine . . . . . . . . C 
Cocaine .......... PU 
Lignocaine . . . . . . . . . U 
Mepivacaine . . . . . . . U 
Oxybuprocaine . . . . . . S 
Prilocaine . . . . . . . . . C 
Procaine .......... S 
Appendices 
D Nutrients and 
Haematinics 
Ascorbic acid . . . . . . S 
Dextrose 
Ethanol 
Folic acid 
Fructose 
Glucose 
Iron preparations . . . . 
Pyridoxine . . . . . . . . 
Tocopherol acetate . . . 
Vitamins ........ . 
s 
u 
s 
s 
s 
s 
s 
s 
s 
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Appendix 3* 
MANAGEMENT OF THE ACUTE ATTACK 
* 
At the outset, it must be stressed again that any patient known or 
thought to have VP ( or AIP) should have a complaint of abdominal discomfort taken seriously. All medication should immediately be 
stopped and should only be restarted once an incipient acute attack has been confidently ruled out. 
Secondly, one should realise that the acute abdomen of porphyria 
often mimics the surgical acute abdomen. As a rule, the porphyric with 
an acute abdomen is more likely to be suffering from an acute attack 
than a coincidental surgical emergency. In VP, the use of Ehrlich's 
reagent will quickly and reliably confirm an acute attack, and the 
temptation to perform an exploratory laparotomy "just in case" should be resisted. This decision is more difficult in AIP, where the Ehrlich's 
test may be positive even in remission. 
Guidelines 
D Admit the patient. Remove any precipitating factors, particularly drugs. 
D Correct dehydration and electrolyte abnormalities. Potassium, 
calcium and magnesium supplements are often required. Once dehydration has been corrected, fluid balance should be handled 
with great care. Inappropriate ADH secretion (SIADH) 
commonly occurs during acute attacks and may result in severe hyponatraemia. Excessive fluid administration ( often intravenously) is a common error in management. Hyponatraemia 
Extracted from Rift et al, 1989. Co-authored by Meissner PN. 
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may be prevented as well as treated by fluid restriction and only 
rarely is it necessary to correct hyponatraemia by the cautious use 
of hypertonic saline. 
D Carbohydrate loading suppresses porphyrin production, though its 
mechanism of action is unknown. This is at present standard 
therapy. The aim is to administer 2000 kCal per day enterally (using 
agents such as oral Hycal). Intravenous IV dextrose can cause fluid 
expansion and aggravate hyponatraemia. If intravenous 
administration cannot be avoided, our practice is to administer one 
litre of a 50% glucose solution (2000 kCal/1) per day. This must be 
given via a central venous line. An equivalent amount of 
carbohdrate given as 10% glucose would require the 
administration of 51 of fluid, which is unacceptable. 
D Treat the symptoms with non-porphyrinogenic drugs. Suitable 
agents are: 
• Pain: dihydrocodeine, morphine, pethidine 
• Vomiting: prochlorperazine, promazine, chlorpromazine 
• Psychosis: promazine, chlorpromazine, trifluoroperazine 
• Convulsions: clonazepam, lorazepam. The use of diazepam is 
contentious, but may be necessary if no other 
drug is available. 
Beta adrenergic blockers may have some anti-porphyrinogenic effect in 
themselves and are thus particularly useful for the control of 
hypertension and tachycardia. 
D A further form of therapy is a haematin infusion. Haematin is 
believed to inhibit the porphyrin pathway by negative feedback of 
ALA synthetase. At present haematin is derived from pooled 
plasma and therefore carries the risk of viral transmission. Its use 
may be complicated by local thrombophlebitis, and it may 
precipitate disseminated intravascular coagulation. The usual dose 
is 4-8 mg/kg/day for 2-3 days. Newer formulations such as 
lyophilised haematin and haem arginate are superior to the older 
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agents. In an emergency, information on their availability can be 
obtained from the Porphyria Service of the the University of Cape 
Town. 
D All patients with acute attacks should be intensively monitored for 
the development of paralysis and respiratory failure, and facilities 
for ventilation should be available. Transfer severe cases to a centre 
with intensive care facilities and expertise in porphyria if necessary. 
The neuropathy of porphyria is reversible and continued 
ventilation is justified in all cases. 
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Porphyrin determination by TLC and quantitative 
fluoroscanning 
A highly sensitive TLC assay for porphyrins in blood (plasma and 
erythrocytes), based on quantitative fluoroscanning, has previously 
been described, well characterized and standardized (Day et al, 1978a). 
The adaptation of these methods to stool and urine was achieved by 
simply substituting erythrocyte or plasma starting material. The 
method is described in full detail below. 
Sample preparation 
3ml of urine or plasma, or approximately 0.3g of stool, were esterified 
in 30ml of a 5% sulphuric acid/methanol solution (v/v) overnight, at 
room temperature in the dark. In the case of stool, the wet weight of 
the sample used was determined and noted. A further aliquot of the 
same stool sample was weighed, allowed to dry overnight at 60° C, and 
the dry weight determined, thus allowing determination of a wet 
weight/dry weight ratio. 
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Extraction 
All procedures were performed in a:darkened room. The stool and 
plasma esterification mixtures were centrifuged at 800Xg for 15 
minutes. The supernatants of plasma or stool mixtures or the urine 
esterification mixture itself were transferred into separating funnels 
and the pH neutralized with 17% ammonia solution. The porphyrin 
esters were then extracted into chloroform. Plasma was extracted into 
a total volume of 10ml of chloroform (2 X 5ml aliquots), urine into a 
total of 20ml (2 X 10ml aliquots) and stool into a total of 45ml (3 X 
15ml aliquots). Where a gross excess of porphyrin was suspected as 
suggested by the initial screening for porphyrins, proportionately more 
chloroform was used in the extraction procedure. 
Quantitative TLC 
The volume of the chloroform extract was noted and precise aliquots 
of each extract were applied in spot form, in semi-dark conditions, to 
TLC plates (Merck Silica gel-60, without fluorescent indicator) using 
a microsyringe (Hamilton). Care was taken to adjust the amount of 
porphyrin esters spotted so that they fell within the linear portion of 
the fluorescence concentration curve. Generally, 30-50µ1 of stool 
extract was spotted ( the exact amount was suggested by to the results 
of an initial screening procedure), 100-300µ1 of the urine extract, and 
50-100µ1 of the plasma extract, after it had been evaporated to dryness 
and an exact 1ml volume of chloroform added. Evaporation of the 
chloroform during the spotting was aided by a constant stream of warm 
air blown over the working area by a fan. Each plate accommodated 9 
spots spaced at 2cm intervals, 2 of these lanes being reserved for 
porphyrin ester standards. Standards containing mixtures of known 
amounts of uro-, heptacarboxylic-, hexacarboxylic-, pentacarboxylic-, 
copro- and mesoporphyrin methyl esters were spotted in these two 
lanes. Mesoporphyrin behaves similarly to protoporphyrin on TLC. 
Pl<!-tes were developed for 45-60 minutes in a solvent system consisting 
of carbon tetrachloride/ dichloromethane/ethyl acetate/ethyl 
propionate in a 2:2:1:1 (v/v) ratio. Each plate was then dipped in an 
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enhancing system consisting of chloroform/dodecane/ hexadecane 
(18:1:1, v/v/v) in order to increase the fluorescence quantum yield. 
This allowed the quantitation of very small amounts of porphyrin ester 
which would otherwise remain undetected. After drying, the plates 
were scanned on a fluoroscanning photodensitometer connected to an 
integrator/recorder unit. Two interference filters were used, the 
incident at 399nm and the fluorescence filter at 620nm. A trace 
showing the peaks of porphyrin ester fluorescence and their integrated 
areas was thus produced. Individual species of porphyrin ester could 
be identified by direct comparison of the retention times of the 
unknown samples and the standards. Examples of such traces are given 
in figure 2.3. 
Calculation of porphyrin concentration 
The integrated peak areas of the various porphyrin esters separated 
on the TLC plates were compared directly with those of the standards 
on the same plate. The porphyrin concentrations were calculated 
according to the following formulae (adapted from Day et al, 1978b): 
Urine and plasma 
Concentration (nmol!l) = [(SA/SV)/(PA/PV)) * [(VF*C)/IV) 
Stool 
Concentration = [(SA/SV)/(PA/PV)] * [(VF*C)*(WW/DW)/WS) 
(nmol/ dry g) 
where 
SA = peak area of sample porphyrin spot 
PA = peak area of relevant standard porphyrin spot 
SV = volume, in 1tl, of sample applied to TLC plate 
PV = volume, in µl, of relevant porphyrin stand applied to 
TLCplate 
VF = final volume of chloroform extract from sample 
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WW 
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SW 
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= initial sample volume of urine 
= initial sample wet weight of stool 
= relevant porphyrin ester standard concentration in nmol/1 
= wet weight of stool sample in g 
= dry weight of stool sample in g 
= wet weight of stool sample esterified in g 
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Urinary ALA and PBG determination 
ALA and PBG concentrations were assayed according to an 
established ion-exchange method (Davis and Andelman, 1967) 
available in "kit" form (Bio-Rad, Munich, West Germany). The 
manufacturers instructions were followed. Reaction of the eluted PBG 
and ALA (after conversion to PBG) with freshly prepared Ehrlich's 
aldehyde produced a colour response which could be gauged 
spectrophotometrically by measuring absorbance at 553nm. 
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Appendix 6 
Establishment of Epstein-Barr virus transformed 
lymphoblast cell lines 
Preparation of transformation medium 
Medium containing Epstein-Barr virus was prepared from 
semi-confluent cultures of the Epstein-Barr virus producing marmoset 
cell line B95/8 (Miller and Lipman, 1973). Fresh Ham FlO medium 
containing 15% foetal calf serum was added to the cells and removed 
4 days later. Any B95/8 cells in this medium were removed by 
centrifugation followed by passage through a 0.45µm membrane filter 
(Millipore). The medium was mixed with an equal volume of Ham Fl 0 
medium containing 15% foetal calf serum. This mixture constituted 
the transformation medium and was effective for at least 3 months 
when stored at 4 ° C. 
Establishment of transformed lymphoblasts 
20ml of blood was taken into heparin from each subject and diluted 
with 1/3rd volume of Ham F-10 nutrient medium. The lymphocytes 
were isolated by layering 10ml aliquots of diluted blood onto 5ml of 
Histopaque solution (Sigma) and centrifuging at 1500Xg for 20 
minutes. The resulting white cell band so formed on the 
Histopaque/blood interface was gently removed by pipette, washed 
twice in Ham F-10 and resuspended in 3ml of transformation medium. 
These cells were then set up for transformation by incubating at 37° C 
in a 5% carbon dioxide environment in a 25cm2 tissue culture flask. 
Small volumes (0.5-lml) of medium were added, generally on 
alternate days, until rapid multiplication of transformed lymphoblasts 
allowed passage into new flasks. This took from 7-21 days and growth 
progress was monitored microscopically. At this stage secondary 
culture could be routinely maintained as a suspension in Ham FlO 
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containing 10% foetal calf serum at densities between 1 and 5X106 
cells/ml. In each case a proportion of transformed lymphoblasts 
underwent step-wise freezing to -180°C and were stored in liquid 
nitrogen. Frozen lymphoblast cell lines could be thawed and grown up 
in culture for repeat assays or further investigations up to 4 years later. 
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Preparation of Epstein-Barr virus transformed 
lymphoblasts. for assay 
To prepare cells for assay the lymphoblast suspension was centrifuged 
at 850Xg for 15min and washed twice in Hanks Balanced Salt Solution 
(HBSS) to remove any residual protein in the medium. The cells were 
counted on a Coulter counter and their viability measured using a 
trypan blue exclusion test. Only cultures of 80% viability were used 
and cell densities were adjusted by addition of a final small volume of 
assay buffer (see below) to yield a density of 250-350X106 cells/ml 
(generally 1-2ml). Lymphoblasts and lymphoblast mitochondria were 
ruptured by sonication at full power (Heat Systems Ultrasonic Inc, 
Model W-10) for 6X30sec periods, the preparation being cooled 
intermittently on ice. Protein concentrations (used ultimately for 
expressing enzyme activities/mg of protein) were determined in an 
aliquot by the Lowry method (Lowry et al, 1951). Protein standard 
curves were constructed using a lmg/ml stock solution of human serum 
albumin (HSA) and diluted in appropriate buffer to yield 
concentrations ranging from 0.01 to lmg/ml. 
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Lymphoblast protoporphyrinogen oxidase assay 
The assay for enzymatic oxidation of protoporphyrinogen to 
protoporphyrin is based on the fluorescent properties of 
protoporphyrin and the non-fluorescent properties of 
protoporphyrinogen. The product of the reaction (protoporphyrin) 
can thus be quantified by direct fluorometry with good specificity and 
sensitivity. Our method was based on the description of such a 
fluorimetric assay previously established and characterized for yeast 
cells, rat liver mitochondria, rat liver homogenates, human skin 
fibroblasts and purified mouse protoporphyrinogen oxidase (Poulsen, 
1976; Brenner and Bloomer, 1980b; Jacobs and Jacobs, 1982; Dailey 
and Karr, 1987). 
Preparation of substrate 
Good substrate is essential for successful assay of protoporphyrinogen 
oxidase as it is extremely unstable and spontaneously undergoes 
autoxidation to protoporphyrin. Time was thus spent in attaining a 
good, reproducible method for substrate production in high yield. The 
method used was as follows: 
An approximately 30,uM solution of protoporphyrin in degassed 
lOmM potassium hydroxide containing 20% ethanol (v/v) was reduced 
by vigorous shaking in a stoppered boiling tube, preflushed with 
nitrogen, using 4% sodium amalgam that had been crushed to a hard, 
grainy consistency, in the dark. Sodium amalgam was produced fresh 
and according to well described methods (Vogel, 1974; Fuhrhop and 
Smith, 1975; Brenner and Bloomer, 198Gb), 2g of the amalgam per ml 
of protoporphyrin solution was used. When reduction was complete, 
as judged by complete disappearance of fluorescence when viewed 
under ultraviolet light, the resultant strongly alkaline solution was 
filtered through a 0.451tm filter (Millipore) and the pH adjusted to 8.5 
by addition of glacial acetic acid. If reduction was not complete within 
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5 minutes it was assumed that full reduction was not attainable and the 
procedure restarted using fresh amalgam and solutions. Experiments 
involving fluorescence measurements before and after reduction 
showed that reduction was always more than 96% complete and the 
concentration of protoporphyrinogen was thus taken as being equal to 
that of the protoporphyrin starting solution. The precise concentration 
of protoporphyrin starting solution was determined 
spectrophotometrically by diluting 0.2ml into 4ml of 2.7M 
hydrochloric acid and measuring absorbance at 554nm using the 
extinction coefficient of EmM of 13.5 (Jacobs and Jacobs, 1982). 
Substrate was always produced immediately prior to use. As long as 
the final protoporphyrinogen solution was kept in the dark, protected 
from the atmosphere by either evacuation or under nitrogen, and not 
shaken vigorously, spontaneous reoxidation was negligible for up to 
3hr after its production. 
Protoporphyrinogen oxidase activity 
The apparent V max activity of protoporphyrinogen oxidase in each 
lymphoblast cell line was determined by measuring the velocity 
( directly proportional to the amount of fluorescence produced) over 
a range of 5 substrate concentrations. The substrate concentrations 
were chosen after an idea of the apparent Km had been obtained for 
the lymphoblast enzyme in a series of substrate concentration versus 
velocity experiments. Initial indications were that the Km was in the 
order of lµM. Hence substrate concentrations ranging from 0.75 to 
2.SµM were used. The detail of the method is as follows: 
Different volumes of substrate, freshly prepared as detailed above, 
were added to corresponding volumes of reaction buffer (50mM 
Tris-HCl pH8.5, lmM EDTA, 3mM dithiothreitol and 1 % Brij-35) to 
give 5 final concentrations ranging between 0.75 and 2.SµM. The 
reaction tubes all contained 0.2ml of sonicated sample preparation in 
reaction buffer and the final volume of reaction mixture was 0.5ml. In 
addition 5 corresponding control tubes were prepared, the only 
difference being the substitution of sample preparation with lmg/ml 
bovine serum albumen fraction V (BSA). 
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BSA was used as a non-enzymatic control instead of the previously 
described heated tissue preparation (Brenner and Bloomer, 1980b; 
Jacobs and Jacobs, 1982) as we experienced difficulty in producing a 
non-turbid solution in the latter. In a separate experiment we 
compared BSA (lmg/ml) with a preparation of lymphoblasts heated 
at 90° C for 15 minutes and were able to show no significant differences 
in the rate of non-enzymatic autoxidation of protoporphyrinogen to 
protoporphyrin under the described conditions. Turbidity in the case 
of heated tissue preparation was minimized by sonication (Brenner 
and Bloomer, 1980b). 
The substrate was added rapidly but at controlled time intervals and 
the reaction was allowed to proceed for 1hr, in the dark, at 37°C. 
Fluorescence was measured at zero time and after 1hr using a 
spectrofluorimeter (Perkin Elmer, Model 204A) by injecting a 150µ1 
aliquot into a flow cell of 60µ1 capacity and set at an excitation 
wavelength of 402nm and an emission wavelength of 630nm. 
Use of a single measurement of protoporphyrin produced after 1hr 
was validated in a time-course experiment where protoporphyrinogen 
oxidase activity was shown to be linear for up to 90min, although an 
approximate lOmin "lag" phase was observed. 
The amount of fluorescence produced enzymatically was calculated by 
subtracting both the amount of fluorescence at time zero (if any) and 
the amount produced non-enzymatically in the controls from the final 
fluorescence readings. A standard solution of known protoporphyrin 
concentration was prepared as a means of relating fluorescence units 
to the actual amount of protoporphyrin present. The relationship 
between substrate concentration and protoporphyrin production 
could be plotted graphically, a double-reciprocal Lineweaver-Burk 
plot giving V max and Km values in each case. 
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Appendix 9 . 
Lymphoblast PBG deaminase assay 
Assay of PBG deaminase activity was accomplished by measuring the 
rate of formation of product, uroporphyrinogen, after its oxidation to 
uroporphyrin. The method has been previously described and 
characterised and, as in the hands of the originators of this particular 
assay (Anderson and Desnick, 1982), the "assay of PBG deaminase by 
measurement of uroporphyrin production was found to be a sensitive, 
reliable and reproducible assay." A similar assay has been applied to 
the measurement of cultured human lymphoblast PBG deaminase 
(Sassa et al, 1978). The assay was linear with time between 
approximately 3 and 75min. Linear ranges of porphyrin fluorescence 
versus uroporphyrin concentration were established and used. The pH 
optimum was 8.2 and the activity obtained in our system was similar 
to that reported for human lymphoblasts and lymphocytes elsewhere 
(Sassa et al, 1978; Anderson and Desnick, 1982). The detail of the 
methodis as follows: 
Lymphoblasts were prepared for assay in reaction buffer (O. lM 
Tris-HCl pH 8.2 and O.lmMDTT added fresh) as described above, the 
PBG deaminase being released by rupture of the cell membrane by 
sonication. The sonicates were centrifuged at 30000Xg for 45min and 
the supernatants used for assay. The reaction mixture contained 100µ1 
of sample and 600µ1 of reaction buffer. A O.SmM PBG solution was 
made up fresh immediately prior to assay and 200µ1 of this solution 
added to start the reaction. The reaction was allowed to proceed in the 
dark, at 37°C in a shaking water bath. The reaction was stopped after 
30min by addition of 100µ1 of 50% TCA after 30min and any 
precipitated protein present (normally invisible) was pelleted by 
centrifugation at lOOOOXg for 20min. The assay tubes were exposed to 
long wave ultraviolet light for 30min in order to oxidize 
uroporphyrinogen formed to its corresponding fluorescent porphyrin 
form. Fluorescence using an excitation wavelength of 405nm and an 
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emission wavelength of 595nm was read in a fluorometer. Activities 
were reported as pmol of uroporphyrin formed/mg of sample 
protein/h. 
Appendix 10 
Form and derivation of the "Hill" equation 
The Hill equation is a simplified velocity equation for allosteric 
enzymes. For a comprehensive treatment of the derivation of a basic 
velocity (vN max) equation and the modification of this equation to 
take into account more than one possible ligand/substrate binding site 
by use of so-called "interaction factors", readers are referred to 
Chapter 7 of Segel's superb book, Enzyme Kinetics (Segel IH, 1975). 
A brief summary follows. 
Consider an enzyme with n equivalent ligand binding sites. If the 
cooperativity in ligand binding is very marked (ie. interaction factors 
a, b, c, and so on, are very small numbers), then the concentrations of 
all enzyme-substrate complexes containing less than n molecules of 
substrate will be negligible at any [S] (where [S] is the substrate 
concentration) that is appreciable to Ks (the intrinsic dissociation 
constant of the enzyme-substrate "reaction"). The velocity equation 
under these circumstances reduces to a general form: 
vN max = [Sr / (K* + [Sr) 
where n is the number of binding sites per enzyme molecule and K* is 
a constant comprising the interaction factors a, b, c, and so on, and the 
intrinsic dissociation constant, Ks. This is known as the Hill equation 
which is a simplified velocity equation that can be converted to a useful 
linear farm as shown below. 
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Thus 
Thus 
Thus 
Which can be written 
Appendices 
nlog[S] + log(V max-v )Iv= logK* 
log(v/(V max-v) = nlog[S]-logK* 
Thus a plot of logv/(V max-v) versus log[S] is a straight line with a slope 
of n. When v/(V max-v) = 1.0, then v = O.SV max and the corresponding 
[S] gives [S]o.s. In this dissertation [S]o.5 has been termed Ko.s. 
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Appendix 11 
Purification of PBG deaminase 
Purification procedure 
We were unable to purify PBG deaminase to homogeneity using the 
method described by Fumagalli et al (Fumagalli et al, 1985). We 
therefore modified this method by incorporating chromatographic 
steps described in another method (Anderson and Desnick, 1980) and 
we added a chromatofocusing step. 
460ml of fresh heparinised blood was obtained from a normal healthy 
volunteer. Hereafter all procedures were carried out at 4°C unless 
otherwise specified. Erythrocytes were obtained by centrifugation 
(2000Xg, 15min), the plasma and buffy layer removed and the 
erythrocytes washed twice with cold 0.9% normal saline and the pH 
adjusted to 8.0 with concentrated ammonia. 
One of the major problems in purifying proteins from erythrocytes is 
their separation from haemoglobin. To this end, haemoglobin was 
specifically denatured using an organic solvent mixture and step-wise 
cooling, a method reported to remove 97% of haemoglobin (Scott, 
1976; Bustos et al, 1980). Cold chloroform/n-butanol (0.4:1, v/v) was 
added to the erythrocytes in a ratio of 0.2 volumes of chloroform 
mixture to 1 volume of erythrocytes in three stages with vigorous 
stirring throughout. The three stages consisted of 30min each at the 
following temperatures: Stage I, 4 to 6° C; Stage II, 4 to -10° C and Stage 
III; -10 to -20° C. The mixture was then allowed to stand in a 20° C water 
bath for lh. Centrifugation (24000Xg, 20min) was followed by dialysis 
of the supernatant against 200 volumes of 0.01M potassium phosphate 
buffer at pH 6.8 for 24h. 
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The dialysate was centrifuged (20000Xg, 20min) and the supernatant 
fractionated by ammonium sulphate precipitation. The 0-30% 
precipitate was discarded and the 30-80% precipitate collected by 
centrifugation (20000Xg, lSmin) and dissolved in a minimal volume 
(36ml) of O.OSM Tris-HCl buffer (pH 7.4) (buffer A). 
This was loaded onto a Sephadex G25 column (2.SXlOOcm, 
equilibrated with buffer A) at a flow rate of 38ml/h. 8min (ie. 5.06ml) 
fractions were collected. The fractions containing activity ( as 
identified by PBG deaminase assay) were pooled and subjected to heat 
tre_atment (Fumagalli et al, 1985) which is designed to separate any 
uroporphyrinogen cosynthetase from the deaminase. The pooled 
fractions were heated to 67°C for lSmin. They were then cooled in an 
ice bath, centrifuged (lOOOOXg, lOmin), and the precipitate discarded. 
The supernatant was concentrated by 80% ammonium sulphate 
precipitation. The pellet was spun down (20000Xg, 15min) and 
redissolved in a minimal volume of buffer A (30ml). 
This was applied to a Sephadex G 100 column (2.SXlOOcm, 
equilibrated with buffer A), the column was run at a flow rate of 28ml/h 
and 8min (3.7ml) fractions collected. 
The fractions showing PBG deaminase activity were pooled and 
concentrated in an Amicon ultrafiltration cell through a PMlO 
membrane down to a volume of 22.5ml. The solution was applied to a 
DEAE Spectra Gel M (Spectrum Medical Industries Inc., Los 
Angeles) column (1.6X20cm, equilibrated with buffer A) and run at a 
flow rate of 3lml/h while 8min (4.1ml) fractions were collected. 
Although linear gradient of 0-0.12M sodium chloride over 12h is 
recommended to elute the protein and was used here (Anderson and 
Desnick, 1980; Fumagalli et al, 1985), we found that PBG deaminase 
eluted in the latter portion of the breakthrough peak, before the 
gradient was run. The fractions containing activity were pooled and 
concentrated using an ultrafiltration cell and a PMlO membrane. A 
buffer change to 7.5ml of 0.025M imidazole-HCl, pH 7.4 (buffer B) 
was simultaneously effected. 
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This was applied to a PBE 94 chromatofocusing column (0.9X30cm, 
equilibrated with buffer B) (Pharmacia, Sweden). The column was run 
at a flow rate of 35ml/h and 4min (2.3ml) fractions collected. Proteins 
were eluted by a pH gradient with Polybuffer 74 ( diluted 1:8 with 
water, pH 4.0) (Pharmacia, Sweden). 
The fractions containing PBG deaminase activity were pooled, 
concentrated and the buffer exchanged using the ultrafiltration cell 
with a PMlO membrane for 0.02M potassium phosphate buffer (pH 
8.0) containing 0.12M sodium chloride (buffer C). The 6ml so obtained 
was applied to a phenyl Sepharose CL 4B column (0.9X14cm, 
equilibrated with buffer C) (Pharmacia) and run at a flow rate of 
25ml/h. 8min (3.3ml) fractions were collected. The column was then 
washed with 53ml of buffer C followed by 47ml of buffer C without 
sodium · chloride. Finally PBG deaminase was eluted by a linear 
gradient of 0-80% (v/v) ethylene glycol over 12h. The pH of the 
alkaline ethylene glycol was adjusted to pH 8.0 with O.OSM phosphoric 
add. Finally, the fractions containing PBG deaminase activity were 
pooled, concentrated and the buffer exchanged in the ultrafiltration 
cell through a PMlO membrane into buffer A to yield 72ml of PBG 
deaminase in solution at a concentration of 0.018mg/ml. 
All protein determinations were measured using Biorad protein dye 
solution (See Appendix 12). 
The purified enzyme could be stored with minimal loss of activity over 
a period of 4 weeks in buffer A at 4°C. 
Analytical sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
This is based on a previously described method (Laemmli, 1970). 
Buffers and solutions were mixed as follows: 
Acrylamide/bis-acrylamide solution (A-bis-A) consisted of 30% 
(w/v) acrylamide and 0.8% (w/v) bis-acrylamide in water, filtered 
and stored in a dark bottle at 4 C. 
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Two resolving gel solutions were prepared, one a 17.5 % resolving 
solution and the other a 7.5% resolving solution. The former 
consisted of7ml of lMTris-HCl, pH 8.8 containing30% glycerol, 
12ml of A-bis-A, 0.3ml of 10% SDS (w/v) made up to 20ml with 
water. The latter consisted of 7ml of lM Tris-HCl, pH 8.8 
containing 7.5% glycerol, 5ml of A-bis-A and 0.3ml of 10% SDS 
made up to 20ml with water. 
Spacer gel was composed of 0.125M Tris-HCl pH 6.8. 
PAGE tank buffer consisted of 0.025M Tris-HC1/0.2M glycine at 
pH8.8 and containing 0.1 % SDS. 
Silver staining reagents were mixed according to manufacturers 
instructions ("Biorad Silver Stain Kit" GL1804, Biorad 
Laboratories, Richmond, California). 
Samples for protein analysis were prepared by boiling for 5min with 
an equal volume of 2% SDS, 0.2% B-mercaptoethanol, 20% glycerol 
and 0.002% bromophenol blue in 0.125M Tris-HCl, pH6.8. 
A3.6% stacking gel in 0.125MTris-HCl, pH6.8 and a 7.5-17.5% linear 
polyacrylamide gradient gel in 0.35M Tris-HCl, pH 8.8 were prepared 
as follows: 
To each resolving solution was added 0.1ml of freshly prepared 
5% ammonium persulphate (w/v) and 0.01ml .of TEMED 
immediately before use. 
16ml of the 17.5% solution was poured into a gradient mixer. 
The 7.5% solution was pumped into the gradient mixer at half 
the rate at which the solution in the mixer was pumped into the 
"slab space" between two upright glass plates (160X180X3mm) 
mounted in a gel pouring stand. Once the gel had been cast a 
small volume of water was layered onto the top of the gel solution 
. . 
usmg a syrmge. 
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Once the resolving gel had set the water was poured off and the 
spacer solution containing 15% ammonium persulphate (freshly 
prepared) and 0.01ml ofTEMED was poured onto the top of the 
gel and a spacer comb with facility for creating 10 sample bays 
was inserted. The spacer gel was allowed to set. 
The gel was then assembled in the vertical slab gel 
electrophoresis unit and the tank filled with tank buffer. 
Prepared samples were introduced using a microsyringe (Hamilton) 
into the sample bays. 
Gels were run at a constant voltage of 50-60V for 18h or until the 
tracker dye advanced to within 1cm of the lower end of the gel. 
After completion of the electrophoresis the glass plates were 
separated and the gel fixed and stained by following the instructions 
of the "Biorad Silver Staining Kit" (Biorad Laboratories, Richmond, 
California). 
The stained gel was destained in 5% acetic acid (volume/volume) for 
approximately 24h, washed in deionised water and finally dried by 
sandwiching between blotting paper and cellophane, using heat and 
vacuum; 
Molecular weight estimation using SOS-PAGE 
Molecular weight was estimated by comparison with standards of 
known molecular weight, namely phosphorylase b (94000), bovine 
serum albumin (67000), ovalbumin (43000), carbonic anhydrase 
(30000) soybean trypsin inhibitor (20100) and -lactalbumin (14400) 
(Pharmacia Electrophoresis Calibration kit, Uppsala, Sweden). The 
relative migration values (Rf) were calculated for each standard using 
the formula Rf= ( distance protein has migrated from the 
top)/( distance from origin to reference point). The protein which had 
travelled the furthest was used as the reference point and the top of 
the resolving gel was taken as the origin. The logs of the standard 
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molecular weights were plotted against these values to obtain a straight 
line. This line was used to determine the molecular weight of the 
purified protein. 
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Protein determination using the "Bradford" technique 
Protein "micro"-assay 
Protein standards were prepared from a O.lmg/ml stock solution of 
HSA. Six standards were prepared, ranging from 1 to 16µg/ml, by 
diluting 0.01, 0.016, 0.04, 0.08, 0.12 and 0.16ml of the HSA stock 
solution up to 0.8ml with buffer A. The blank consisted of 0.08ml of 
buffer A alone. 
Samples were prepared by diluting 0.002 to 0.2ml of protein samples 
up to 0.8ml with buffer A. 0.2ml of Biorad dye concentrate (Bio-Rad 
Laboratories, Richmond, California) was added to all standards, 
blanks and samples, and mixed thoroughly by vortex mixing. The 
solutions were allowed to stand for Smin at room temperature and the 
absorbance against the reagent blank at 595nm determined. Protein 
concentrations were established by comparison of unknowns to the 
standard curve as determined by linear regression analysis. 
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Appendix 13 
Porphyrin data of VP patients 
Stool porphyrins 
The mean concentrations of all stool porphyrins in the complete series 
of 221 VP and normal subjects used to establish the range of ALA and 
PBG concentrations encountered in VP patients are contrasted in 
figure App.1. Table App.1 details the actual range and occurrence of 
the parameters within the VP group. 
Porphyrin fluorescence remaining at the origin after the TLC plate was 
developed (porphyrin "X" - see Chapter 7, Diagnosis of VP) was noted 
in 92% of the VP cases and in 19% of the normal controls, but was not 
quantified. 
LOG (nmol/dry g) 
9999.999 ~ 
1000 a: 
URO 7 8 6 PSEUDO ISO COPRO PROTO 
- NORMAL CONTROLS ELZi QUIESCENT VP c:J ACUTE VP 
Figure App.1: Log of the mean porphyrin concentrations in stool samples from the normal 
controls and 221 quiescent VP's and 2 acute VP's used as unequivocally 
diagnosed VP patients in the study. Abbreviations as follows: URO, Uroporphyrin; 
7, Heptacarboxylic porphyrin; 6, Hexacarboxylic porphyrin; 5, Pentacarboxylic 
porphyrin; PSEUDO, Pseudo-pentacarboxylic porphyrin; ISO, lsocoproporphyrin; 
COPRO, Coproporphyrin; PROTO, Protoporphyrin. 
200 Appendices 
Table App.1: Analysis of stool porphyrin data. Porphyrin concentrations are in nmol 
porphyrin/dry g. For the acute group the two values given in the standard 
deviation (SD) column are the values obtained for each of the two cases. The 
small number of data points in this group does not allow meaningful statistics. 
Mean SD p Proportion (%) 
(Range) >2 SD's above 
normal mean 
NORMAL CONTROLS (88) 
Uroporphyrin 0.19 0.35 5.9 
(0-1.74) 
7COOH porphyrin Trace 1.1 
(0-0.10) 
6COOH porphyrin 0 0 
5COOH porphyrin 0.13 0.52 4.8 
(0-3.30) 
Pseudo 5COOH Trace 2.3 
(0-0.50) 
lsocoproporphyrin 0 0 
Coproporphyrin 28.3 25.8 0 
(0.1-65.8) 
Prcitoporphyrin 104.4 64.5 3.4 
(2.1 -232) 
-- ----- -------------------- -- ----------------- --- -- -- -- ---- ----------- -- ---------
QUIESCENT VP (221) 
Uroporphyrin 1.41 4.52 0.5 21 .0 
(0-47.90) 
7COOH porphyrin 1.14 4.35 0.048 15.4 
(0-35.80) 
6COOH porphyrin 0.57 2.86 0.364 6.6 
(0-25.6) 
<10-3 5COOH porphyrin 29.2 16.9 83.3 
(0-261) 
<10"3 Pseudo 5COOH 27.8 47.1 46.1 
(0-298) 
lsocoproporphyrin 2.43 12.73 0.131 11 .0 
(0-161) 
<10"3 Coproporphyrin 286.7 300.0 76.3 
(22.5-1773) 
<10"3 Protoporphyrin 1136 992 95.6 
(207.4-5776) 
-------------- --- -- ---------------------------------------------------------- ----
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Table App.1: Continued 
Mean SD p Proportion (%) 
(Range) >2 SD's above 
normal mean 
ACUTE VP (2) 
Uroporphyrin 1.6 1.38; 1.76 100 
7COOH porphyrin 0.02 0.01; 0.03 100 
6COOH porphyrin Trace -; .01 50 
5COOH porphyrin 72.6 62.5; 82.7 100 
Pseudo 5COOH 45.7 23.0; 68.4 100 
I socoproporphyrin 11.3 8.0; 14.6 100 
Coproporphyrin 1007 769; 1245 100 
Protoporphyrin 1545 1469; 1621 100 
(A} Quiescent VP 
Significant elevations of proto-, copro-, pseudo- pentacarboxylic and 
pentacarboxylic porphyrin were present in this group. 
There was a small shift in favour of protoporphyrin excretion in the 
VP population as evidenced by the change in mean protoporphyrin: 
coproporphyrin ratio from 3.7:1 in the normal group to 4.0:1 in the 
non-acute VP group. This is very similar to earlier published figures 
for TLC analysis in VP patients in the Cape Province (Bales et al, 1980; 
Day, 1986). Elevated isocoproporphyrin was present in 11 % of the 
quiescent VP cases. While the mean was significantly raised, it cannot 
be considered diagnostic of VP as it is of PCT.Nevertheless it is a good 
index of porphyrin metabolic "activity" as it was almost always found 
in those patients with high levels of faecal and urinary porphyrin 
excretion. 
An important feature of VP stool porphyrin profiles was the presence 
in most cases of either pentacarboxylic- ( 46.1 % of cases) or 
pseudo-pentacarboxylic porphyrin (83.3% of cases). Although there 
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may be difficulty in distinguishing these two porphyrins, the 
observation of a peak of porphyrin fluorescence inthe pentacarboxylic 
porphyrin "retention area" appears to be of great importance in the 
diagnosis of VP as it appears extremely infrequently in normal stools 
and seldom in other types of porphyria. Indeed, pseudopenta- or 
pentacarboxylic porphyrin were more frequently significantly elevated 
than there was coproporphyrin (83.3 versus 76.3% ). 
(B) Acute VP 
The profile of the two patients in the acute VP group was similar to 
that seen in the quiescent VP group, though the porphyrin 
concentrations were exagerrated (values shown in table App.1 and 
figure App.1). The mean stool porphyrin values were significantly 
higher than the mean of the quiescent group but fell comfortably 
within the same range. Reliable statistics were not possible as there 
were only two data points in this group. However, there appears to be 
no clear marker of the acute attack in the stool porphyrin profiles, 
though highly elevated isocoproporphyrin was noted in both. 
Urinary porphyrins 
Figure App.2 contrasts the mean urinary porphyrin values in the same 
series of VP patients. Table App.2 details the analyses. 
(A) Quiescent VP 
Urinary porphyrin excretion in the quiescent VP group was highly 
variable and ranged from completely normal patterns and 
concentrations, to profiles exhibiting marked elevations of all 
porphyrins. There were statistically significant elevations in the means 
of all porphyrin intermediates. However, since the excretion of hepta-, 
hexa- and pentacarboxylic porphyrin intermediates in normal subjects 
is zero, or near-zero, an elevation in a few VP patients will suffice for 
the means to differ significantly. This is shown in the last column of 
table App.2 which indicates the proportion of values falling more than 
two SD's above the mean of the normal group. The most consistent 
changes were mild elevation in copra- and uroporphyrin, the means 
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of which were increased by a factor of 3.7 and 2.8 respectively. Both 
were increased to amounts more than two standard deviations above 
the mean of the normal group in approximately 30% of cases ( table 
App.2, last column). 
(B) Acute VP 
In this group there were elevations in all porphyrin species present. 
LOG (nmol/10mmol creatlnlne) 
9999.999 ~ 
1000 ~ 
URO 7 6 5 COPRO 
- NORMAL CONTROLS l'2Zi QUIESCENT VP O ACUTE VP 
Figure App.2: Log of the mean porphyrin concentrations in urine samples from 93 normal 
controls, 221 quiescent VP's and 4 acute VP's. 
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Table App.2: Analysis of urinary porphyrin data. Porphyrin concentrations are given in 
nmol/ 1 Ommol creatinine. The small number of data points in the acute group does 
not allow meaningful statistical comparisons. " 
Mean SD p Proportion (%) 
(Range) >2 SD's above 
normal mean 
NORMAL CONTROLS (93) 
Uroporphyrin 14.1 10.9 5.4 
(0-57.9) 
7COOH porphyrin 0.13 0.59 3.2 
(0-4.62) 
6COOH porphyrin 0 0 
5COOH porphyrin 0.03 0.33 2.2 
(0-3.14) 
Coproporphyrin 100.3 . 106.2 4.3 
(0.1 -543.5) 
QUIESCENT VP (221) 
Uroporphyrin 39.3 60.8 <10-3 33.8 
(0-508.5) 
<10"3 7COOH porphyrin 19.2 65.3 21 .3 
(0-640) 
<10-3 25.0 6COOH porphyrin 4.8 26.7 (0-369) 
5COOH porphyrin 42.7 149.1 
<10"3 21 .3 
(0-1751) 
<10-3 Coproporphyrin 367.4 750.0 32.4 
(8.9-6698) 
ACUTE VP (4) 
Uroporphyrin 3972 681 100 
(3105-4 769) 
7COOH porphyrin 726 636 100 
(267-1627) 
6COOH porphyrin 471 457 100 
(131-1144) 
5COOH porphyrin 1659 · 961 100 
(642-2950) 
Coproporphyrin 4039 1886 100 
(2009-6553) 
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Plasma porphyrins 
Results of the plasma analyses in quiescent VP where performed (see 
below) are summarized in table App.3. Uro- and protoporphyrin were 
elevated in comparison to normal values extracted from the literature 
(Moore et al, 1987). Elevated coproporphyrin occurred as a complex 
termed "PU" (Peak Unknown (Day et al, 1978a)) in 88% of the 85 
samples; the significance of this is discussed below. 
Plasma porphyrin analysis by TLC was found to be troublesome 
although it did, in some cases, yield useful descriptive and diagnostic 
information. It was often impossible to determine the identity or 
quantity of a particular porphyrin species precisely. This may be 
because endogenous factors present in the plasma survive the 
extraction procedure, bind to the porphyrins and alter (to varying 
degrees) their behaviour on TLC. 
Nevertheless enough information is available to be able to comment 
on a previous detailed analysis of plasma porphyrins in VP (Day et al, 
1978a). These workers described a dominant complex of 
Table App.3: Plasma porphyrin data obtained from the analysis of 85 quiescent VP cases. 
All data is quoted as nmol/1 of plasma. PU, "Peak Unknown". Normal ranges from 
Moore et al, 1987. 
Mean SD Normal Proportion(%) 
ranges >2 SD's above 
normal mean 
QUIESCENT VP (85) 
Uroporphyrin 2.4 3.6 <1 .6 50.6 
7COOH porphyrin 0 0 
6COOH porphyrin 0 0 
5COOH porphyrin Trace 0.2 1.2 
PU 8.9 9.2 88.2 
Coproporphyrin 0.4 1.7 <2.2 7.1 
Protoporphyrin 19.1 30.1 <3.0 82.4 
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coproporphyrin and a membrane phospholipid constituent (possibly 
cholesterol) which constituted the predominant plasma porphyrin in 
a series of VP subjects. This complex had the same retention time as 
coproporphyrin in our TLC system but produced a distinctive sharp 
line instead of the more usual diffuse spot and is termed "PU". In our 
series of 85 plasma analyses, PU did not appear quite as ubiquitous in 
our VP population as in the previous study, appearing in 75 of the 85 
(88.2% ), but, when present, was unmistakable. It is therefore 
principally of use as a confirmatory marker of VP, making a valuable 
contribution to the biochemical "fingerprint" of VP. 
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General comment on Porphyrin analyses 
In the light of the porphyrin data presented in Appendix 13, one factor 
is clear. Data obtained from TLC or HPLC porphyrin analyses is highly 
informative and, in the absence of haem synthetic enzyme assays, should 
be _considered necessary, for the accurate differential diagnosis of the 
porphyrias. Indeed, the information derived from the distribution of 
porphyrin types alone may be more valuable in diagnosis than a mere 
comparison of porphyrin concentrations with normal values. There are 
some instances where total porphyrin content in a sample lies within 
or just outside control ranges, as is the case with some patients with 
poorly expressed biochemical features. In these cases it is still possible 
to make a diagnosis of porphyria on the basis of a distinctive 
chromatographic pattern. 
The usefulness of this type of biochemical data must not, however, be 
overestimated. We would suggest that it is extremely useful in 
identifying VP ( except in the case of silent VP) and further in classifying 
the porphyria as acute or quiescent VP. It also allows a diagnosis of 
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latent VP (clear biochemical features but clinically asymptomatic) 
which is of great value in identifying otherwise healthy (possibly 
unsuspecting) individuals at risk. 
Although more efficient and precise than simple screening tests and 
the older solvent-extraction techniques, "quantitative porphyrin 
profiling" still results in a number of equivocal results. Because VP is 
highly variable in its expression interpretation of these results is 
difficult. 
Thus determination of the true incidence of the disease and its 
sub-categories awaits the development of more precise tests such as 
would be afforded by a reliable, practical protoporphyrinogen oxidase 
activity assay and the techniques of molecular biology. 
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Abbreviations 
g gram pmol picamole 
mg milligram sec second 
µg microgram IDlil minute 
1 litre h hour 
ml millilitre cm centimetre 
µl microlitre mm millimetre 
M molar (moles/litre) µm micrometre 
mmol millimole % percent 
µmol micromole oc degrees 
nmol nanomole centigrade 
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